Evaluating the role of hyaluronic acid products in the treatment of infertility by Maree, Lara
Evaluating the Role of Hyaluronic Acid Products In the Treatment 
of Infertility 
by Lara Maree 
Thesis presented in partial fulfilment of the requirements for the degree Master of 
Science in Medical Sciences (Reproductive Biology: Biochemistry) in the Faculty of 
Medicine and Health Sciences at the University of Stellenbosch. 
Supervisor: Dr.Marie-Lena Windt De Beer 
March 2017
i 
Declaration 
By submitting this thesis, I declare that the entirety of the work contained therein is my own, 
original work, that I am the authorship owner thereof (unless to the extent explicitly 
otherwise stated) and that I have not previously in its entirety or in part submitted it for 
obtaining any qualification. 
Date: March 2017 
 Copyright © 2017 Stellenbosch University 
All rights reserved 
Stellenbosch University  https://scholar.sun.ac.za
  ii 
Abstract 
 
Hyaluronic acid is (HA) a naturally existing macromolecule and present in several HA based 
products aiming to improve the outcomes of assisted reproduction.  Hyaluronic acid is produced 
by the human cumulus cells and is therefore naturally present in the female reproductive tract. 
During physiological intracytoplasmic sperm injection (PICSI®), spermatozoa that are able to 
bind to solid-state HA, have a chromatin structure with high DNA chain integrity associated with 
fertilization competence and normal chromosomal constitution. The addition of HA into transfer 
media is based on several properties that characterize it as an implantation-enhancing molecule. 
Its viscosity is believed to facilitate the integration of the embryos into the fluid secretions of the 
intrauterine environment as it has been shown to increase cell-to-cell and cell-to-matrix adhesion. 
The presence of the CD44 receptor for HA, expressed on both the embryo and the supporting 
network of the human endometrium, suggests the action of HA during the process of 
implantation.  
The aim of the study was to evaluate retrospectively the role of hyaluronic acid in the PICSI® 
procedure and prospectively also its use in embryo transfer medium.   
The retrospective study involved the review of 388 patients whose treatment involved the 
fertilization of their ova by either physiological intracytoplasmic sperm injection (PICSI®) or 
traditional intracytoplasmic sperm injection (ICSI). In vitro fertilization (IVF) was used as a control 
group. PICSI® involves the use of a specialised culture dish that has three gel-like microdots of 
HA attached to the bottom surface of its interior. These HA dots provide an additional parameter 
whereby spermatozoa with a normal chromosome composition can be selected for injection. 
Strict exclusion criteria were applied to eliminate variables other than the fertilization method that 
could have influenced treatment outcomes. The comparison showed no statistically significant 
improvement in ART outcome, at Drs Aevitas Fertility Clinic (Vincent Pallotti Hospital, Pinelands, 
South Africa), when PICSI® dishes were used to select spermatozoa for injection. Outcomes 
measured included; fertilization rate, embryo quality, pregnancy and miscarriage rates.  
 
The prospective study evaluated the treatment outcomes of patients who underwent embryo 
transfer with specialized embryo transfer medium, EmbryoGlue® (EG) in comparison with a 
historically similar patient population who underwent embryo transfer with traditionally employed 
culture media at the same clinic (Drs Aevitas Fertility Clinic). The HA contained in EG acts as a 
specialised adherence compound supporting the implantation of a transferred embryo in the 
endometrium. The comparison showed no statistically significant improvement in clinical 
pregnancy, ongoing clinical pregnancy nor in miscarriage rates when adjustments were made for 
confounding factors.   
 
The results of the study have produced valuable information that will inform future use of HA 
products in the treatment of patients attending Drs Aevitas Fertility Clinic. 
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    Opsomming 
 
Die makromolekule, hualuroonsuur (HS), wat natuurlik voorkom, is teenwoordig in verskeie 
produkte wat die uitkoms van geassisteerde reproduktiewe tegnieke (GAT) kan verbeter. 
Hualuroonsuur word deur menslike kumulusselle geproduseer en is dus natuurlik teenwoordig in 
die vroulike reproduktiewe traktus. Tydens fisiologiese intrasitoplasmatiese sperm inspuiting 
(PICSI®), bind spermatosoa met hoë DNA integriteit, wat geassossieer word met 
bevrugtingspotensiaal en normale chromosomale samestelling, aan die hualoroonsuur in 
gelvorm. Die byvoeging van hualoroonsuur in embrio terugplasingsmedia word gebasseer op die 
eienskap dat die viskositeit van hualoroonsuur die integrasie van die embrio met die sekresies 
van die intra-uteriene holte en dus ook inplantasie bevorder. Dit word toegeskryf aan beter sel tot 
sel en sel tot matriks adhesie. Die teenwoordigheid van CD44 reseptore vir HA, teenwoordig op 
beide die embrio en die endometrium, bevestig die rol van hualoroonsuur tydens die inplantasie 
proses. 
 
Die doel van die studie was om die rol van hualoroonsuur tydens die PICSI® prosedure sowel as 
die embrio terugplasingsprosedure te bepaal.  
 
Die restrospektiewe studie, wat 388 pasiente ingesluit het, het gepoog om die produk PICSI® 
wat hualoroonsuur bevat, te vergelyk met klasieke intrasitoplasmatiese sperm inspuiting [ICSI]. 
Die kontrole groep was pasiente wat met behulp van die in vitro bevrugtings metode [IVB] 
behandel is.  Tydens die PICSI® prodsedure word ‘n gespesialiseerde kultuur bakkie, wat drie 
druppels HS in gelvorm op die oppervlak bevat, gebruik. Hierdie hualoroondruppels bied die 
voordeel dat spermselle met normale chromosoomsamestelling geselekteer kan word. Streng 
uitsluitingskriteria is toegepas om alle ander veranderlikes wat uitkoms kan beïnvloed, te 
elimineer. Die vergelyking van data by die Drs Aevitas fertiliteitskliniek (Vincent Pallotti Hospitaal, 
Pinelands, Suid Afrika),het geen statisties beduidende verbetering in uitkoms tydens die PICSI® 
prosedure aangedui nie. Uitkoms is gemeet aan persentasie bevrugting, embriokwaliteit, 
swangerskap- en miskraam koers. 
 
Die prospektiewe studie het die behandelingsuitkoms tussen pasiente wat embrioterugplasing 
ondergaan het met EmbryoGlue® (EG) medium en histories soortgelyke pasiente wat histories 
embrioterugplasings ondergaan het met tradisionele kultuur medium, by dieselfde kliniek (Drs 
Aevitas fertiliteitskliniek) vergelyk. Die EG medium bevat hualoroonsuur wat volgens studies 
implantasie van die embrios bevorder. Die resultate het, na aanpassing van strengelveranderlike 
faktore, geen stasties beduidende verbetering in kliniese swangerskap, voortgaande 
swangerskap of miskraam koers tydens die gebruik van die EG medium aangedui nie. 
 
Die resultate van die studie het waardevolle inligting rakende toekomstige gebruik van HS 
produkte tydens die behandeling van pasiente by die Drs Aevitas fertiliteitskliniek verskaf. 
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Chapter 1 
 
Background Information & Literature Review  
 
Introduction 
 
Assisted reproductive techniques (ART) treatments involve the application of sophisticated 
ovarian stimulation protocols, continuous patient monitoring and delicate follicle aspiration 
whereby mature oocytes are harvested and fertilized in the in vitro laboratory setting. The 
embryos are then cultured in specialized media for approximately 5 days before a variety of 
invasive and non-invasive techniques may be employed to select, what we believe to be, the 
most implantation competent embryos for transfer. A result of failed implantation often baffles 
clinicians and scientists alike and necessitates further investigation into ways in which we can 
support embryo implantation; improve clinical pregnancy and live birth rates (Balaban, et al, 
2011).  Routine practice also involves a semen analysis for the male partner before assessing 
the female partner. If abnormal parameters are encountered during routine semen analysis, the 
addition of functional sperm tests may be used to further assess sperm normalcy and 
fertilization capabilities (Jeyendran et al, 1984; World Health Organization, 2010).   
 
Continuous research to improve ART outcome also involves amongst others, improved sperm 
selection methods (Appendix VII & VIII) in advanced in vitro fertilization methods and improved 
adhesion and implantation to the endometrium (Achache et al, 2006). In the current study the 
effect of physiological intracytoplasmic sperm injection (PICSI®), a sperm selection method and 
the use of EmbryoGlue® (EG) transfer medium, a hyaluronic acid (HA) based product, on ART 
outcome will be specifically investigated. 
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1.1 The History of Assisted Human Reproduction 
 
1.1.1 The History of IVF 
 
Our collective understanding of the molecular mechanisms involved in the fertilization process 
began with studies in non-mammalian species, such as amphibians, where fertilization occurs 
outside the body. The first reported observation of sperm penetrating an oocyte was in 1852 
and published the year thereafter (Clarke, 2006). Subsequent non-mammalian studies further 
helped define the specific experimental conditions that enabled the first successful in vitro 
fertilization of mammalian oocytes in 1959 (Bavister, 2002).  
 
In 2015 a collection of papers published in Reproductive Biomedicine & Society Online (Elder & 
Johnson, 2015a, Elder & Johnson, 2015b) describes the collaboration of Robert Edwards and 
Patrick Steptoe in the years spanning 1969-1978 that ultimately lead to the birth of the world’s 
first IVF baby, Louise Joy Brown on 25 July 1978. It should be mentioned however, that the 
true origins of IVF date back as far as 1878 to basic research studies and work on hamster and 
rabbit gametes (Yanagimachi & Chang, 1964). The success of Edwards & Steptoe in achieving 
the world’s first IVF birth is therefore also owed to numerous pioneering scientists who came 
before them. In late 1968, Edwards & Steptoe initially focussed their collective efforts on 
perfecting all elements of the laparoscopic oocyte retrieval procedure including the technical 
aspects and instruments necessary, induction of ovulation, timing of aspiration and ovarian 
stimulation protocols.  
 
Aspiration equipment similar to that used in modern ART clinics was developed in September 
1969 (Elder & Johnson, 2015a).  A bypass valve allowed the optimization of suction pressure 
used to aspirate the follicles after it was determined that pressure greater than 12cm Hg may 
result in oocyte damage (Elder & Johnson, 2015a).  The optimal timing of human chorionic 
gonadotropin (HCG) administration, used to induce the maturation of follicles, was indicated by 
the presence of urinary oestrogens in excess of 75ug/day detected in 24-hour samples (Elder & 
Johnson, 2015a). The analysis of recovered research notes from 1969 indicated that HCG was 
administered between 29-31 hours before aspiration. The timing of HCG trigger was based on 
availability of the theatre & operating team rather than maturation of the follicles. The dosage of 
HCG used for trigger ranged between 3000 and 12 000IU and was based on the doses of 
gonadotropins used for follicular stimulation in the cycle. A standard protocol for follicle 
stimulation and maturation, consisting of three injections of human menopausal gonadotropin 
(HMG) between days 2-9 and 5000IU of HCG on days 9-11 of the menstrual cycle was later 
adopted (Elder & Johnson, 2015a). Edwards & Steptoe used the presence of a corpus luteum 
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to determine whether ovulation had taken place prior to oocyte retrieval as the duration 
between HCG administration and the retrieval procedure varied. Oocyte retrieval was carried 
out on days 10-12 of the menstrual cycle and the interval between HCG trigger and oocyte 
retrieval was gradually adjusted from 28.75-29.50 hrs to 32.0-33.5 hrs in March 1970 (Elder & 
Johnson, 2015a). 
 
1.1.2 Follicle Stimulation Regiments 
 
Edwards & Steptoe optimized their ovarian stimulation regiments by adjusting the doses of 
HMG to regulate follicular development, and HCG to induce follicular maturation, in stimulated 
patient cycles over a number of years (Elder & Johnson, 2015b). The resulting follicle 
measurements, number and apparent maturity of oocytes retrieved were compared among 
different stimulated cycles and their findings published in Nature magazine in 1970 (Edwards, 
Steptoe & Purdy, 1970). The initial doses of HMG administered were conservative considering 
the lack of available information regarding potential ovarian response as well as the potential 
risk of patients developing ovarian hyperstimulation syndrome. In 1969 two ampules of 
Pergonal were administered in a single dose early in the menstrual cycle. The number of HMG 
ampules administered steadily increased to three doses of two, three or four ampules on days 
6, 8 and 10 of the menstrual cycle after it was observed that lower doses were effective only in 
extending time to menstruation. They succeeded in taking control of patients’ menstrual cycles 
with repeated injections of these higher doses of HMG and by 1972 the success rate in oocyte 
retrieval had increased from 83% to 95%. In 1973 high doses of HMG were found to result in 
increased oestrogen production and secretion during the follicular phase of stimulated cycles. 
Edwards & Steptoe began to replace Pergonal with clomiphene citrate stimulation as high 
oestrogen levels during the follicular phase had negative consequences on the resulting luteal 
phase endometrium (Elder & Johnson, 2015b). The use of HCG to induce follicle maturation in 
natural cycles was also attempted in an effort to address the elevated oestrogen levels. In the 
period between 1973 and 1978 Pergonal-stimulated, clomiphene citrate-stimulated and natural 
cycles were carried out in parallel but none resulted in the establishment of an ongoing 
pregnancy (Elder & Johnson, 2015b). Edwards & Steptoe changed their approach in 1978, 
abandoning stimulation with exogenous hormones focussing instead on meticulous endocrine 
monitoring, including urinary total oestrogen in natural cycles. They reported greater success in 
the retrieval of functionally mature oocytes in natural cycles (Elder & Johnson, 2015b). 
 
In addition to the ground-breaking work of Edwards & Steptoe, the tireless efforts of scientists 
and clinicians that followed over the last three decades have informed the collective present-
day understanding of all aspects of human reproduction. Modern techniques for ovarian 
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stimulation, oocyte retrieval, assisted fertilization, embryo culture, sperm preparation and 
cryopreservation have made possible the birth of some 5 million babies worldwide (Mansour et 
al, 2014). 
 
1.1.3 Standard IVF 
 
Standard IVF is a process whereby good quality spermatozoa are added to the immediate 
culture environment surrounding retrieved mature oocytes and incubated together at 37 ºC (6% 
CO2) overnight. The cumulus complex is stripped from each oocyte the following morning to 
allow fertilization evaluation (Appendix XII Standard Operating Protocol: In Vitro Fertilization). 
Successful fertilization, indicated by the presence of two pronuclei and two polar bodies, cannot 
however be achieved through standard IVF when there are severe male factors contributing to 
the etiology of a couples’ infertility. The percentage of normally fertilized oocytes and number of 
embryos generated by conventional IVF is significantly lower when semen characteristics were 
below reference ranges in terms of concentration, motility and morphology. Sperm morphology 
is considered to be the most accurate predictor of prognosis (Coetzee et al, 1998; Ombelet et 
al, 1995; Kruger et al, 1988; Menkveld et al, 2001).  
 
In order to treat male factor infertility, more advanced fertilization techniques including; 
intracytoplasmic sperm injection (ICSI), physiological intracytoplasmic sperm injection (PICSI®) 
and intracytoplasmic morphologically selected sperm injection (IMSI) have been developed. 
These will be discussed in section 1.4 Advanced Methods of Fertilization.  
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1.2 Infertility: A Global Overview 
 
The clinical definition of infertility, as provided by the World Health Organisation, is “a disease 
of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 
months or more of regular, unprotected sexual intercourse” (World Health Organization, 2010). 
 
1.2.1 Prevalence and Distribution  
In 2012, a systematic analysis of 277 health surveys illustrated national, regional, and global 
trends in infertility prevalence since 1990 (Mascarenhas et al, 2012). In analysing demographic 
and reproductive health surveys, researchers used a consistent algorithm to calculate infertility. 
A 5-year exposure period based on union status, contraceptive use and the desire for a child 
was used a demographic measure of infertility. Live birth was used as outcome and biases 
were corrected for in instances of incomplete information. Little changes in infertility rates were 
found over two decades, apart from specific regions in Sub-Saharan African and South Asia, 
taking into account global population growth and a declining tendency in the preferred number 
of children per household. The aetiological causes of the reported trends were undetermined 
and further studies are needed to clarify causes (Mascarenhas et al, 2012). The consensus 
among publications is that the question of calculating a single global estimate of infertility 
prevalence is complicated by lacking data in developing countries as well as variability in 
demographic definitions of infertility, outcome measures used and inconsistent research 
settings (Dyer, 2009).  According to Ombelet et al (2008) more than 70 million couples are 
believed to suffer from infertility worldwide, with the prevalence of primary and secondary 
infertility varying widely. Infection is cited as the most common cause of infertility among men & 
women in Africa with regional prevalence rates as high as 30-40% (Dyer et al, 2002). 	
 
The most common causes of female subfertility include; advanced maternal age, ovulatory 
abnormalities or complete anovulation, tubal obstruction or disease, uterine factor, and 
adhesions or endometriosis (Healy et al, 1994). Male factor subfertility may be the result of 
varicocele, obstructive azoospermia, excessive scrotal heat or testicular injury, presence of 
anti-sperm antibodies, a genetic factor or exposure to environmental factors such as pesticides 
or industrial chemicals (Whorton et al, 1977; der Kretser, 1997). Idiopathic subfertility, where 
there is no demonstrable physiological cause to explain failure to conceive, represents 
approximately 5-10% of the infertile population seeking treatment (Hewitt et al, 1985). A small 
proportion of couples are affected by a combination of both male and female factors (Adamson 
& Baker, 2003).  
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A vast body of literature exists to demonstrate an age-dependent decline in female fertility. A 
retrospective population-based study on women age 22-44 years in Denmark, Germany, Italy & 
Spain evaluated the associated risk of maternal & paternal age combined into a single variable 
in a multivariate logistic regression analysis. The reference group used was couples where both 
partners fall into the 20-29 years grouping. Results were adjusted for a number of factors 
including; reproductive history and country and reported a higher risk of miscarriage in women 
35 years and older consistent with previous publications (de La Rochebrochard & Thonneau, 
2002). Novel results included the observation that couples composed of a woman 35 years or 
older combined with a male partner of 40 years and over were at a significantly increased risk 
of all potentially adverse outcomes (de La Rochebrochard & Thonneau, 2002). It was 
concluded that the risk of adverse pregnancy outcome, particularly miscarriage, is greatest 
when both partners are of advanced age (de La Rochebrochard & Thonneau, 2002).  
 
Fewer studies evaluating the possible adverse effect of advancing paternal age on reproductive 
capability are available (Broekmans et al, 2007). Advanced paternal age has also been 
associated with impaired neurocognitive outcomes during infancy and childhood based on 
finding drawn from the US Collaborative Perinatal Project (Saha et al, 2009). A number of 
outcome measures including various well-known intelligence and achievement scales designed 
for children were applied at 8 months, 4 years and 7 years. Analyses were examined after 
being adjusted for potential confounding factors and advanced paternal age was consistently 
associated with poorer test scores in all neurocognitive assessments except the Bayley Motor 
score at all age intervals (Saha et al, 2009). Conversely, a 2011 systematic review of existing 
literature included 10 studies and reported insufficient evidence to support an unfavourable 
effect of paternal age on ART outcomes (Dain et al, 2011).  Further concerns regarding age 
associated male infertility have recently arisen following studies illustrating a high prevalence of 
isolated sperm DNA damage in older men (Das et al, 2013).  
 
This list of causes for subfertility is by no means exhaustive and is only one of the many factors 
influencing the potential outcome of treatment. The success of any given infertility treatment is 
multifactorial, the diagnostic findings regarding the initial cause of subfertility, ovarian response 
to stimulation, number of oocytes harvested, quality of resulting embryos and endometrial 
receptiveness are some of the factors determining the likelihood of an ongoing pregnancy and 
live birth (Boivin et al, 2007).  
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1.2.2 Current Success Rates 
 
The European Society of Human Reproduction and Embryology has published 14 monitoring 
reports on the results of medically assisted reproduction treatments including both assisted 
reproductive technology (ART) and intrauterine insemination (IUI) cycles initiated in Europe 
within various time periods. Trends and fluctuations are also discussed in each report. The 
most recent of such publications was published in Human Reproduction in 2014 and reported 
data from national registries of individual countries on European cycles initiated in 2010 (Kupka 
et al, 2014). 
 
The participants included 31 European countries, 991 clinics and 550 296 ART treatment 
cycles. It should be mentioned that the findings are limited by a lack of standardized reporting 
method among European countries and authors have suggested results be interpreted with 
caution.  Despite noting some fluctuations in the number of countries, reporting the overall 
number of initiated ART cycles has continued to increase with each new year. Pregnancy rates 
were comparable to that reported from 2009 (Kupka et al, 2014). In respect of different 
treatments, the following pregnancy rates were reported; IVF clinical pregnancy rates per 
aspiration and per transfer increased to 29.2% and 33.2% respectively. The corresponding 
clinical pregnancy rates following ICSI treatment also indicated an increase from 28.8% in 2009 
to 32.0% in 2010. The pregnancy rate of frozen embryo cycles reported was 20.3% per 
thawing. The delivery rate of singleton, twin and triplet pregnancies, combined between IVF 
and ICSI cycles, were 79.4%, 19.6% and 1.0%, respectively. The total multiple delivery rate 
was therefore 20.6% compared with the 20.2% reported in 2009. Although only marginally 
lower than the multiples rate of 2009, the decline in multiples rate is likely due to a movement 
towards single embryo rather than multiple embryo (three or more) transfers. Over half a million 
ART cycles were reported in 2010 consistent with reports of consistently expanding numbers of 
ART treatments per year (Kupka et al, 2014). 
 
A retrospective, cross-sectional survey on the utilization, effectiveness and safety of ART 
procedures performed globally from 2008 to 2010 was recently published in Human 
Reproduction (Dyer et al, 2016). Data from nearly 2500 ART clinics from approximately 61 
countries was included. The International Committee for Monitoring Assisted Reproductive 
Technologies (ICMART) developed forms and methods for the processing of data aggregated 
by country. It was concluded that the global utilization and effectiveness of ART remained 
relatively constant with only a 6.4% increase in the number of aspirations between 2008 and 
2010. There was an increase in the rate of single embryo transfers from 25.7% in 2008 to 
30.0% in 2010 as well as a 27.6% increase in the number of FET cycles globally over the 
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period stated (Dyer et al, 2016). While the report accounts for approximately two-thirds of 
global ART activity, it is limited by the quality and completeness of submissions from individual 
countries. The South African Register of Assisted Reproductive Techniques (SARA) has also 
recently been implemented for the monitoring of ART activity in sub-Saharan Africa. The 2013 
SARA report conveyed that fertilization rate per aspiration is comparable between IVF (95.3%) 
and ICSI (94.9%) (Dyer, 2013). Clinical pregnancy rates for IVF/ICSI have remained constant 
over the past 5 years but an increase in the multiple pregnancy rate from 14.4% in 2012 to 
26.6% in 2013 has been reported. The increase in multiple pregnancy rate may be the result of 
better reporting of outcomes rather than a true increase but such a high multiples rate 
nevertheless motivates further efforts to move towards single embryo transfers in the future 
(Dyer, 2013). 
 
1.2.3 Research to Improve Success Rates 
 
In the field of assisted reproduction, research is often dedicated to what are considered the 
most relevant parameters in determining the outcome of infertility treatments. A large number of 
recent publications have focussed on the improvement of ongoing pregnancy and live birth 
rates while others aim to develop new techniques to reduce the frequency of high order multiple 
pregnancies, commonly associated with assisted reproduction treatments (Ombelet et al, 
2005). In the quest to improve ART success ongoing research efforts include; the development 
of more sophisticated embryo and sperm selection techniques as well as strategies to enhance 
implantation rates, such as HA product usage.  
 
a. Embryo selection 
  
Widespread research exists to demonstrate the crucial nature of embryo selection in the 
treatment of patients wishing to conceive by assisted reproductive technologies. Embryologists 
employ various embryo selection strategies at different developmental stages, from oocyte to 
blastocyst stage, with the aim of identifying the most implantation competent embryo(s), with 
the highest potential to result in an ongoing singleton pregnancy, for transfer (Montag et al, 
2013). 
 
Embryo selection can be divided into two primary groups; invasive and non-invasive techniques 
(Kotze et al, 2013). Non-invasive selection techniques include morphological assessment of 
oocytes and embryos directly following aspiration and throughout the cleavage-stages of 
development leading to the formation of the blastocyst (Fisch et al, 2001). Blastocyst evaluation 
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includes grading of the expansion and appearance of both the trophectoderm cells and the 
inner cell mass (Alfarawati et al, 2011). Although all three parameters are important, the 
predictive strength of the trophectoderm grading is greater than that of the inner cell mass 
grading (Ahlstrom et al, 2011; Gardner & Lane, 1997). Pronuclear morphology may also be 
assessed although this technique is used mainly in research rather than informing the decision 
of which embryo to select for transfer in most private clinics (Balaban et al, 2001). Invasive 
procedures involve the biopsy of polar bodies, blastomeres or trophectoderm cells to enable 
the screening of the oocyte or embryo’s genetic constitution for abnormalities (Tarin & 
Handyside, 1993). The timing of the first post fertilization mitotic division in early zygotes may 
also predict viability. Early cleavage has been studied extensively with numerous studies 
reporting that early cleavage is not only associated with increased developmental potential 
(Fenwick et al, 2002; Windt et al, 2004) and improved embryo quality (Fu et al, 2009) but with a 
greater likelihood of blastulation (Van Montfoort et al, 2004). A study including the analysis of 
178 single embryo transfers reported a significantly higher clinical pregnancy rate (50%) after 
transfer of “early cleavage” embryos when compared with “no early cleavage” embryos (26.4%) 
(Salumets et al, 2003). Embryos were checked for early cleavage at 25-27 hours post 
insemination or ICSI and selection for transfer was based on day 2 embryo morphology and 
growth rate, not early cleavage (Salumets et al, 2003). Current embryological dogma has been 
called into question by researchers evaluating the relationship between ploidy status and 
blastocyst formation of fast cleaving embryos (Luna et al, 2008). A retrospective study 
evaluating the blastulation, implantation, pregnancy and birth rates resulting from fast embryo 
transfers reported a significantly greater blastulation rate in the intermediate (72.7%) and fast 
cleaving (54.2%) groups when compared with slow cleaving (38%) groups (Luna et al, 2008). 
Similarly, a reptrospective study has also reported a negative association with abnormal early 
cleavage (Phan et al, 2014). A study that evaluated 1557 embryos from 203 ICSI cycles with 
array comparative genomic hybridization (a-CGH), the relationship between embryo 
morphology and development and chromosomal status was evaluated. Day 3 embryos were 
biopsied and all 23 chromosome pairs were analysed. The researchers reported greater 
incidence of chromosomal abnormalities in both slow- and fast cleaving embryos when 
compared with embryos that followed traditional cleaving patterns consistent with days post 
insemination (Phan et al, 2014). The assessment of embryos through the metabolomic profiling 
of embryo culture media has also been investigated as a useful adjunct to current 
morphological embryo assessment (Botros et al, 2008). 
 
Invasive procedures involving the biopsy of polar bodies, blastomeres or trophectoderm cells 
enable the screening of the oocyte or embryo’s genetic constitution for chromosomal 
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abnormalities such as aneuploidy as well as many monogenic diseases (Mastenbroek et al, 
2007). Pre-implantation genetic screening (PGS) involves the use of comparative genomic 
hybridization (CGH) or whole genome amplification (WGA) to identify the presence of genetic 
abnormalities of single disaggregated embryonic cells (Voullaire et al, 1999). PGS was reported 
by Voullaire et al in 1999 following their modification of a technique used to screen the whole 
genome’s DNA in tumours developed by Kallioniemi et al (1994). CGH has since been adapted 
to be more efficient and thorough in its screening and is presently referred to as array-CGH 
(Phan et al, 2014). Embryos with chromosomal abnormalities are causally linked with poor 
implantation rates and the selection of embryos based on normal chromosomal constitution 
therefore results in the improvement of both implantation and ongoing pregnancy rates in ART 
facilities (Gianaroli et al, 1997; Phan et al, 2014).  
 
The analysis of transcriptomes and proteomes obtained from biopsied embryonic tissue has 
also proven useful in further understanding the coordination of the series of complex 
developmental events leading to blastocyst stage but its usefulness in a routine clinical setting 
has not yet been established (Montag et al, 2013).  
 
A number of studies including a recent study using time-lapse monitoring by Kirkegaard et al. 
(2012) have confirmed the importance of maintaining the integrity of the embryo throughout 
development and have detailed the possible negative effects of blastomere removal on 
continuing embryo development (Cimadomo et al, 2016). In lieu of this, recent focus has shifted 
to the improvement and establishment of new non-invasive techniques where the investigation 
itself has no possible effect on the embryo (Kotze et al, 2012). 
 
A novel selection tool called time-lapse imaging involves the incubation of embryos in a 
specialized incubator with built in camera that enables the recording and retrospective analysis 
of key developmental activity known as morphokinetics (Desai et al, 2014). This technique has 
been used to classify the risk of aneuploidy in respective embryos allowing a ranking of embryo 
competency and further assisting the process of embryo selection (Campbell et al, 2013; 
Costa-Borges et al, 2016). Time lapse has recently also enabled the study of various cleavage 
anomalies and multinucleation (Desai et al, 2014; Liu, 2016). A 2016 prospective, randomized, 
controlled trial assessed whether the addition of time-lapse morphokinetics in the selection of 
embryos for transfer improved pregnancy rates. The study included a total of 235 patients, 116 
of which were randomized to conventional once-daily morphologic embryo screening (CS) and 
119 to additional time-lapse kinetic monitoring (TLM). The intrauterine clinical pregnancy (TLM 
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68% vs. CS 63%) and implantation rates (TLM 51% vs. CS 45%) were not statistically 
significantly different (Goodman et al, 2016). The Biennial review of infertility explains that 
although over 20 morphokinetic markers have been identified using TLM, these biomarkers 
have not been properly validated in prospective randomized controlled studies and their 
application remains experimental (Bormann et al, 2015). An algorithm, the KIDScore, has also 
been developed to enable the ranking of cleavage stage embryos according to their blastocyst 
formation potential. The algorithm was based on the retrospective evaluation of 3275 embryos 
transferred on Day 3, conducted in 24 separate clinics, and is reported to have superior 
predictive power in comparison with other available blastocyst prediction algorithms (Petersen 
et al, 2016). 
 
b. Sperm selection 
 
Sperm selection techniques for use during ICSI have also evolved to enable the visualization of 
sperm under higher-magnification so that morphology can be assessed using the IMSI 
technique (Boitrelle, 2014). The physiology of sperm can also be assessed with the use of new 
hyaluronic acid (HA) based products such as PICSI® dishes (Huszar et al, 2006).  
 
Other sperm selection methods less commonly used are annexin VI bead [MACS] columns and 
zona pellucida (ZP) selected sperm (Liu et al, 1989, Liu et al 2011). Spermatozoa preparation 
by magnetic activated cell sorting (MACS) eliminated apoptotic spermatozoa based on the 
presence of externalized phosphatidylserine residues (Dirican et al, 2008). The sorting of 
spermatozoa with MACS prior to gradient centrifugation prepatation resulted in greater 
percentages of morphologically normal spermatozoa as well as improving cleavage and 
pregnancy rates in oligoasthenozoospermic ART cases (Dirican et al, 2008). A prospective, 
randomized, triple-blinded trial in Spain evaluated the extent to which removing presumptive 
apoptotic sperm cells from frozen samples affects sperm quality. Other measured outcomes 
included the fertilization, cleavage, implantation and pregnancy rates following ICSI with MACS 
sorted spermatozoa. A total of 237 couples undergoing ICSI cycles with donor ova were 
included and no statistically significant improvements were observed in any of the measured 
outcomes (Romany et al, 2014). 
 
In a study with 106 couples undergoing ICSI treatment with ejaculated sperm the use of ZP-
bound spermatozoa for ICSI produced higher embryo quality rates and significantly improved 
implantation rates in comparison with conventional ICSI (Liu et al, 2011). A 2016 study 
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confirmed that ZP-bound spermatozoa used for ICSI significantly improved embryo quality 
rates although fertilization and cleavage rates remained unchanged (Jin et al, 2016).  
 
c. Improved Implantation Potential  
 
One of the many remaining research questions among professionals in the ART community is 
the matter of supporting successful implantation following embryo transfer, regardless of day of 
transfer. The concept of endometrial receptivity and the need for synchronization between the 
embryo and the endometrium remains widely debated among professionals in the reproductive 
medicine community. The process of implantation is multivariate and requires a reciprocal 
dialogue between the endometrium and the transferred embryo(s) (Bergh & Navot, 1992). The 
timing of embryo transfer in relation to embryonic development and maturity of the endometrial 
lining is therefore crucial in the determination of outcome. Studies on the peri-implantation 
period have enabled the detection of embryonic signalling between cycle days 20 and 24, the 
presumed window of implantation (Bergh & Navot, 1992). In a study by Bergh & Navot (1992) 
33 pregnancies resulted in deliveries following 75 embryo transfers. Embryos of the same age 
were transferred on different days within the day 15 to day 19 window. These days each 
represent different stages of endometrial maturation with unique hormonal and histological 
profiles. Embryonic age and endometrial maturation were compared with individual hCG linear 
regression models and day 19 was found to have the steepest slope of hCG detection relative 
to days 15 and day 16 (Aplin, 2000). It was concluded that implantation depends on embryonic 
age irrespective of endometrial maturation between cycle days 20 to 24, the presumed window 
of implantation (Bergh & Navot, 1992). The adequacy of induced endometrial cycles following 
hormonal manipulation has been experimentally evaluated in terms of various histological and 
hormonal criteria. A particular set of histological, hormonal and morphological criteria are used 
to classify endometrial normalcy and receptivity to embryos (Aplin, 2000; Sharkey & Macklon, 
2013).  
 
The Cochrane Library published a review of Assisted Reproductive Technology in Cochrane 
Reviews in 2015. The main results of the review organized interventions categorically as either 
effective, promising, ineffective, possibly ineffective and those where no conclusions were 
possible due to lack of evidence (Farquhar et al, 2015). Interventions classified as effective can 
be observed in Table 1. 
 
Table 1: Effective interventions in ART treatment.  
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Pre-ART and adjuvant strategies • Endometrial injury 
• Growth hormone use 
• Metformin use in PCOS patients 
• Surgical treatment for tubal disease 
Down-regulation with agonist or antagonist • GnRHa protocols for pituitary suppression 
• GnRH antagonist treatment 
• Long term pituitary down-regulation before IVF 
Ovarian stimulation • Recombinant versus urinary gonadotropin use 
• Long-acting FSH versus daily FSH 
Ovulation triggering • Recombinant versus urinary hCG for final 
oocyte maturation 
• GnRHa versus hCG for triggering in antagonist 
cycles 
Oocyte retrieval • Individualized pain relief during oocyte retrieval 
Laboratory phase • Low oxygen for embryo culture 
Embryo transfer • Ultrasound versus “clinical touch” for catheter 
guidance 
• Adherance compounds (hyaluronic acid) in 
transfer media 
• Single embryo transfer versus double embryo 
transfer 
Luteal phase support • Progesterone as best method of luteal support 
Prevention of ovarian hyperstimualtion syndrome • Intravenous hydroxyethyl  
• Cabergoline 
• GnRH antagonist protocols 
• GnRHa versus hCG for oocyte triggering in 
antagonist cycles 
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1.2.4 Hyaluronic Acid/ Hyaluron products 
Hyaluronic acid (Hyaluronan, HA) is a naturally existing macromolecule produced by the human 
cumulus cells present in varying concentrations throughout the female reproductive tract and 
the endometrium (Salamonsen et al, 2001). HA is a unique linear glycosaminoglycan (GAG) 
with a negative charge that attracts water and allows significant expansion of its solvent domain 
beyond the actual polymer volume (Salamonsen et al, 2001). This property plays a role in 
enabling cell-cell contact in a number of biological processes while HA also provides a matrix 
for cell migration. Additionally, HA facilitates cellular signalling during implantation by binding to 
receptor CD44 expressed on both the embryo and in the stroma of the endometrium 
(Salamonsen et al, 2001). The distribution of HA varies as the endometrium undergoes 
extensive remodelling throughout the various phases of the menstrual cycle. These changes in 
HA deposition have been studied using a highly specific binding peptide for histochemical 
localization. The HA deposition in the stromal compartment was found to peak during the mid-
proliferative (days 5-10) and mid-secretory (days 19-23) phases of the cycle. In contrast, the 
deposition of HA around blood vessels was found to remain constant throughout the cycle 
(Salamonsen et al, 2001). HA has been shown to increase both cell-to-cell and cell-to-matric 
adhesion known to promote successful implantation of the embryo (Huszar et al, 2007). The 
viscosity of a HA solution is believed to prevent expulsion during the transfer process while 
facilitating the integration of embryos into the viscous intrauterine secretions. Studies on mice 
comparing the use of embryo transfer medium with and without HA resulted in improvement in 
both implantation and foetal development rates where hyaluronic acid was present (Turley & 
Moore,1984).  
 
Several hyaluronic acid (HA) based products aiming to improve overall ART outcomes 
are currently available on the market including PICSI® dishes and EmbryoGlue® (discussed in 
section 1.4 Advanced Methods of Fertilization and section 1.2.3 Research to Improve Success 
Rates). 
 
SpermSlow is a product that assists the sperm selection process by slowing the movement of 
spermatozoa to allow better visualization of morphology where good morphology is associated 
with functional maturity, fertilization capability and normal chromosomal constitution (Sun et al, 
2006). The use of SpermSlow has been suggested as a more natural, and biodegradable, 
substitute for PVP conventionally used for ICSI cases (Huszar, 2012). A prospective 
randomized control trial comparatively evaluated the use of PICSI® dishes and Sperm Slow in 
sperm hyaluronic binding selection for fertilization by intra-cytoplasmic sperm injection. It was 
found that there is no significant difference in clinical efficiency of the two systems in selecting 
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hyaluronic acid bound spermatozoa (Parmegiani et al, 2012). A retrospective comparison 
between PVP-ICSI and HA-ICSI illustrated a significant improvement in both embryo quality 
and implantation rates associated with spermatozoa physiologically selected with HA-ICSI 
(Parmegiani et al, 2010a).  
 
EmbryoGlue® (EG) by Vitrolife is an embryo transfer-specific medium containing a 
unique combination of hyaluronic acid and recombinant albumin. The hyaluron contained in EG 
acts as a specialised adherence compound supporting the implantation of a transferred embryo 
in the endometrium (Simon et al, 2003). Initial studies on mice comparing the use of embryo 
transfer medium with and without HA resulted in an improvement in both implantation and fetal 
development rates where hyaluronic acid was present (Turley & Moore, 1984). (Discussed in 
section 1.2.3 Research to Improve Success Rates). 
 
Details of the proposed working mechanism of EG have been discussed in subsection 1.2.3, 
“Research to Improve Success Rates” but briefly it has known been to increase both cell-to-cell 
and cell-to-matric adhesion necessary for effective communication between the embryo and 
endometrium during implantation (Huszar et al, 2007). Additionally, the viscosity of a HA 
solution is believed to prevent expulsion during the transfer process while facilitating the 
integration of embryos into the viscous intrauterine secretions. 
 
In 2005, a study designed to evaluate the usefulness of EG in improving pregnancy rates 
included 310 fresh embryo transfers, 154 of which were transferred following incubation in the 
HA-enriched medium. Possible confounding factors such as age, duration of infertility, previous 
IVF cycles, total gonadotropin dose, oocyte number and number of embryos transferred were 
similar in the control and treatment groups. The resulting pregnancy rates were not significantly 
different and they concluded the use of EG in fresh transfers did not improve resulting 
pregnancy rate (Ravhon et al, 2005). A prospective randomized study that followed showed an 
overall increase in implantation and clinical pregnancy rates where EG was favoured above 
conventional transfer medium (Urman et al., 2008). Interestingly, the use of EG had the 
greatest beneficial effect on patients who had previously failed cycles and in women with poor-
quality embryos (Urman et al., 2008). A meta-analysis published by the Cochrane Collaboration 
research network in 2010 concluded that high concentrations of HA in a transfer medium 
(EmbryoGlue® by Vitrolife) resulted in evidence of treatment effects for clinical pregnancy rate 
and multiple pregnancy rate, with higher rates in the hyaluronic acid groups (Bontekoe et al, 
2010). HA groups are labelled either as high (0.5 mg/ml), low (0.125mg/ml) or no HA (0.0 
mg/ml) (Bontekoe et al, 2010). 
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The increase in multiple pregnancy rates requires further studies with single embryo transfer as 
the policy of transferring more than one embryo is a possible confounder. No evidence of an 
effect on live birth rate was found (Bontekoe et al, 2010). The review article that followed the 
Cochrane review mentioned that low concentrations of HA in transfer medium has no effect on 
clinical pregnancy rate and that live birth rate (LBR) was found not to have improved 
significantly (Bontekoe et al, 2010). LBR had not been the end point for many of the studies 
included and this was thought to explain the lack of evidence supporting higher LBR (Bontekoe 
et al, 2010). A 2014 meta-analysis on almost 10 000 embryo transfers carried out at various 
Japanese clinics further confirmed the findings of the Cochrane report evaluating the use of 
high concentrations of HA in embryo transfer medium (Hashimoto et al, 2014). The meta-
analysis concluded that the use of EmbryoGlue® as transfer medium resulted in a significant 
increase in both implantation and pregnancy rates. Miscarriage rates were not significantly 
different (Hashimoto et al, 2014).  
 
In 2014, the Cochrane Collaboration published an update of their previous meta-analysis also 
entitled “Adherence compounds in embryo transfer media for assisted reproductive 
technologies (Review)”. The updated review included 16 truly randomized controlled trials with 
a total of 3898 total participants.  Out of those included, 14 studies reported CPR as endpoint 
and 6 studies also included LBR. The use of EG for embryo transfer, when compared with the 
use of culture medium containing little or no hyaluronic acid, resulted not only in an 
improvement of successful implantation rates but also in an overall increase of 8% live birth 
rates, regardless of embryo transfer day (Bontekoe et al., 2014).  
 
However, a 2015 cohort study performed on 229 retrospectively enrolled patients found no 
significant improvement in ART outcomes after routine use of EG. Decreased abortion (15.8% 
vs. 19%) and increased multiple pregnancy rates (20.6% vs. 15.6%) in the study group were 
not statistically significant (Safari et al, 2015).  Patients in both groups were comparable in 
terms of etiology of infertility, history of implantation failure and rates of good quality embryos to 
limit confounding variables (Safari et al, 2015). Additional abstracts from oral and poster 
presentations at the American Society for Reproductive Medicine (ASRM) scientific congress & 
expo were published by Fertility and Sterility in September 2013 (Hambiliki et al, 2010; Said et 
al, 2013; Singh et al, 2015). A study from the Center for Reproductive Medicine of New Mexico, 
Albuquerque including 179 frozen embryo replacement cycles reported that the use of EG as 
post-thaw culture and transfer medium did not improve the measured clinical outcomes in 
frozen embryo replacement cycles (Said et al, 2013). The measured outcomes included clinical 
and ongoing pregnancy, and implantation rate per embryo transferred (Said et al, 2013). 
Another study investigating the addition of HA to embryo transfer media in cleavage-stage 
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frozen embryo transfers resulted in increased biochemical pregnancy and implantation rates 
but live birth rate remained unchanged (Hambiliki et al, 2010). 
 
A prospective case-control study conducted at the assisted reproductive centre of a tertiary 
care hospital involved 84 women undergoing fresh non-donor IVF or ICSI cycles (Singh et al, 
2015). In the control group (n=42), embryos were transferred to conventional blastocyst culture 
medium and those in the treatment group (n=42) were transferred into 50 μL of EG for 10 min 
prior to transfer inside the uterine cavity. In an effort to limit possible confounding factors the 
exclusion criteria included women age >35 years, those with poor ovarian reserve, and 
possible causes of failure of implantation such as diabetes mellitus, hypertension and 
autoimmune diseases. The resulting clinical pregnancy rate in the treatment group was 7% 
higher than that of the control group; the difference was not statistically significant (Singh et al, 
2015). A significant difference (p=0.04) in clinical pregnancy rate was observed in a subset 
(n=12) of treatment patients who had previous failed ART cycles. In the treatment group, 50% 
[6/12] of patients achieved successful implantation where none of the patients [0/11] in the 
control group did (Singh et al, 2015).  
 
The use of EG remains controversial among ART professionals, as it is difficult to conclude the 
favourable role of EG in treatment cycles of patients with good prognosis. The improvement in 
implantation rates observed in patients with previous failed cycles and recurrent implantation 
failure demands further investigation.  
 
The first phase of this study is a retrospective comparison between conventional ICSI and 
PICSI®; on various treatment outcomes. The second phase is a prospective study to determine 
the usefulness of a different HA product, EG, in a unique clinical setting.  
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1.3 The Process of Fertilization 
 
1.3.1 Capacitation 
 
An oocyte must undergo meiotic maturation and be in metaphase II in order to fertilize 
successfully. Similarly, a spermatozoon must also undergo a series of biochemical and 
physiological changes before it is able to initiate the process of fertilization (Küpker et al, 1998). 
In vivo, capacitation of the spermatozoon occurs upon exposure to the high quantities of 
extracellular ions. The female reproductive tract contains co-operative factors, such as Ca2+ 
and Na+ ions that drive the capacitation process resulting in functionally mature, mobile and 
fertile sperm (Suarez & Pacey, 2006). During capacitation, the functional coupling of signal 
transducing pathways destabilizes the spermatozoon’s plasma membrane. The removal and 
mobilization of several surface compounds, such as cholesterol and glycoproteins, also drives 
the capacitation process (Bailey, 2010). These biophysical membrane changes result in a 
hyperpolarization of membrane potential followed by the influx of extracellular bicarbonate. The 
increased intracellular bicarbonate stimulates adenyl cyclase resulting in increased production 
of signalling molecule Camp (Bailey, 2010). Cells respond by the rapid influx of extracellular 
calcium. During the capacitation process, membrane fluidity increases, the net surface charge 
is altered and there is the potential for fusion of the acrosomal membrane. In its capacitated 
state, the spermatozoon is able to respond to molecular signals from the oocyte and the 
cumulus-oocyte complex (COC) that surrounds it (Guraya, 2000). The capacitation process can 
also be induced with specialized synthetic media in an in vitro setting (Shih et al, 2016). 
 
 1.3.2 Hyperactivation 
 
The penetration of the COC causes changes in the frequency and pattern of the 
spermatozoon’s flagellar movement. The frequency of flagellar movement increases and 
patterns of movement become three-dimensional. This hyperactivation of motility aids the 
spermatozoon in penetrating the cumulus mass as it propels itself towards the oocyte (Ickowicz 
et al, 2012).  
 
 1.3.3 The Acrosome Reaction 
 
The acrosome reaction is an exocytotic process initiated by intracellular signals following 
spermatozoon interaction with the three glycoproteins, ZP1, ZP2 and ZP3, of the oocyte zona 
pellucida (ZP) (Brucker & Lipford, 1995). The influx of calcium ions and cytoplasmic 
alkalinisation during adhesion to the ZP are key intracellular signals responsible for the initiation 
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of the acrosome reaction and activation of receptors in the sperm head. During the acrosome 
reaction, the plasma membrane fuses with the outer acrosome membrane releasing the 
enzymatic contents of the acrosome that further aid in oocyte penetration and fusion (Brucker & 
Lipford, 1995). Hyaluronidase is one of the enzymes present during this reaction, it aids in the 
digestion of the cumulus complex that surrounds the oocyte (Ickowicz et al, 2012). Upon 
reaching the PVS the fusion receptors of the spermatozoon will begin to interact with the 
oolemma of the oocyte (Allen & Green, 1997). 
 
1.3.4 Sperm-Oocyte Binding and Fusion 
 
Located between the inner acrosomal membrane and the plasma membrane in the posterior 
region of the sperm head lies the equatorial segment of the spermatozoon, a key participant in 
the fusion reaction (Kaji & Kudo, 2004). Once this equatorial segment binds with microvilli 
covering the surface of the oocyte, except in the region of its meiotic spindle, the sperm 
nucleus is released into the ooplasm. Oocyte-activating proteins, such as oscillin that trigger 
calcium oscillations, are released during fusion when fertilization occurs normally (Wakai & 
Fissore, 2013).  During ICSI the fusion of the membrane is bypassed and damage to the sperm 
plasma membrane, prior to injection, instead allows sperm-associated oocyte activating factor 
(SAOAF) to exit the spermatozoon (Dozortsev et al, 1997). The disruption of the plasma 
membrane by immobilizing the spermatozoon before ICSI is necessary for fertilization to occur 
successfully (Yanagida et al, 2001). 
	
1.3.5 Chromatin structure, Fragmentation & Abnormality 
 
Spermatogenesis is the development of mature spermatozoa from primordial germ cells 
(Gunes et al, 2015). The functional maturity and fertilization capability of a spermatozoon are 
determined by the ability of its DNA repair mechanisms to maintain genomic integrity as it 
matures (Gunes et al, 2015). The three main origins of DNA damage in the 
male germline include; endogenous or exogenous reactive oxygen species (ROS) 
involving abasic sites, base modifications, single-strand and double-strand breaks and DNA 
proteins cross links (Torregrosa et al, 2006). Defects in sperm chromatin packaging can 
interfere with the protamination of sperm chromatin, the crucial replacement of histones 
by protamines, which protects its genome from oxidative damage in the harsh environment of 
the female reproductive tract (Ward, 2010). Protoamination also assists in the compaction 
required to fit the male haploid genome into the nucleus of each spermatozoon (Torregrosa et 
al, 2006). The final nuclear shape acquisition of the spermatozoon assists in the safe 
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and accurate transmission of the genetic information from the male to the oocyte in a usable 
format prior to fertilization (Agarwal & Said, 2003).  	
 	
A study examining sperm chromatin defects by flow cytometric sperm chromatin structure 
assay concluded that the probability of achieving pregnancy declines as a direct function of the 
percentage of sperm with defects in their chromatin structure (Spano et aI, 2000). Any DNA 
damage or abnormality may result in male infertility. Sperm with abnormal morphology may 
have functional receptor defects that would hinder their ability to bind with the glycoproteins on 
the surface of the oocyte (Agarwal & Said, 2003). 
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1.4 Advanced Methods of Fertilization 
 
1.4.1 The Development of intracytoplasmic sperm injection (ICSI) 
 
ICSI technique, is a micromanipulation fertilization technique routinely employed in modern 
assisted reproduction facilities globally. The technique was first applied to human gametes in 
the early 1990s (Tarlatzis & Bili, 1998) but its use was described in sea urchin studies as early 
as 1962 (Hiramoto, 1962). Live spermatozoa of three unique sea urchin species were 
microinjected into oocytes from the same respective species but no activation was reported in 
microinjected unfertilized eggs. Injected eggs were however successfully fertilized by 
insemination from their exterior (Hiramoto, 1962). The first mammalian application of ICSI, 
resulted in the live birth of 6 undersized experimental mouse fetuses (Lin, 1966). Ten years 
thereafter, human and hamster spermatozoa were microinjected into hamster oocytes but few 
oocytes survived the procedure (Uehara & Yanagimachi, 1976).  
 
Several alternative fertilization techniques were developed as it became apparent globally that 
the percentage of normally fertilized oocytes and number of embryos generated by 
conventional IVF was significantly lower when semen characteristics were below reference 
ranges in terms of concentration, motility and morphology (Tournaye et al, 2002).The first 
experimental technique was partial zona dissection (PZD). Sperm could easily enter the oocyte 
through the artificial opening to reach the oolemma but results were found to be unpredictable 
and therefore unreliable (Palermo et al, 1992). Subzonal insemination (SUZI) technique, 
involving the microinjection of few motile sperm through the zona pellucida (ZP) into the 
perivitelline space (PVS), soon followed. With approximately 20% normal fertilization of oocytes 
following SUZI, the majority of patients had only one or two embryos available for transfer per 
cycle. It was concluded that the pregnancy and live birth rates following both PZD and SUZI 
techniques were too low to implement in routine clinical practice (Palermo et al, 1992). In 1992, 
the Lancet published the first pregnancy and live birth data of treatment cycles where embryos 
were generated and replaced following the ICSI technique in humans (Palermo et al, 1992). 
Previous success with ICSI treatment had been exclusively in animal studies. IVF researchers 
in the USA and Singapore also conducted ICSI trials and although they observed greater 
fertilization rates than was demonstrated in PZD and SUZI and transferred cleavage stage 
embryos, no pregnancy was established (Lanzendorf et al, 1988). 
 
ICSI is effective in the treatment of a variety of male factors but in order to generate a normally 
fertilized embryo the spermatozoon selected for microinjection into an oocyte must have both a 
functional genome and a centriole (Bhattacharya et al, 2001). ICSI is usually performed with 
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ejaculated sperm when indicated for by poor motility, low concentration or poor morphology as 
well as oligoasthenoteratozoospermia (OAT), failed fertilization in IVF or even the presence of 
antisperm antibodies (Bhattacharya et al, 2001). In cases of obstructive azoospermia, such as 
the congenital absence of the vas deferens (CBAVD), or disturbances in spermatogenesis, 
sperm may be retrieved from the epididymis and testis. Testicular or epididymal biopsy may 
also be carried out for patients with non-obstructive azoospermia, post vasectomy patients, 
patients with severe impotence or paraplegic patients (Monga et al, 1999).  Depending on the 
physiology of the male partner, microsurgical epididymal sperm aspiration (MESA), 
percutaneous sperm aspiration (PESA) or testicular sperm extraction (TESE) open biopsy 
technique can be performed (Friedler et al, 1997). ICSI is also the preferred method of 
fertilization in cases involving human immunodeficiency virus and hepatitis C virus-
serodischordant couples with infected male partner to reduce the risk of transmission 
(Mencaglia et al, 2005). 
 
1.4.2 10 Years of ICSI: A Review 
 
In 2002, 10 years after the first live birth resulting from ICSI, a Serono Symposia International 
Conference on ICSI was held at the Vrije Universiteit Brussel (VUB). Healthcare professionals 
from around the globe gathered to review outcomes of several thousand ICSI cycles and to 
compare them with conventional in-vitro fertilization cycles. In terms of ovarian oocyte retrieval, 
fertilization, cleavage and implantation rates, ICSI results were comparable to conventional IVF 
as summarised in Table 1.1 (Van Steirteghem, Devroey & Liebaers, 2002).  
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Table 1.1 Comparing IVF and ICSI Outcomes in Europe in 1998. 
  
IVF 
 
ICSI 
 
Cycles started 
 
51 471 
 
34 576 
 
Aspirations 
 
46 474 
 
33 133 
 
Aspirations/ cycle started (%) 
 
90.3 
 
95.8 
 
Embryo transfers 
 
40 980 
 
30 460 
 
Embryos transferred/ aspiration (%) 
 
88.2 
 
91.9 
 
Pregnancies 
 
11 384 
 
8 419 
 
Pregnancies/ embryos transferred (%) 
 
27.8 
 
27.6 
 
Deliveries 
 
8 950 
 
6 510 
 
Deliveries/ cycle started (%) 
 
17.4 
 
18.8 
 
During the period reviewed, ICSI accounted for approximately 40% of treatment cycles 
according to reports published by IVF/ICSI registries. In 2002, a randomised controlled trial 
comparing IVF and ICSI for the treatment of non-male factor infertility followed the observation 
that there was a global tendency to use ICSI as the standard fertilization method even when 
sperm parameters were within normal reference ranges (Bhattacharya et al, 2001).  
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1.4.3 Physiologic Intracytoplasmic Sperm Injection (PICSI®) 
 
Physiologic intracytoplasmic sperm injection (PICSI®) involves the use of a specialised culture 
dish during the fertilization procedure (Huszar et al, 2007). A PICSI® dish has three microdots 
of hyaluronan (HA) attached to the bottom surface of its interior (Appendix VII). These HA dots 
provide an additional parameter whereby normal spermatozoa can be selected for injection 
(Huszar et al, 2007). Dr. Gabor Huszar of the Yale School of Medicine patented the PICSI® 
sperm selection devices after two decades of focussed research on potential biochemical 
markers of sperm maturity and development.  A biotech company, Biocoat, announced the 
FDA’s clearance of the new product, PICSI® dishes, in 2006 (Huszar et al, 2007). PICSI® 
dishes function on the principle that the HA receptors of functionally mature sperm will bind to 
areas of the dish coated with HA thereby improving the process of sperm selection by adding a 
basis for the assessment of sperm maturity (Huszar et al, 2007; Prinosilova et al, 2009).  
 
During spermiogenesis the hyaluronic acid binding sites on the surface of the spermatozoa are 
formed as the result of plasma membrane remodelling (Prinosilova et al, 2009). According to 
research, spermatozoa that are able to bind to solid-state hyaluronic acid have a chromatin 
structure with high DNA chain integrity associated with fertilization competence and normal 
chromosomal constitution (Yagni et al, 2010). Another 2010 study also concluded that the 
selection of spermatozoa using the PICSI® method leads to a higher number of spermatozoa 
without DNA fragmentation and resulted in a relative improvement of resultant embryo quality 
(Parmegiani et al, 2010a).  
 
The design of the study included three prospective studies where the main measured outcomes 
included; assessments of the DNA fragmentation rate and nuclear morphology of HA bound 
spermatozoa in comparison with non-bound spermatozoa. The authors reported reduced DNA 
fragmentation and improved nucleus normalcy compared with non-bound spermatozoa. The 
injection of bound spermatozoa also significantly improved both the development and quality of 
embryos in a randomized study (Parmegiani et al, 2010b). However, a 2014 Cochrane review 
of advanced sperm selection techniques for assisted reproduction included the evaluation of 
two randomized controlled trials with a total of 581 patients. The concluding remarks published 
in a summary of their findings stated that current evidence was insufficient to permit the 
evaluation of advanced sperm selection strategy effectiveness in ART. No statistically 
significant difference was reported between groups in terms of the following measured 
outcomes; fertilization rate, pregnancy rate, cleavage rate, embryo quality, implantation rate, 
spontaneous abortion and live birth rate (McDowell et al, 2014).  
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A systematic review and meta-analysis searched PubMed and Cochrane for studies, published 
up to June 2015, describing the clinical outcome of ICSI cycles in which spermatozoa were 
selected based on their ability to bind to hyaluronic acid (Beck-Fruchter et al, 2016). The only 
restriction applied to the search was species- humans. Only full-text articles, with control group 
and specified sperm selection technique were included. The Downs and Black Checklist 
(Downs & Black, 1998) was used to assess the quality of the seven studies included and meta-
analysis was done where data was available (Ciray et al, 2008; Van Den Bergh et al, 2009; 
Parmegiani et al, 2010a; Parmegiani et al, 2010b; Choe et al, 2012;  Majumdar & Majumdar, 
2013;  Worrilow et al, 2013). The fertilization rate could be calculated and compared in all 
seven studies, with more than 9700 injected oocytes in total. Meta-analytic pooling of all data 
indicated no association between HA based sperm selection technique and fertilization rate. 
Subgroup meta-analysis of the prospective studies also indicated no improvement in 
fertilization rate where HA binding was used to select sperm. Clinical pregnancy rate was 
calculated per cycle started and included nearly 1300 ART cycles. Meta-analytic pooling of data 
again revealed no association between sperm selection technique and pregnancy rate. 
Secondary outcomes measured included cleavage rate, which showed a significant difference 
in favour of conventional ICSI. Embryo quality, provided in only two studies from the same 
research group, demonstrated an improvement in embryo quality in the HA binding group. 
Miscarriage rates were comparable in conventional ICSI and PICSI® groups. Live birth rate 
was reported for three studies and meta-analysis showed no difference between the two 
groups. The available clinical literature simply does not support the use of HA binding assays in 
all ICSI cycles and the identification of patients that may benefit from PICSI® technique 
requires further investigation (Beck-Fruchter et al, 2016).   
 
1.4.4 Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) 
 
During conventional ICSI, spermatozoa are viewed and selected under 400 times magnification 
(Antinori et al, 2008). At this magnification, spermatozoa with subtle nuclear morphological 
malformations carrying various structural abnormalities may be classified as normal. The 
described limitations of ICSI were alleviated by a method of motile sperm organellar 
morphology examination (MSOME) at 1,500 times magnification introduced by Bartoov et al in 
2001. An optical magnification of up to 1,500 times allows real time fine nuclear morphology 
assessment on motile spermatozoa (Bartoov et al, 2001). The high power differential 
interference contrast optics of an inverted microscope may be further enhanced by digital 
imagining to provide up to 6,000 times magnification (Bartoov et al, 2001). Oocyte 
microinjection using MSOME criteria is referred to as Intracytoplasmic morphologically selected 
sperm injection (IMSI). A normal nucleus has been defined as having an oval shape with 
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smooth configuration and less than four percent occupied by vacuoles. A nucleus comprised of 
greater than four percent vacuoles likely indicates poor chromatin integrity. Specific 
malformations indicating structural subcellular sperm abnormalities may involve the acrosome, 
the postacrosomal lamina, the nucleus, the neck, tail and the mitochondria (Bartoov et al, 
2002). Acrosomal abnormalities include a partial or vesiculated acrosome, or spermatozoa may 
entirely lack an acrosome and postacrosomal lamina. Nuclear abnormalities may be identified 
as being undersized, enlarged, short or locally disordered (Berkovitz et al, 2005).  Immaturity 
may be indicated by the presence of a cytoplasmic droplet in the neck region. The absence of a 
tail, a coiled or broken tail, multiple tails or an abnormally short tail relative to head and 
midpiece size is also considered abnormal (Berkovitz et al, 2005).  
 
Matched control comparison studies have found that the most important factor influencing ICSI 
outcome is the presence of a morphologically normal sperm nucleus (Bartoov et al, 2002; 
Berkovitz et al, 2005 & 2006). A prospective randomized trial further assessed the usefulness 
and possible advantages of the IMSI technique over conventional ICSI. Treatment group 
outcomes were compared in terms of pregnancy, miscarriage and implantation rates and found 
that IMSI resulted in a significantly (p=0.004) higher pregnancy rate (39.2%) over ICSI (26.5%) 
when applied to cases of severe male factor infertility (Antinori et al, 2008). Patients with two or 
more failed treatment cycles had a pregnancy rate of 29.8% following IMSI versus a 12.9% 
pregnancy rate following ICSI (p=0.017). Miscarriage rates were also significantly reduced in 
the same subgroup following IMSI treatment (17.4% versus 37.5%) (Antinori et al, 2008). The 
clinical outcomes of the IMSI treatment group suggest that IMSI may improve IVF success 
rates in a selected group of patients with male factor infertility. However, a randomized sibling-
oocyte study including 350 ICSI cycles to alleviate male infertility was one of a number of 
studies that found no difference in oocyte fertilization rate nor in embryo development between 
IMSI and conventional ICSI cycles (De Vos et al, 2013). A literature review of MSOME and 
IMSI techniques included twelve years’ worth of data (Setti et al, 2013) and concluded that 
when conventional ICSI was compared with IMSI outcomes, IMSI consistently outperformed 
ICSI in terms of the percentage of top-quality embryos generated, implantation and pregnancy 
rates as well as reducing miscarriage rates (Setti et al, 2010). A Cochrane Review evaluated 
only truly randomized controlled trials (RCT) comparing ICSI and IMSI and concluded that 
results from RCTs do not support the clinical use of IMSI (Teixeira et al, 2013). The evidence 
for improved clinical pregnancy was considered to be of very low quality and no evidence of 
effect on live birth or miscarriage rates was found (Teixeira et al, 2013). 
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1.5 Aim & Objectives  
 
Aim 
 
The aim of this study was to evaluate two HA products: PICSI® dishes (MidAtlantic Devices, 
Origio, Harrilabs, South Africa) and EmbryoGlue® (EG) (VitroLife, Kat Medical, South Africa) at 
the Drs Aevitas Fertility Clinic, Pinelands. 
 
Objectives 
 
A retrospective record review evaluated the ART outcomes of patients treated with PICSI® in 
comparison with traditionally employed ICSI and IVF techniques [2013-2015].  
 
Primary objective 
To compare the OPR between the PICSI and ICSI groups using the IVF patient group as 
control. 
 
Secondary objective  
To compare the fertilization rate, embryo quality rate [day 2, 3 and 5] and miscarriage rate 
between the PICSI and ICSI groups using the IVF patient group as control. 
 
- patient demographics (female age, number of oocytes aspirated, embryo quality and number 
of embryois transferred) were included in the analysis. 
 
This comparison will allow it to be determined whether there is a statistically significant 
improvement in ART outcome in Drs. Aevitas Fertility Clinic, when PICSI® dishes were used to 
select spermatozoa for injection. 
 
A prospective study was done to evaluate the ART outcomes of patients who underwent 
embryo transfer (September 2015-May 2016) with EG in comparison with a historically similar 
patient population who underwent embryo transfer with traditionally employed culture media 
(Cleavage or Blastocyst Medium, Quinn’s Advantage Medium, SAGE) at the same clinic in 
2014.  
 
Primary objective 
To compare the CPR between the EG transfer patient group and standard transfer patient 
group. 
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Secondary objective  
To compare the fertilization rate, embryo quality rate [day 2, 3 and 5] and miscarriage rate 
between EG transfer patient group and standard transfer patient group 
 
 - patient demographics (female age, number of oocytes aspirated, embryo quality and number 
of embryois transferred were included in the analysis,  
 
This comparison will allow it to be determined whether there is a statistically significant 
improvement in ART outcome, in Drs. Aevitas Fertility Clinic, when the use of EG is 
implemented as standard protocol. These results will inform future use of HA products to 
improve patient treatment outcomes in the clinic. 
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1.6 Hypotheses  
 
Retrospective study 
 
The patients in the PICSI® treatment group are expected to have significantly improved 
outcomes in terms of fertilisation rate, embryo quality rate [day 2, 3 and 5], OPR and 
miscarriage rate when compared with the ICSI treatment group using an IVF group as a 
control. 
 
Prospective study 
The implementation of EG used as an embryo transfer medium will result in a significant 
increase in CPR while reducing miscarriage rate compared to the historically similar group with 
standard embryo transfer medium. 
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Chapter 2 
 
Retrospective Study: The Comparison of PICSI ® vs. ICSI on ART outcome 
 
2.1 Materials & Methodology  
 
2.1.1 Study Population 
 
o All PICSI®, ICSI and IVF ART cycles on the clinic spread sheet [2014-2015] – 
including oocyte donor cycles 
 
§  Exclusion criteria: 
•  < 3 MII ova 
• <  3 embryos on day 2 
•  No clinical pregnancy result 
• Female age ≥38  
• HIV or Hepatitis B positive patients 
• Frozen Embryo Transfer (FET) cycles 
• Some male factors (Testis Biopsy & OATS) 
• Cycles that made use of more than one fertilization technique 
 
The exclusion criteria were designed to further lessen all possible confounding factors. Patients 
with less than 3 mature ova retrieved or less than 3 embryos on Day 2 of culture were excluded 
based on poor prognosis associated with such a low number of available ova. The known effect 
of advanced maternal age was limited by excluding female patients over age 38. Patients with 
HIV or Hepatitis B were not included on the basis that their health status may influence their 
ability to achieve pregnancy. Male patients who underwent testis biopsy to retrieve sperm or 
were diagnosed with oligoasthenoteratozoospermia (OAT) were excluded from the study to 
limit the influence of immunological factors and known poor prognosis. Frozen embryo transfer 
cycles could not be assessed as data regarding the cycle from which the embryos arose was 
incomplete in terms of embryo quality on specific days evaluated and total number of ova 
available following aspiration. Patients for whom clinical pregnancy results were unavailable 
could not be included as this was one of the primary outcomes measured in the study. Patient 
cycles that made use of more than one fertilization technique were excluded as fertilization 
method determined the grouping of patients. 
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2.1.2 Study Design  
 
A retrospective record review: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ICSI GROUP PICSI® GROUP 
Confounding Factors: 
 
-Female Age (Age of Ova) 
-Total number of available ova per patient 
-Number of mature ova available per patient 
-Number of Embryos Transferred 
-Number of Good Quality Embryos Transferred 
-Donor ova 
-Surrogacy status 
 
Outcomes Measured: 
 
-Fertilization Rate (%) 
-Embryo Quality [Day 2, 3 & 5] 
-Ongoing Pregnancy Rate (%) 
-Miscarriage Rate (%) 
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2.1.3 Study Objectives 
 
 
Primary objective 
To compare the OPR between the PICSI and ICSI groups using the IVF patient group as 
control. 
 
Secondary objective  
To compare the fertilization rate, embryo quality rate [day 2, 3 and 5] and miscarriage rate 
between the PICSI and ICSI groups using the IVF patient group as control. 
 
- patient demographics (female age, number of oocytes aspirated, embryo quality and number 
of embryois transferred) were included in the analysis. 
 
2.1.4 Definitions of Pregnancy & Miscarriage  
 
For this retrospective study, pregnancy is presented as ongoing pregnancy (OP) and is defined 
as the presence of fetal heart with or without final outcome after 20 weeks gestation. Ongoing 
pregnancy rate [OPR] is expressed per embryo transfer [%].  
 
Miscarriage was definied as the spontaneous loss of a clinical pregnancy that occurs before 20 
completed weeks of gestational age (18 weeks post fertilization) (Zegers-Hochschild et al, 
2009). Miscarriage rate was expressed per transfer [%].  
 
2.1.5 Data Management & Statistical Analysis 
 
All relevant data from eligible PICSI® and ICSI cycles was captured and stored on a spread 
sheet similar to that of the standard clinic database. 
 
The confounders assessed, to ensure that the ICSI and PICSI® groups were not statistically 
significantly different, include; age of ova, total number of ova available per patient, number of 
mature ova available per patient, number of embryos transferred, number of good quality 
embryos transferred. The effect of donor ova and surrogacy status was also assessed.  
 
The outcomes measured and compared between the two groups included; fertilization rate (%), 
embryo quality [Day 2, 3 & 5], clinical pregnancy rate (%) and miscarriage rate (%). The IVF 
group was used as reference unless otherwise indicated. 
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Data captured included:  
 
1. Ongoing pregnancy rate [OPR]  
2. Miscarriage rate  
3. Ova age (not female recipient age) 
4. Total number of ova retrieved 
5. Number of mature (metaphase II) ova retrieved 
6. Fertilization rate – ova fertilized/ MII ova retrieved [%] 
7. Number of good quality embryos (GQE) on day 2, 3 and 5 respectively 
8. Total number of embryos transferred 
9. Number of good quality embryos (GQE) transferred 
10. Cycle number of treatment 
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2.1.6 Procedures  
 
Ovarian stimulation 
Female partners underwent controlled ovarian hyper-stimulation according to standardized 
stimulation protocols. The appropriate stimulation protocol is determined based on patient 
presentation and medical history, namely; diagnosis, physiology, endocrinology and age. 
Standard stimulation protocols include; i. Short Protocol, ii. Long  Protocol, iii. Natural Cycle, iv. 
Modified Natural Cycle and v. Antagonist Protocol. Stimulation protocol sub-types were 
designated individualized codes for the purpose of accurate data collection. 
 
Stimulation involves administration of gonadotrophin-releasing hormone agonist (GnRHa) 
followed by human menopausal gonadotrophins (HMG) and/or pure follicle stimulating hormone 
(FSH) from cycle day 3. Follow-up procedures included estradiol determinations and 
ultrasonographical measurements of the Graafian follicle. Once the leading follicle had reached 
a diameter of 18mm. Human chorionic gonadotropin (HCG) was administered to induce 
ovulation. 
 
Aspiration and gamete handling 
Standard procedures were used [Appendix III & XII]. 
 
Semen preparation 
Sample characteristics such as sperm count and motility determined the semen preparation 
method used. Standard wash and swim-up techniques, using HEPES buffered sperm 
preparation medium, were used to isolate motile spermatozoa during semen preparation when 
possible. Gradient (90%, 45%) centrifugation method was used for samples with parameters 
below reference ranges as determined by the World Health Organisation (WHO, 2010). 
[Appendix XI]. 
 
ICSI Method 
Refer to Appendix I & II. 
 
PICSI® Method 
Refer to Appendix VII. 
 
IMSI Method 
Refer to Appendix VIII. 
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Embryo culture and evaluation 
Standard protocol descriptions for Embryo Culture & evaluation can be observed in Appendix 
III. 
 
Embryo transfer 
Standard protocol was used. Embryos selected for transfer were placed in 1ml CO2 
equilibrated, warmed [37°C] culture medium (Cleavage or Blastocyst medium, SAGE) before 
embryo transfer. Thereafter standard routine embryo transfer protocol was followed. [Appendix 
XIV] 
 
Embryo Quality 
Embryo quality was evaluated according to standard protocol in the clinic based on the work of 
Veeck, 1999 & Veeck et al,  2003. [Appendix IV].  Blastocyst grading is according to a modified 
Gardner & Schoolcraft grading system [Appendix V]. 
 
Embryo Vitrification & Warming 
Refer to Appendix XIII. 
Pregnancy 
Ongoing pregnancy (OP) is defined as the presence of fetal heart with or without final outcome 
after 20 weeks gestation for the purposes of the study. Ongoing pregnancy rate [OPR] is 
expressed per embryo transfer [%].  
 
Miscarriage 
Miscarriage was definied as the spontaneous loss of a clinical pregnancy that occurs before 20 
completed weeks of gestational age (18 weeks post fertilization) (Zegers-Hochschild et al, 
2009). Miscarriage rate was expressed per transfer [%]. 
 
Consent Forms 
Waiver of consent was approved by the Health Research Ethics Committee (Ethics Reference 
#: S15/03/052). 
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2.2 Results  
 
2.2.1 Patient Population 
The patient population included in the retrospective study was comprised of 388 patients. The 
respective sample sizes of relevant procedure groups were as follows; 41 IVF patients, 184 
ICSI patients and 163 PICSI® patients. The exclusion criteria were designed to eliminate 
variables other than the fertilization method (ICSI or PICSI®) that could potentially have 
influenced treatment outcomes. The comparison of PICSI® and ICSI treatment groups was the 
primary focus of this portion of the study. Cycles that made use of more than one fertilization 
technique, such as those where the number of ova retrieved for a single patient were divided 
into IVF and ICSI groups, were excluded from the analysis to limit confounding factors. The IVF 
treatment group was used as the reference group in the regression analyses but the estimated 
contrast between PICSI® and ICSI treatment groups was the main objective.   
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2.2.2 Potential Confounders 
 
To ensure an unbiased comparison between the ICSI and PICSI® treatment groups, 
adjustments were made for confounders. A comparison between the treatment groups with 
respect to potential confounders are provided in Table 2.1 and graphical presentation using 
side-by-side boxplots are provided in Figures 3.1 - 3.4. 
 
Table 2.1 Descriptive statistics and comparison of potential confounders for the three 
treatment groups; PICSI® and ICSI (ref IVF). 
 
Variable IVF (n=41) 
Mean (SD) 
PICSI® (n=163) 
Mean (SD) 
ICSI (n=184) 
Mean (SD) 
p-value 
 
Age of ova (years) 
 
30.732 (4.64) 
 
30.767 (4.62) 
 
29.913 (5.10) 
 
0.229 
 
Total ova (number) 
 
11.9 (7.3) 
 
12.9 (7.7) 
 
13.7 (7.6) 
 
0.344 
 
Mature ova (number) 
 
10.6 (6.2) 
 
10.9 (6.6) 
 
11.0 (6.2) 
 
0.936 
Total Transferred 
(number) 
 
2.07 (0.57) 
 
1.97 (0.56) 
 
2.14 (SD ± 0.74) 
 
0.05981 
GQE Transferred 
(number) 
 
1.65 (0.70) 
 
1.56 (0.76) 
 
1.62 (SD ± 0.80) 
 
0.5361 
 
1: chi-square test 
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Age of Ova  
 
A box and whisker plot in Figure 2.1 illustrates the mean age of ova, within each of the defined 
treatment groups. To account for those patients making use of donor ova, the age of ova was 
used rather than the age of female patient being treated. Each box represents the distribution 
of all ova ages among patients in respective group; the horizontal line within each box indicates 
the median or 50th percentile of the given group. The bottom margin of each box further 
represents the 25th percentile and the top margin represents the 75th percentile. Mean ova 
ages where: 30.73 (SD ± 4.64) years among IVF patients, 30.77 (SD ± 4.62) years among 
PICSI® patients and 29.91 (SD ± 5.10) years among ICSI patients (Table 2.1). An analysis of 
variance (ANOVA), which looks at intergroup and intragroup variability, found no significant 
difference, as indicated by an adjusted p value of 0.229 (significance is indicated by p= <0.05). 
 
	
 
Figure 2.1 A box plot illustrating the distribution of patient ages within respective procedure 
groups evaluated; PICSI® and ICSI (ref IVF). 
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Total Number of Ova Per Patient 
 
A box and whisker plot in Figure 2.2 illustrates the mean number of ova retrieved per patient. 
The number of total ova retrieved per patient was very similar among IVF, ICSI and PICSI® 
groups. The means are 11.9 (SD ± 7.3) ova per IVF patient, 12.9 (SD ± 7.7) ova per PICSI® 
patient and 13.7 (SD ± 7.6) ova per ICSI patient (Table 2.1). Points plotted on the graph 
represent single events that are outlying in this distribution. These events are likely accounted 
for by patients that experienced ovarian hyperstimulation syndrome (OHSS) or patients with 
polycystic-ovarian syndrome (PCOS). There was no significant difference as indicated by an 
adjusted p value of 0.344 (ANOVA).  
 
 
 
Figure 2.2 A box plot illustrating the total number of ova retrieved per patient within 
respective treatment groups; PICSI® and ICSI (ref IVF). 
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Number of Mature [MII] Ova Per Patient 
 
The number of mature, Metaphase II, ova retrieved per patient within each treatment group is 
represented as a box and whisker plot (Figure 2.3). Mean numbers of mature ova retrieved 
where: 10.6 (SD ± 6.2) ova per IVF patient, 10.9 (SD ± 6.6) ova per PICSI® patient and 11.0 
(SD ± 6.2) ova per ICSI patient (Table 2.1). The mean number of mature ova retrieved per 
patient among treatment groups and found no significant difference, as indicated by an 
adjusted p-value of 0.936 (ANOVA).  
 
 
 
Figure 2.3 A box plot illustrating the number of mature, Metaphase II, ova retrieved per 
patient within respective treatment groups; PICSI® and ICSI (ref IVF). 
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Embryos Transferred 
 
The total number of embryos transferred per patient for IVF, PICSI® and ICSI treatment groups 
respectively is represented in Table 2.2. The mean number of GQE transferred is two in all 
three procedure groups (Figure 2.4).  A chi-square test comparing proportional profile between 
treatment groups was not significant (p=0.0598).  
 
Table 2.2 Number of embryos transferred per patient in respective groups; PICSI® and 
ICSI (ref IVF). 
 
Number Transferred IVF  PICSI® ICSI 
1 2 (4.88%) 10 (6.13%) 6 (3.26%) 
2 31 (75.61%) 130 (79.75%) 137 (74.46%) 
3 7 (17.07%) 17 (10.43%) 32 (17.39%) 
4 0 (0.00%) 0 (0.00%) 0 (0.00%) 
5 0 (0.00%) 0 (0.00%) 1 (0.54%) 
6 0 (0.00%) 0 (0.00%) 2 (1.09%) 
Total: 41 (100.00%) 163 (100.00%) 184 (100.00%) 
 
Patients in the ICSI group tended to have more embryos transferred compared to patients in 
the PICSI® treatment group. In the ICSI group, 19% of patients had more than two embryos 
transferred whereas only 10% of PICSI® patients had more than 2 transferred (Table 3.2). A 
Fishers exact confirmed no significant overall difference in group profiles (p=0.536)  
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Figure 2.4  A box plot illustrating the number of GQE transferred per patient within 
respective treatment groups; PICSI® and ICSI (ref IVF). 
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2.2.3 Measured Outcomes  
 
Based on the hypothesis, patients in the PICSI® treatment group were expected to have better 
outcomes in terms of fertilisation rate, embryo quality rate [day 2, 3 and 5], ongoing clinical 
pregnancy rate, and miscarriage rate when compared with the ICSI treatment group. The 
measured outcomes summarized in Table 2.3 show no statistically significant differences 
between PICSI® and ICSI treatment groups. The absolute number of mature ova fertilized per 
patient was comparable in PICSI® and ICSI groups, as well as the fertilization rate. The 
estimated median difference in fertilization rate between ICSI and PICSI® is 3.1% (95% CI: -2.0 
to 8.3%), p=0.226. Although not statistically significant, PICSI® or ICSI fertilization technique 
did have a marginal effect on the rate of successful fertilization. The differences in the 
proportion of good quality embryos resulting from PICSI® and ICSI were not statistically 
significant on embryo culture days 2, 3 or 5. In testing for overall procedure effect without using 
IVF as reference, the calculated risk difference of PICSI® compared with ICSI was 7.6% (95% 
CI: -3.1 to 18.3%). A 7.6% lower clinical pregnancy rate in the PICSI® treatment group, was 
found not to be significant (p=0.164). Finally, a Fishers exact indicated no statistical significant 
difference in the miscarriage rates among ICSI and PICSI® treatment groups (p=0.779). 
 
Table 2.3 Comparison of the measured outcomes for the respective groups; PICSI® and 
ICSI (ref IVF). 
 
Variable IVF (n=41) 
Mean (SD) 
PICSI® (n=163) 
Mean (SD) 
ICSI (n=184) 
Mean (SD) 
p-
value 
Number ova Fertilized 8.6 (5.1) 8.3 (5.0) 8.8 (5.1) 0.6853 
Fertilization Rates (%) 0.837 (0.2) 0.774 (0.2) 0.804 (0.2) 0.0799 
Embryo Quality Day 2 (%) 0.65 (0.2) 0.54 (0.2) 0.56 (0.2) 0.318 
Embryo Quality Day 3 (%) 0.46 (0.2) 0.39 (0.2) 0.40 (0.2) 0.597 
Embryo Quality Day 5 (%) 0.24 (0.2) 0.21 (0.2) 0.23 (0.2) 0.120 
OPR (%) 53.66% [22/41] 40.40% [61/151] 48.33% [87/180] 0.196 
Miscarriage Rate (%) 2.44% [1/41] 5.52% [9/163] 4.35% [8/184] 0.779 
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Number Fertilized 
 
The number of mature, Metaphase II, ova that successfully fertilized per patient is represented 
as a box and whisker plot in Figure 2.5. Mean numbers of mature ova fertilized were 8.6 (SD ± 
5.1) ova per IVF patient, 8.3 (SD ± 5.0) ova per PICSI® patient and 8.8 (SD ± 5.1) ova per ICSI 
patient (Table 2.3). The mean number of mature ova fertilized per patient among treatment 
groups was compared by ANOVA and there was no significant difference (p= 0.6853).  
 
 
 
Figure 2.5  A box plot illustrating the number of mature ova fertilized per patient within 
respective treatment groups; PICSI® and ICSI (ref IVF). 
0
10
20
30
40
FE
R
TM
II
IVF PICSI ICSI
N
um
be
r o
f  
M
II 
 O
va
  F
er
til
iz
ed
 P
er
 P
at
ie
nt
 
IVF PICSI 
 
ICSI 
p50=8  
p50=7   p50=7  
*p50=median 
Stellenbosch University  https://scholar.sun.ac.za
  45 
Fertilization Rate 
 
The fertilization rates of available MII ova were 83.7% [201/240] in the IVF group, 77.4% 
[1298/1677] in the PICSI® group and 80.4% [1211/1506] in the ICSI group (Table 2.3). The 
points plotted below the whiskers represent cases of complete fertilization failure (Figure 2.6). 
The mean fertilization rates of MII ova among treatment groups was compared by ANOVA and 
there was no significant difference (p=0.0799).  
 
 
 
Figure 2.6  A box plot illustrating the probability, between 0 and 1, of successful fertilization 
occurring in available MII ova among respective treatment groups; PICSI® and 
ICSI (ref IVF). 
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of 0.0811 indicated no group effect. Estimating the specific contrasts, the estimated median 
difference in fertilization between IVF and PICSI® is 9.2% (95% CI: 0.9% to 17.5%) with 
PICSI® lower than IVF. A p value of 0.029 confirms that the difference is significant. The 
estimated median difference in fertilization between IVF and ICSI of 6.1% (95% CI: -2.2% to 
14.3%) with ICSI lower than IVF, was not significant (p=0.148). The estimated median 
difference in fertilization rate between ICSI and PICSI® is 3.1% (95% CI: -2.0 to 8.3%), 
p=0.226. There was no significant difference in fertilization rate of MII ova between PICSI® and 
ICSI techniques.  
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Embryo Quality Rate 
 
The box and whisker plot (Figure 2.7) based on raw data contains descriptive statistics that 
serves to illustrate the tendency of a decline in number of good quality embryos during the 
culture period regardless of fertilization technique employed. Points plotted beyond the 
whiskers of the box plot represent cases with a large number of ova available at the given time 
point.  
 
 
 
 
Figure 2.7  A box plot illustrating the absolute number of GQE, based on specified criteria, 
on embryo culture days 2, 3 and 5 within each treatment group; PICSI® and 
ICSI (ref IVF). 
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[51/219] good quality on day 5. The profiles of ICSI and PICSI® are nearly identical across all 
days evaluated and very similar to the IVF control group (Figure 2.8). 
 
 
 
Figure 2.8  A box plot illustrating the percentage of GQE at each time point for respective 
treatment groups; (PICSI® and ICSI (ref IVF)) over all embryo culture days of 
study (Day 2,3 & 5). 
 
A two-sample t test, with equal variances, compared the proportions of good quality embryos 
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significant. 
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Table 2.4  Comparison of GQE rate between PICSI® and ICSI groups. 
 
Day Sample 
Size 
PICSI® Sample 
Size 
ICSI Mean 
Difference 
95% 
Confidence 
Intervals 
p-value 
2 160 0.54 177 0.56 -0.02 -.06 to.02 0.318 
3 160 0.39 176 0.40 -0.01 -.06 to .03 0.597 
5 120 0.21 135 0.25 -0.03 -.8 to .01 0.120 
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Ongoing Pregnancy Rates (OPR) 
 
The OPR were 53.66% [22/41] in the IVF treatment group, 48.33% [87/180] in the ICSI 
treatment group and 40.40% [61/151] in the PICSI® treatment group and the intergroup 
differences observed were not significant (p=0.196) (Table 2.3). These OPR are represented 
as a bar chart in Figure 2.9. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9  A bar chart showing the OPR of the three respective treatment groups; PICSI® 
and ICSI (ref IVF). 
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Difference=Surrogate Not Used/ Surrogate Used) was not significant (p=0.849). In terms of the 
number of available mature ova per patient the risk ratio was 0.7% p=0.064. 
 
In testing for overall procedure effect without using IVF as reference, the calculated risk 
difference of PICSI® compared with ICSI was 7.6% (95% CI: -3.1 to 18.3%). A 7.6% lower 
OPR in the PICSI® treatment group, was not significant (p=0.164).  
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Miscarriage Rates 
 
The miscarriage rate for the IVF treatment group was 2.44% [1/41], 4.35% [8/184] in the ICSI 
treatment group and 5.52% [9/163] in the PICSI® treatment group (Table 2.3 & Figure 2.10). 
The study used a unified definition of pregnancy loss for all types of miscarriages, at various 
stages of pregnancy, to form a single binary outcome. A Fishers exact indicated no statistical 
significant difference in the miscarriage rates among IVF, ICSI and PICSI® treatment groups 
(p=0.779). 
 
 
 
 
 
Figure 2.10  A bar chart showing the miscarriage rates for each of the three respective 
treatment groups; PICSI® and ICSI (ref IVF). 
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2.3 Discussion  
 
The study found no significance in terms of fertilization rate, number of good quality embryos 
on day 2, 3, or 5 nor in OPR or miscarriage rates between PICSI® and ICSI. Although not 
statistically significant, ICSI outcomes were consistently superior compared with PICSI® in all 
measured outcomes.  
 
Confounding Factors 
 
To ensure that the ICSI and PICSI® groups could be compared statistically, the following 
potential confounding factors were assessed with the appropriate statistical tests; age of ova, 
total number of ova, number of mature ova available per patient, total number of embryos 
transferred and number of good quality embryos transferred. The effect of donor ova use and 
surrogacy status were also assessed. Statistical analyses with p-values of <0.05 were 
considered statistically significant. When interpreting statistical findings, it is important to note 
that the failure to detect statistically significant differences does not simply imply equivalence. 
An inadequate sample size can result in the failure to detect a difference (Cleophas & 
Zwinderman, 2012). In other instances, although detected, a statistically significant difference 
may not have clinical significance. We are confident that the reported outcomes were mainly 
due to fertilization (ICSI and PICSI®) technique. 
 
The factors identified and analysed as potential confounders were based on relevant literature. 
Age of ova (female age) was identified as a potential confounder based on the vast body of 
literature that exists to demonstrate an age-dependent decline in female fertility (Steiner & 
Jukic, 2016). The following age-related abnormalities affect the developmental competence of 
oocytes. Meiotic incompetence or inability to complete meiotic maturation could result in 
oocytes incapable of fertilization. Errors in meiosis that are compatible with fertilization may 
lead to compromised embryo viability and genetic abnormalities.  Cytoplasmic deficiencies, 
expressed in various stages before or after fertilization, also become more common with 
advancing age (Armstrong, 2001). Maternal aging-associated oocyte aneuploidy is equally well 
documented (Kuliev et al, 2003). Oocyte donation has the potential to extend the reproductive 
potential in women of advanced reproductive age. Studies have reported improved outcomes 
with regard to fertilization rates, number of embryos transferred, embryo implantation rate and 
clinical pregnancy rates in women below 40 years of age (Sauer et al, 1990 & 1992). Donor 
status therefore also needed to be accounted for in statistical workings for patients making use 
of oocyte donation due to premature ovarian failure or advanced maternal age. In the current 
study oocyte age was not significantly different between the ICSI and PICSI® groups (30.8 and 
29.9 years respectively) and had therefore no impact on the pregnancy or miscarriage rates. 
Stellenbosch University  https://scholar.sun.ac.za
  54 
The total number of available ova per patient was identified as a potential confounder as 
studies have documented the association between number of eggs and live birth rate in IVF 
treatment. All IVF cycles performed in the UK from 1991 to 2008 were analysed to produce a 
nomogram to predict the live birth rate following IVF based on the number of eggs and the age 
of the female. The number of eggs shown to maximize live birth rate is 15 (Sunkara et al, 
2011). The number of mature ova available per patient is also a predictor of outcome and 
although immature oocytes retrieved have the potential to mature in vitro and to fertilize 
normally, studies have illustrated that resultant embryos are of poorer quality and have reduced 
implantation potential compared to their mature counterparts (Reichman et al, 2010). Embryos 
derived from in vitro matured oocytes have also been observed to have particularly high 
aneuploidy rates, mainly complex mosaics (Strassburger et al, 2010). In the current study, the 
total number of ova and the number of mature ova were not significantly different between the 
ICSI and PICSI® groups (13.7 vs. 12.9 and 11.0 vs. 10.9 respectively) and therefore had no 
impact on the pregnancy or miscarriage rates. 
 
The total number of embryos transferred was assessed based on findings that elective single 
embryo transfers result in a lower pregnancy rate than a double embryo transfer in a fresh 
cycle (Martikainen et aI, 2001). Based on a systematic review of the Cochrane Central Register 
of Controlled Trials, elective single embryo transfers are however associated with a higher 
chance of delivering a term singleton live birth compared with double embryo transfer 
(McLernon et al, 2010). The multiple pregnancy rate after elective single embryos transfers is 
comparable with that observed in spontaneous pregnancies and is an important consideration 
to support efforts in reducing dizygotic twin rates in ART (Thurin et al, 2004). In the current 
study, the number of embryos transferred was not significantly different between the ICSI and 
PICSI® groups (2.14 vs. 1.97) and had therefore no impact on the pregnancy or miscarriage 
rates. 
 
The quality of embryos transferred was assessed, as blastocyst grading remains the greatest 
predictor of developmental potential, successful implantation and embryo transfer outcome 
(Balaban et al, 2000). The graduated embryo score predicts blastocyst formation and 
pregnancy rate from cleavage-stage embryos (Fisch et al, 2001) and transfer of good quality 
embryos results in increased pregnancy rates (Rienzi et al, 2005). In the current study, the 
number of good quality embryos transferred was also not significantly different between the 
ICSI and PICSI® groups (1.62 vs. 1.56) and had therefore no impact on the pregnancy or 
miscarriage rates. 
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Benefit of PICSI® for Sperm Selection 
 
 
For sperm used in ICSI fertilization, current sperm selection techniques depend solely on 
sedimentation (gradient centrifugation) or migration of the sperm (swim-up) in combination with 
morphological assessment. Important characteristics such as DNA integrity, apoptosis, 
membrane maturation and ultrastructure of the spermatozoa are not considered (Said & Land, 
2011). The use of specialized PICSI® culture during the fertilization of oocytes provides an 
additional parameter for the selection of normal spermatozoa. The binding of spermatozoa to 
the hyaluronic acid microdots on the bottom surface of the dish serve as a biochemical marker 
to identify functionally and developmentally mature spermatozoa for injection (Huszar et al., 
2006. 2007, 2012).  Spermatozoa able to bind to the hyaluronic acid have a chromatin structure 
with high DNA chain integrity associated with fertilization competence and normal chromosomal 
constitution (Yagni et al, 2010). The use of PICSI® dish spermatozoa culture during the 
fertilization of oocytes provides an objective parameter in the evaluation and selection of 
spermatozoa for injection, minimizing inter- and intra-individual variation. The operator must still 
assess the morphological features of the bound spermatozoa to select a single spermatozoon 
for injection. Use of the PICSI® technique is not appropriate for patients with below normal 
sperm concentration and/or motility as the effectiveness of the dish depends on the mobility of 
spermatozoa to reach and bind to the microdots.  
 
Comparison of Results with the Relevant Literature 
 
 
PICSI® and Fertilization Rate 
 
The results of the current study showed no significant improvement in fertilization rate for 
PICSI® over ICSI (77.4% vs 80.4%, respectively). 
 
The literature reporting on fertilization and PICSI® is contradictory. According to research, 
spermatozoa able to bind to solid-state hyaluronic acid have a chromatin structure with high 
DNA chain integrity associated with fertilization competence and normal chromosomal 
constitution (Yagni et al, 2010). However, a 2014 Cochrane review reported no statistically 
significant difference in fertilization rate for PICSI® over other fertilization methods (McDowell 
et al, 2014). A recent 2016 meta-analysis was published by Beck-Fruchter et al. This 
systematic review and meta-analysis searched PubMed and Cochrane for studies, published 
up to June 2015, describing the clinical outcome of ICSI cycles in which spermatozoa were 
selected based on their ability to bind to hyaluronic acid (Beck-Fruchter et al, 2016). The only 
restriction applied to the search was species- humans. Only full-text articles, with control group 
and specified sperm selection technique were included. The Downs and Black Checklist 
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(Downs & Black, 1998) was used to assess the quality of the seven studies included and meta-
analysis was done where data was available (Ciray et al, 2008, Van Den Bergh et al, 2009, 
Parmegiani et al, 2010a, Parmegiani et al, 2010b,  Choe et al, 2012,  Majumdar & Majumdar, 
2013,  and Worrilow et al, 2013). Pooling of all data also indicated no association between 
hyaluronic acid based sperm selection technique and fertilization rate. The fertilization rate 
could be calculated and compared in seven studies, with more than 9700 injected oocytes in 
total. Subgroup meta-analysis of the prospective studies also indicated no improvement in 
fertilization rate where hyaluronic acid binding was used to select sperm. The results of the 
current study therefore agree with the literature. 
 
PICSI® and Embryo Quality 
 
The results of the current study showed no significant improvement in embryo quality (culture 
day 2, 3 and 5) for PICSI® over ICSI (day 2: 54% vs. 56%, day 3: 39% vs. 40% and day 5: 21% 
vs. 23%, respectively). 
 
Once again, the data from the literature is controversial. A 2010 study concluded that the 
selection of spermatozoa using the PICSI® method leads to a higher number of spermatozoa 
without DNA fragmentation and resulted in a relative improvement of resultant embryo quality 
(Parmegiani et al, 2010a). The design of the study included three prospective studies where the 
main measured outcomes included; assessments of the DNA fragmentation rate and nuclear 
morphology of HA bound spermatozoa in comparison with non-bound spermatozoa. The 
authors reported reduced DNA fragmentation and improved nucleus normalcy compared with 
spermatozoa immersed in PVP. The injection of bound spermatozoa also significantly improved 
both the development and quality of embryos in a randomized study (Parmegiani et al, 2010b). 
The meta-analysis by Beck-Fruchter et al, (2016) also reported that embryo quality, provided in 
only two studies from the same research group, demonstrated an improvement in the 
hyaluronic acid binding group. Secondary outcomes measured included cleavage rate, which 
showed a significant difference in favour of conventional ICSI.  
 
The 2014 Cochrane review included the evaluation of two randomized controlled trials - a total 
of 581 patients - and concluded however that there was no statistically significant difference 
reported between groups in terms of embryo quality (McDowell et al, 2014), and is in 
agreement with the current study. 
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PICSI® and OPR 
 
The results of the current study showed no significant improvement in OPR for PICSI® over 
ICSI (40.40% vs. 48.33%, respectively). 
 
A 2010 retrospective record review of 293 couples treated with PICSI® versus 86 couples 
treated with conventional ICSI concluded that the injection of HA-bound spermatozoa 
significantly improved both implantation rates (17.1% vs. 10.3%) and embryo quality 
(Parmegiani et al, 2010b).  
 
The concluding remarks for the Cochrane review (McDowell et al, 2014) stated that current 
evidence was insufficient to permit the evaluation of advanced sperm selection strategy 
effectiveness in ART. No statistically significant difference was reported between groups in 
terms of pregnancy rate, implantation rate and live birth rate. In the Beck-Fruchter et al. meta-
analysis study (2016), CPR was calculated per cycle started and included nearly 1300 ART 
cycles. Meta-analytic pooling of data again revealed no association between PICSI® sperm 
selection technique and pregnancy rate. Live birth rate was reported for three studies and 
meta-analysis showed no significant difference between the two groups. These results from the 
majority of the literature is in agreement with the current study. 
 
PICSI® and Miscarriage rate  
 
The results of the current study showed no significant difference in miscarriage rate between 
PICSI® and ICSI cycles (5.52% vs 4,35%, respectively). 
The data from the literature support this outcome since spontaneous miscarriage rates were 
comparable or not significantly different in conventional ICSI and PICSI® groups (McDowell et 
al., 2014; Beck-Fruchter et al., 2016).  
 
Limitations of the study 
 
 
The results differ from the hypothesis in that a statistically significant improvement in pregnancy 
rates with PICSI® compared with conventional ICSI fertilization method was expected. These 
results may be due to small sample sizes in both the PICSI® (163 patients) and ICSI (184 
patients) treatment groups, although well matched. A retrospective study has a number of 
disadvantages. When stratifying from an endpoint, one cannot determine causation; only 
identify association. The study is subject to confounding and even when adjusted for, there may 
be other risk factors present that were not identified or measured. Sample size also affects the 
robustness of study findings, and although the study was adequately powered, larger sample 
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sizes would have optimized study design (Hess, 2004). Female and male diagnosis could not 
be assessed as potential confounders based on the way in which data is captured in the clinic.  
Diagnostic factors (etiology of infertility) such as endometriosis could therefore not be adjusted 
for. Endometriosis, even at mild stage, may have a direct negative effect on oocyte 
development, embryogenesis and patients with severe endometriosis have a statistically 
significant lower pregnancy rate and implantation rate than their non-affected counterparts 
(Barnhart et al, 2002). The mechanisms by which endometriosis impairs fertility are varied but 
proposed dynamics include alteration in inflammatory response, autoimmune factors and local 
paracrine action of cytokines (Barnhart et al, 2002). Conditions such as hydrosalpinges 
(Vandromme et al, 1995 & Chu et al, 2015) or fibroids (Somigliana et al, 2011) are also 
associated with poorer outcomes. The availability of data in any retrospective study relies on 
the collection of data by other persons, for purposes other than research. The specific 
indication for ICSI treatment at the particular private clinic is unknown and cancelled cycles or 
freeze-all cycles were not included in the data captured. It follows therefore that the 
completeness and accuracy of data available for analysis is a factor to consider in any a 
retrospective study. The numbers analysed were significantly reduced due to the use of 
exclusion criteria to lessen all possible confounding. Subgroup analysis could not be completed 
due to small resulting sample sizes from which significance could not be determined.  
 
Conclusion & Recommendations 
 
Based on the results of the present study and a comprehensive literature review, routine 
application of PICSI® dishes in all ICSI cycles does not result in improved outcomes in terms of 
fertilization, embryo quality, clinical pregnancy rate or reduced miscarriage rate.  
 
Although hyaluronic acid is a plausible candidate for improved sperm selection based on its in 
vivo role as a natural selector, routine application of PICSI® technique in all ICSI cycles should 
be considered carefully until the identification of patients that may benefit from PICSI® 
technique is investigated further. In order to improve cost effectiveness, only patients who have 
had previously failed ICSI cycles, have had complete fertilization failure with conventional ICSI, 
arrested embryo development, have known sperm DNA integrity abnormalities and ICSI 
patients with low hyaluronan binding score (HBA score) should be considered for PICSI® 
treatment. Further research should include a sample size large enough to detect differences in 
subgroups based on potential confounders, randomization should be considered and measured 
outcomes should include live birth rate.  
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Chapter 3 
 
Prospective Study: The Effect of EmbryoGlue [EG] On ART Outcome 
 
3.1 Materials & Methodology  
 
3.1.1 Study Population 
 
o All consenting couples undergoing ART treatment at the Drs Aevitas Fertility Clinic 
[September 2015-May 2016] who had a transfer with EG as an embryo transfer 
medium – EG Treatment group.  
 
o A historically similar group of couples at the Drs Aevitas Fertility Clinic [January –
December 2014] who had transfer with standard medium (Cleavage or Blastocyst 
Medium, Quinns Advantage, SAGE) as an embryo transfer medium  -  Control 
group.  
 
§ The following exclusion criteria were designed to further lessen all 
possible confounding:  
 
• No clinical pregnancy result 
• HIV or Hepatitis B positive patients 
• No consent  
• No oocytes and/or embryo transfer 
• Time in EG <10minutes prior to transfer 
• No EG used in treatment group 
 
Donor oocyte cycles and FET cycles were included in the study. 
Relevant data was captured and stored to allow statistical analysis of the following confounders 
between the groups: female age (age of ova), total number of available ova per patient, number 
of mature ova available per patient, fertilization rate (%), number of embryos transferred, 
number of of good quality embryos (GQE) transferred and cycle number. 
 
The outcomes measured and statistically analysed to ascertain possible significant differences 
between the two groups were clinical pregnancy rate, ongoing clinical pregnancy (%) and 
miscarriage rate (%). 
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3.1.2 Study Design  
Main outcomes to analyse: 
 
To ensure that the control and treatment group outcomes can be attributed to the use of EG 
alone, the groups were compared in terms of the following confounding factors: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTROL GROUP 
[Transfer with Cleavage or 
Blastocyst Medium] 
TREATMENT GROUP 
[Transfer with EG]  
Confounding Factors: 
 
-Female Age (Age of Ova) 
-Total number of available ova per patient 
-Number of mature ova available per patient 
-Fertilization rate 
-Number of good quality embryos on Day 2,3 & 5 
-Number of Embryos Transferred 
-Number of Good Quality Embryos Transferred 
-Cycle number 
-Donor ova status 
-Surrogacy Status 
Outcomes Measured: 
 
-Clinical Pregnancy Rate (%) 
-Ongoing Pregnancy Rate (%) 
-Miscarriage Rate (%) 
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3.1.3 Study Objecftive 
 
Primary objective 
To compare the CPR and OPR between the EG transfer patient group and standard transfer 
patient group. 
 
Secondary objective  
To compare the fertilization rate, embryo quality rate [day 2, 3 and 5] and miscarriage rate 
between EG transfer patient group and standard transfer patient group 
 
 - patient demographics (female age, number of oocytes aspirated, embryo quality and number 
of embryois transferred were included in the analysis,  
 
3.1.4 Definitions of Pregnancy & Miscarriage 
Clinical pregnancy (CP) is defined as a pregnancy diagnosed by ultrasonographic visualization 
of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic 
pregnancy and multiple gestational sacs are counted as one clinical pregnancy (Zegers-
Hochschild et al, 2009). Clinical pregnancy rate [CPR] is expressed per embryo transfer [%] 
 
Ongoing pregnancy (OP) is defined as the presence of fetal heart with or without final outcome 
after 20 weeks gestation for the purposes of the study. Ongoing pregnancy rate [OPR] is 
expressed per embryo transfer [%]. 
 
Miscarriage was definied as the spontaneous loss of a clinical pregnancy that occurs before 20 
completed weeks of gestational age (18 weeks post fertilization) (Zegers-Hochschild et al, 
2009). Miscarriage rate was expressed per transfer [%].  
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3.1.5 Data management & Statistical Analysis 
All relevant data from eligible cycles was entered on a spread sheet similar to that of the 
standard clinic database spread sheet.  
 
Data captured included:  
 
1. Clinical pregnancy rate 
 
2. Ongoing pregnancy rate 
 
3. Miscarriage rate   
 
4. Ova age (not female recipient age) 
 
5. Total number of ova retrieved 
 
6. Number of mature (metaphase II) ova retrieved 
 
7. Fertilization rate – ova fertilized/ MII ova retrieved [%]
 
8. Number of good quality embryos (GQE) on day 2, 3 and 5 respectively 
 
9. Total number of embryos transferred 
 
10. Number of good quality embryos (GQE) transferred 
 
11. Cycle number of treatment 
 
 
There are some differences in the baseline profiles of the control and treatment groups; this 
can be explained by the nature of the study; a comparative study using retrospective data as 
control and prospective data as treatment group. The difference in clinical profile between the 
two groups was taken into account when assessing potential confounding factors.  
 
A logistic regression model of clinical pregnancy on group adjusted for other factors and 
confounders was used to estimate the adjusted odds ratio and 95% confidence intervals for 
EG. Possible interaction of factors with EG use was also investigated. The additional factors 
included in the model were; the number of good quality embryos returned (categorical); day of 
embryo transfer, donor ova status, age of ova, number of good quality embryos transferred and 
total number of embryos transferred. The number of ova available per patient was not adjusted 
for because that information was not captured for those patients who underwent frozen embryo 
transfers (17% of patient data). The missing data was accounted for and was determined not to 
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have any serious bias or effect, the model without adjustment for number of ova was not 
significantly different from model without this covariate. This regression model approach is a 
powerful tool to compensate for the observational nature of the study by trying to imitate the 
conditions and advantages associated with a randomized controlled trial.  
 
The statistical tests used for the purpose of the study included the following;  
 
• Analysis of variance (ANOVA):  
ANOVA is a collection of statistical models used to analyse and quantify intergroup and 
intragroup variability 
 
• Pearson Chi2 test 
A chi-square test for independence or association used to discover if there is a 
relationship between two categorical variables.  
 
• A quantile non-parametric logistic regression model 
Quantile regression is a type of regression analysis used to obtain a comprehensive 
analysis of the relationship between variables. It is a powerful tool to adjust for 
confounding and can be used to closely simulate the conditions of randomization.  
 
• Fisher’s exact test 
-Fisher’s exact is a statistical significance test to determine if there are non-random 
associations between two categorical variables; it is more accurate than chi-squared 
test and is used when sample sizes are too small for chi-squared analysis. 
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3.1.6 Procedures 
 
All ART procedures were similar for the retrospective and prospective study except for embryo 
transfer methodology in the prospective study. 
 
Ovarian stimulation 
Female partners underwent controlled ovarian hyper-stimulation according to standardized 
stimulation protocols. The appropriate stimulation protocol is determined based on patient 
presentation and medical history, namely; diagnosis, physiology, endocrinology and age. 
Standard stimulation protocols include; i. Short Protocol, ii. Long  Protocol, iii. Natural Cycle, iv. 
Modified Natural Cycle and v. Antagonist Protocol. Stimulation protocol sub-types were 
designated individualized codes for the purpose of accurate data collection. 
 
Stimulation involves administration of gonadotrophin-releasing hormone agonist (GnRHa) 
followed by human menopausal gonadotrophins (HMG) and/or pure follicle stimulating hormone 
(FSH) from cycle day 3. Follow-up procedures included estradiol determinations and 
ultrasonographical measurements of the Graafian follicle. Once the leading follicle had reached 
a diameter of 18mm. Human chorionic gonadotropin (HCG) was administered to induce 
ovulation. 
 
Aspiration and gamete handling 
Standard procedures were used [Appendix III & XII]. 
 
Semen preparation 
Sample characteristics such as sperm count and motility determined the semen preparation 
method used. Standard wash and swim-up techniques, using HEPES buffered sperm 
preparation medium, were used to isolate motile spermatozoa during semen preparation when 
possible. Gradient (90%, 45%) centrifugation method was used for samples with parameters 
below reference ranges as determined by the World Health Organisation (WHO, 2010). 
[Appendix XI]. 
 
ICSI Method 
Refer to Appendix I & II. 
 
PICSI® Method 
Refer to Appendix VII. 
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IMSI Method 
Refer to Appendix VIII. 
 
Embryo culture and evaluation 
Standard protocol descriptions for Embryo Culture & evaluation can be observed in Appendix 
III. 
 
Embryo transfer 
Standard protocol was used but with modifications for study protocol. 
 
EG Treatment Group: Embryo transfer  
Embryos selected for transfer were placed in 0.5 ml CO2 equilibrated, warmed [37°C] EG 
medium for at least 10 minutes, but not longer than 30 minutes, before embryo transfer. 
Thereafter standard routine embryo transfer was followed. [Appendix XIV] 
 
Control Group: Embryo transfer  
Embryos selected for transfer were placed in 1ml CO2 equilibrated, warmed [37°C] culture 
medium (Cleavage or Blastocyst medium, SAGE) before embryo transfer. Thereafter standard 
routine embryo transfer protocol was followed. [Appendix XIV] 
 
Embryo Quality 
Embryo quality was evaluated according to standard protocol in the clinic based on the work of 
Veeck, 1999 & Veeck et al,  2003. [Appendix IV].  Blastocyst grading is according to a modified 
Gardner & Schoolcraft grading system [Appendix V]. 
 
Embryo Vitrification & Warming 
Refer to Appendix XIII. 
Pregnancy 
Clinical pregnancy (CP) is defined as a pregnancy diagnosed by ultrasonographic visualization 
of one or more gestational sacs or definitive clinical signs of pregnancy. It includes ectopic 
pregnancy and multiple gestational sacs are counted as one clinical pregnancy (Zegers-
Hochschild et al, 2009). 
 
Ongoing pregnancy (OP) is defined as the presence of fetal heart with or without final outcome 
after 20 weeks gestation for the purposes of the study.  
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Miscarriage 
Miscarriage was definied as the spontaneous loss of a clinical pregnancy that occurs before 20 
completed weeks of gestational age (18 weeks post fertilization) (Zegers-Hochschild et al, 
2009). Miscarriage rate was expressed per transfe [%].  
 
Consent Forms 
Patient information leaflet and consent forms were approved by the Health Research Ethics 
Committee [Appendix IX]. (Ethics Reference #: S15/04/090). 
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3.2 Results  
 
3.2.1 Patient Population   
 
The patient population included in the prospective study was comprised of 870 patients. The 
respective sample sizes of relevant treatment groups were; 197 patients in the EG treatment 
(EG embryo transfer) group and 673 patients in the control (classical embryo transfer) group. 
The exclusion criteria were designed to allow for a comparison of embryo transfer with and 
without high concentrations of HA. The comparison of embryo transfers with or without EG as 
transfer medium was the primary focus of this portion of the study. The two groups were not 
matched, but logistic regression analysis was performed to adjust for all possible confounding 
influences.  
 
3.2.2 Subgroup Analysis: Estimating possible differences between groups 
 
The resulting differences between the control and EG subgroups regarding oocyte age, number 
of embryos transferred donor ova status and cycle number is presented in Table 3.1. 
 
When comparing the number of patients younger than 36 and those 36 and over, the age 
distribution was comparable and not significantly different, between the control and EG groups; 
61.72% of control and 61.72% of EG patients were younger than 36 years, (p=0.397). There 
was a significant difference in control and EG group profiles in terms of number of embryos 
transferred per patient (p=0.0027). In the control group, 6.82% more transfers with 2 or more 
embryos were performed. Also, in the control group, only 17.80% of the patients made use of 
donor ova while 26.90% of the EG group patients used donor ova. This 9.1% difference in the 
number of patients who made use of donor ova in respective groups was significant (p=0.005). 
Cycle number was not available for all patients included in the study, however no significant 
difference in profile of cycle number between groups was detected with the available data, 
which included 686/870 of the total patients; 42.35% of the control patients had two or more 
cycles compared to 46.67% in the EG group (p=0.346).  
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Table 3.1 Subgroup analysis comparing control and EG clinical profiles 
 
Variable Group Control EG Total 
 
Age of Ova 
<36 years 
 
61.72% 
[416/674] 
58.38% 
[115/197] 
60.96% 
[531/871] 
≥ 36 years 
 
38.28% 
[258/674] 
41.62% [82/197] 39.04% 
[340/871] 
 
Number 
Transferred 
1 embryo 
 
16.02% 
[108/674] 
22.84% [45/197] 17.57% 
[153/871] 
≥ 2 embryos 
 
83.98% 
[556/674] 
77.16% 
[152/197] 
82.43% 
[718/871] 
 
Donor Ova Status 
No donor ova 
 
82.20% 
[554/674] 
73.10% 
[114/197] 
80.14% 
[698/871] 
Donor ova  
 
17.80% 
[120/674] 
26.90% [53/197] 19.86% 
[173/871] 
 
Number of ART 
Cycles Attempted 
First cycle 
 
57.65% 
[309/536] 
53.33% [80/150] 56.71% 
[389/686] 
≥ 2 cycles 
 
42.35% 
[227/536] 
46.67% [70/150] 43.29% 
[297/686] 
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3.2.3 Measured Outcomes 
 
Clinical Pregnancy [CP] (Fetal Sac) outcome:  Unadjusted, Crude Comparison 
 
A Pearson Chi2 Test was used to analyse and compare the CP outcomes of control and EG 
treatment groups. The analysis was initially performed on the crude, unadjusted data. CP data 
was available for 100% of the patients [673/673] in the retrospective control group and in 96.1% 
[197/205] for the EG group. There was a statistically significant difference (p=0.004) in the 
number of fetal sacs among patients in the control group compared with that of patients in the 
EG group (Table 3.2). Interestingly, the proportional twin-rate in the EG group (13.20%) was 
also more than double that of the control group (6.39%).  
 
Table 3.2 Number of fetal sacs in the control and EG groups. 
 
Fetal Sac (#) Control EG Total 
0 67.61% [455/673] 58.88% [116/197] 65.63% [571/870] 
1 25.56% [172/673] 26.40% [52/197] 25.75% [224/870] 
2 6.39% [43/673] 13.20% [26/197] 7.93% [69/870] 
3 0.45% [3/673] 1.52% [3/197] 0.695 [6/870] 
 
A binary analysis of CP, regardless of fetal sac number followed (Table 3.3). The CP rate 
differed 8.73% between the EG (41.12% [81/197]) and the control groups (32.39% [218/673]). 
Interestingly, the proportional twin-rate in the EG group (13.20%) was also more than double 
that of the control group (6.39%). The crude odds ratio was 1.46 (95% CI: 1.05 to 2.02) 
indicating a 46% greater likelihood in achieving CP following embryo transfer with EG medium. 
This unadjusted comparison of raw data showed a significant difference (p=0.023) in the CP 
profiles of the two groups. 
 
Table 3.3  CPR, regardless of fetal sac number, in control and EG groups. 
 
Fetal Sac Control EG Total 
None 67.61% [455/673] 58.88% [116/197] 65.63% [571/870] 
Any number 32.39% [218/673] 41.12% [81/197] 34.37% [229/870] 
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Clinical Pregnancy [CP] (Fetal Sac) outcome:  Adjusted for covariates  
 
The subgroup analysis is the underpinning of the final model, in none of the factors that are part 
of the model are there any subgroup effects thus, only the main effects model is presented; 
where the effect of EG is adjusted for covariates: day of ET, age of ova, number of GQE ET, 
total number ET and donor ova status. 
 
The results of the adjusted logistic regression model are presented in Table 3.4. The adjusted 
OR for EG is 1.37 (95% CI: 0.97 to 1.96) indicating a 37% greater likelihood in resultant clinical 
pregnancy than the control but the adjusted effect is no longer significant (p=0.078). The age of 
ova (p=0.785), and the total number of embryos transferred (p=0.238) had no significant effect 
on CP either. The day of embryo transfer (p=0.022), donor ova status (p=0.040) and number of 
good quality embryos transferred (p=<0.001) were all significant factors in the determination of 
CP outcome. The use of donor ova was associated with a 66% greater likelihood in achieving 
CP. The number of GQE returned was specifically strongly associated with higher odds for a 
positive CP, increasing in likelihood as number transferred increased. A locally weighted scatter 
plot smoother (LOWESS) represents this relationship (Figure 3.1). 
 
Table 3.4 OR outcomes for CP in the adjusted, logistic regression model. 
 
Variable Odds Ratio [OR] 95% Confidence Interval p-value 
EG (ref Control) 1.37 0.97 to 1.95 0.078 
Day of Embryo Transfer 1.17 1.02 to 1.33 0.022 
Donor Ova 1.66 1.02 to 2.70 0.040 
Age of Ova 0.99 0.96 to 1.03 0.785 
Number GQ ET (ref 0)   <0.001 
1 GQ ET 2.73 1.48 to 5.02 0.001 
2 or more GQ ET 7.14 4.02 to 12.70 <0.001 
Total Number ET 0.86 0.67 to 1.10 0.238 
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Figure 3.1  A LOWESS (Locally Weighted Scatterplot Smoothing) graph representing OR 
for CP according to the number of GQE transferred in the control and EG 
groups. 
 
The absence of an interaction between the number of good quality embryos returned and the 
use of EG or not is reflected in Table 3.5. Although the observed profile of CP differs there is no 
statistical difference (p=0.4946), hence the effect of EG was estimated without an interaction 
term in the model.  
 
Table 3.5  CPR according to number of GQE transferred in the control and EG groups. 
 
 Control EG 
Number Good Quality Returned Fetal Sac(s) 
0 9.38% [3/32] 11.32% [12/106] 
1 31.03% [18/58] 25.91% [57/220] 
2 or more 56.07% [60/107] 43.06% [149/346] 
Total 41.12% [81/197] 32.44% [218/672] 
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Ongoing Pregnancy Rate [OPR] (Fetal Heart):  Unadjusted, Crude Comparison 
 
A Pearson Chi2 Test was used to compare the crude unadjusted data for OPR (fetal hearts) 
resulting in control and EG groups. Results were similar to that of CPR (fetal sacs).  However, 
the number of fetal hearts detected per patient within control and EG groups was not 
significantly different (p=0.059) (Table 3.6) although the proportional twin rate in the EG group 
(13.71%) was once again almost double that of the control group (7.88%). 
 
Table 3.6 Number of fetal hearts detected per patient in control and EG groups. 
 
Fetal Heart Control EG Total 
0 68.80% [463/673] 60.91% [120/197] 67.01% [583/870] 
1 23.03% [155/673] 24.87% [49/197] 23.45% [204/870] 
2 7.88% [53/673] 13.71% [27/197] 9.20% [80/870] 
3 0.30% [3/673] 0.51% [1/197] 0.34% [3/870] 
 
The binary analysis of OPR (unadjusted) regardless of fetal heart number is presented in Table 
3.7.  The CP rate differed 7.893% between the EG (39.09% [77/197) and the control (31.20% 
[210/673]) groups. The crude OR was 1.41 (95%CI: 1.02-1.97) and was statistically significant 
(p=0.039) indicating a 41% greater likelihood in achieving an OPR when EG was used as 
embryo transfer medium. The analysis indicated that the differences in OPR was statistically 
significant between two groups (p=0.038). 
 
Table 3.7 OPR, regardless of fetal heart number in control and EG groups. 
 
Fetal Heart Control EG Total 
No Fetal Heart 68.80% [463/673] 60.91% [120/197] 67.01% [583/870] 
Any number of Fetal Hearts 31.20% [210/673] 39.09% [77/197] 32.99% [287/870] 
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Ongoing Pregnancy Rate [OPR] (Fetal Heart):  Adjusted for covariates  
 
The effect of EG was adjusted for covariates: day of ET, ova age, number of GQE ET, one 
GQE ET, ≥ 2 GQE ET, total number ET and donor ova. 
 
A logistic regression model results for OPR are shown in Table 3.8. The adjusted OR for EG is 
1.34 [95% Cl: 0.94 to 1.91], indicating a 34% greater likelihood in achieving OPR compared to 
the control group. The adjusted effect is not significant (p=0.108). The age of ova was not 
significant (p=0.513) nor was the total number of embryos transferred (p=0.114) or donor ova 
status (p=0.087). The day of embryo transfer was a significant determinant for OPR outcome 
(p=0.027). The number of GQE returned is strongly associated with OPR, with a much higher 
OR [OR=6.64 (95% CI: 3.73 to 11.82)] for OPR when 2 or more GQE are returned (p=0.001) 
compared to none. 
 
Table 3.8  OR outcomes for OP in the adjusted, logistic regression model.  
 
Variable Odds Ratio 95% Confidence Interval p-value 
EG (ref Control) 1.34 0.94 to 1.91 0.108 
Day of Embryo Transfer 1.16 1.02 to 1.32 0.027 
Donor Ova 1.53 0.94 to 2.50 0.087 
Age of Ova 0.99 0.95 to 1.02 0.513 
Number GQ ET (ref 0)   <0.001 
1 GQ ET  2.52 1.37 to 4.66 0.003 
2 or more GQ ET 6.64 3.73 to 11.82 <0.001 
Total Number ET 0.82 0.63 to 1.05 0.114 
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Miscarriage rate:  Unadjusted Comparison 
 
A Pearson Chi2 Test was used to compare the crude unadjusted data for miscarriages in the 
control and EG groups. The study used a unified definition of pregnancy loss for all types of 
miscarriages, at various stages of pregnancy, to form a single binary outcome. The miscarriage 
rates in the control (5.49%) and the EG groups (6.60%) was not significantly different 
(p=0.556). The crude OR [OR= 1.22 (95% CI: 0.63 to 2.34)] for miscarriage showed no 
significant difference in likelihood of miscarriage between groups (p=0.557), thus no further 
adjustment was made (Table 3.9). 
 
Table 3.9  Miscarriage rate, regardless of pregnancy stage, in control and EG groups. 
 
Miscarriage Control EG Total 
No spontaneous abortion 94.51% [637/674] 93.40% [184/197] 94.26% [821/871] 
Miscarriage  
 
5.49% [37/674] 6.60% [13/197] 5.74% [50/871] 
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3.3 Discussion  
 
The study found significance in favour of EG only in crude analysis of the data and when no 
adjustments were made for confounding. Unadjusted comparison in respect of CPR (fetal sac 
rate) and OCPR (fetal heart rate) both indicated significant differences among control and EG 
group- outcomes. After adjustment for confounding factors - oocyte age, day of transfer, total 
number of embryos transferred, number of GQE transferred and donor ova status however, 
regression analysis showed the differences in CPR and OCPR were no longer significant. In 
the analysis of CPR, the day of embryo transfer, use of donor oocytes and number of GQE 
were significant confounding factors. Ova age and total number of embryos transferred were 
not significant factors. For OCPR the day of embryo transfer and number of GQE stayed 
significant confounding factors, but ova age, total number of embryos transferred and use of 
donor oocytes were not significant. 
 
Subgroup analysis  
 
A subgroup analysis was performed for oocyte age, number of embryos transferred, donor ova 
status and cycle number to determine if the two groups were comparable. The age distribution 
profiles of the two groups did not differ significantly, nor the profiles of cycle number. There was 
a significant difference in group-profile’s in terms of number of embryos transferred per patient. 
In the control group, 6.82% more transfers with two or more embryos were performed. In the 
treatment group, 26.90% of the patients made use of donor ova compared to 17.80% of the 
control group. This 9.1% difference in the number of patients who made use of donor ova in 
respective groups was also significant. In the final regression analysis, the number of embryos 
transferred and the donor status were included as confounding factors and adjusted for.  
 
Clinical Pregnancy Rate (CPR) outcomes and confounding factors 
 
The unadjusted, crude comparison indicated a significant improvement in CPR when EG was 
used as transfer medium (41.12% vs. 32.39%). The crude odds ratio indicated a 46% greater 
likelihood in achieving CP following embryo transfer with EG. When a logistic regression model 
with odds ratios was applied to adjust for potential confounders, differences in group outcomes 
were no longer significant in terms of CPR. The adjusted odds ratio indicated 37% greater 
likelihood in achieving CP following embryo transfer with EG but the adjusted effect was no 
longer significant. The day of embryo transfer had a significant effect on the likelihood of 
achieving CP – the odds ratio indicated a 17% greater likelihood in achieving CP with Day 5 
embryo transfers. The use of donor ova and the number of good quality embryos transferred 
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were also associated with significantly higher odds of achieving CP. The use of donor ova was 
associated with a 66% greater likelihood in achieving CP while the likelihood of CP increased 
directly with the number of GQE returned. When one GQ embryo is transferred, it results in a 
273% greater likelihood in CP compared with the transfer of a poor quality embryo. In contrast, 
the effects of ova age and total number of embryos transferred were not significant.  
 
Ongoing Pregnancy Rate (OPR) outcomes and confounding factors 
 
The unadjusted comparison indicated a significant improvement in OPR when EG was used as 
transfer medium (39.09% vs. 31.20%). The crude odds ratio indicated a 41% greater likelihood 
in achieving OPR following embryo transfer with EG. When adjustments were made for 
confounding using the same logistic regression model with OR, OPR differences were also no 
longer significantly affected by the use of EG. The adjusted OD indicated a 34% greater 
likelihood in achieving OPR in the EG group compared to control group.  The day of embryo 
transfer was found to have a significant interaction with the effect of EG, where day 5 transfer 
was associated with a 16% greater likelihood in OPR. Again, the number good quality embryos 
transferred was strongly associated with ongoing pregnancy, with much higher odds for 
ongoing pregnancy when two or more GQE are returned. However, the effect of ova age was 
not significant, nor was the total number of embryos transferred or donor ova status. 
 
Miscarriage Rate 
 
The unadjusted comparison in miscarriage rate in the C and EG groups (6.60% vs. 5.49%) 
indicated no significant difference in group profiles, thus no adjustments were made. A unified 
definition of pregnancy loss for all types of miscarriages, at various stages of pregnancy, was 
used to form a single binary outcome. 
 
Confounding Factors 
 
The confounding factors oocyte age, total number of embryos transferred and number of GQE 
transferred have been discussed in the retrospective analysis section. Younger  age of oocytes 
are associated with better prognosis as oocyte abnormalities and aneuploidy become 
increasingly common with increasing age. (Armstrong, 2001, Kuliev et al, 2003). The transfer of 
two or more embryos results in higher pregnancy rates than single embryo transfers 
(Martikainene et aI, 2001). The transfer of GQE is positively associated with pregnancy 
outcome, likelihood of positive pregnancy outcome increases directly as number of GQE 
increases (Rienzi et al, 2005). In the present study, the number of GQE transferred was a 
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significant factor in determining the likelihood of positive CP and OP and this outcome agrees 
with the literature. In contrast with available literature, the present study found no significance 
associated with age of ova nor with total number of embryos transferred. This may be 
explained by the high number of patients that made use of donor ova, associated with improved 
outcome (Sauer et al, 1990 & 1992). The reason total number of embryos transferred was not a 
significant factor may be the result of confounders not adjusted for in the study; potentially the 
etiology of infertility.  
 
Study outcomes confirmed evidence in literature that the day of transfer can have an effect on 
outcomes. Studies have illustrated a favourable association between blastocyst culture to day 5 
& 6 and live birth rate, particularly for patients with good prognosis (Blake et al, 2004). The 
present study indicated greater likelihood in achieving OP with day 5 transfers similar to what 
the literature indicates. Blastocyst, day 5, transfer increases the live birth rate per couple (Blake 
et al., 2007) and  ongoing and cumulative pregnancy rates in comparison with day 3 transfers 
where at least 4 embryos were available (Fernandez-Shaw et al, 2015). The influence of donor 
ova use on outcome has been investigated extensively. An American retrospective record 
review of 27 959 fresh donor oocyte IVF cycles found that with the use of donor ova women 
between age 39 and 45 were able to achieve similar implantation, CP and live birth rates 
compared with their younger counterparts (Yeh et al, 2014). The present study found a 
significant benefit in donor ova use in terms of CP with a 66% increase in the odds of achieving 
CP but found no significant difference in likelihood of OP, possibly due to the fact that EG isn’t 
specifically indicated for cycles making use of donor ova but rather for a specific sub-group of 
patients with particular etiology of infertility.  
 
Comparison of Results with the Relevant Literature 
 
The results of the current study showed no significant benefit for EG over classical transfer 
medium when confounding factors were considered in logistic regression analysis. EG did 
however result in an improved CPR and OPR in crude analysis (41.12% vs. 32.39% and 
39.09% vs. 31.20% respectively). The use of EG remains controversial among ART 
professionals, as it is difficult to conclude the favourable role of EG as routine transfer medium 
in all treatment cycles.  
 
A prospective, randomized, controlled study analysed the use of HA-enriched transfer medium 
in a total of 825 day 3 and 457 day 5 embryo transfer cycles. Pregnancy rates were compared 
in terms of day of embryo transfer, women’s age, quality of embryos transferred and presence 
of previous implantation failures to adjust for confounding. The study found significant 
increases in CPR and implantation rate with the use of HA-enriched transfer medium. The 
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beneficial effect was greater in patients over 35 years of age, women who had previously failed 
cycles and women with poor embryo quality (Urman et al, 2008). A Cochrane review of 
adherence compounds in embryo transfer media for ART included 15 studies evaluating HA. 
Although there was no evidence of a treatment effect on live birth rate, there was evidence of 
significant treatment effect on both CPR and multiple pregnancy rate. (Bontekoe et al, 2010). A 
2014 meta-analysis on almost 10 000 embryo transfers carried out at various Japanese clinics 
further confirmed the findings of the 2010 Cochrane report evaluating the use of high 
concentrations of HA in embryo transfer medium. The meta-analysis concluded that the use of 
EG as transfer medium resulted in a significant increase in both implantation and pregnancy 
rates. Miscarriage rates were not significantly different (Hashimoto et al, 2014). In 2014, the 
Cochrane Collaboration published an update of their first meta-analysis also entitled 
“Adherence compounds in embryo transfer media for assisted reproductive technologies 
(Review)”. The updated review included 16 truly randomized controlled trials with a total of 
3898 total participants.  Out of those included, 14 studies reported CPR as endpoint and 6 
studies also included LBR. The use of EG for embryo transfer, when compared with the use of 
culture medium containing little or no hyaluronic acid, resulted not only in an improvement of 
successful implantation rates but also in an overall increase of 8% live birth rates, regardless of 
embryo transfer day (Bontekoe et al., 2014). The results from the crude unadjusted analysis in 
the present study agreed with these findings, but once adjustments were made for 
confounders, improvements in CP and OP rates were no longer significant. Individual studies 
identify and adjust for different confounders, thus the results are causally linked with the 
exclusion criteria and confounder adjustments made. Additionally, patients were accepted into 
the EG treatment group regardless of indication. EG is not indicated for a general patient 
population. The potential beneficial effect of EG is applicable for patients of advanced maternal 
age (poor embryo quality), previously failed cycles and/or recurrent implantation failure. 
 
In 2005, a study designed to evaluate the usefulness of EG in improving pregnancy rates 
included 310 fresh embryo transfers, 154 of which were transferred following incubation in the 
HA-enriched medium. Possible confounding factors such as age, duration of infertility, previous 
IVF cycles, total gonadotropin dose, oocyte number and number of embryos transferred were 
similar in the control and treatment groups. The resulting pregnancy rates were not significantly 
different and they concluded the use of EG in fresh transfers did not improve resulting 
pregnancy rate (Ravhon et al, 2005). Additional abstracts from oral and poster presentations at 
the American Society for Reproductive Medicine (ASRM) scientific congress & expo were 
published by Fertility and Sterility in September 2013. A study from the Center for Reproductive 
Medicine of New Mexico, Albuquerque including 179 frozen embryo replacement cycles, 
reported that the use of EG as post-thaw culture and transfer medium did not improve the 
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measured clinical outcomes in frozen embryo replacement cycles. The measured outcomes 
included clinical and ongoing pregnancy, and implantation rate per embryo transferred (Said et 
al, 2013). A prospective case-control study conducted at the assisted reproductive centre of a 
tertiary care hospital involved 84 women undergoing fresh non-donor IVF or ICSI cycles. In the 
control group (n=42), embryos were transferred to conventional blastocyst culture medium and 
those in the treatment group (n=42) were transferred into 50μL of EG for 10 min prior to 
transfer inside the uterine cavity. In an effort to limit possible confounding factors the exclusion 
criteria included women age >35 years, those with poor ovarian reserve, and possible causes 
of failure of implantation such as diabetes mellitus, hypertension and autoimmune diseases. 
The resulting CPR in the treatment group was 7% higher than that of the control group; the 
difference was not statistically significant. A significant difference in CPR was however 
observed in a subset (n=12) of treatment patients who had previous failed ART cycles. In the 
treatment group, 50% [6/12] of patients achieved successful implantation where none of the 
patients [0/11] in the control group did (Singh et al, 2015). A 2015 cohort study performed on 
229 retrospectively enrolled patients also found no improvement in ART outcomes following the 
routine use of EG in all treatment cycles (Safari et al, 2015).   
 
Studies that have demonstrated marginal improvements in achieving clinical pregnancy and 
reducing miscarriage rate with the use of EG were likely subject to a number of confounders, 
not all studies were randomized controlled and regression analysis was not applied in all cases 
to account for the limitations of study design. The present study also concluded no significant 
improvement in measured outcomes when EG was used for all patient cycles regardless of 
infertility etiology and when confounding factors were adjusted for. 
  
Limitations of the study 
 
The results differ from the hypothesis in that a statistically significant improvement in CP and 
OP rates, after adjusting for confounding factors, did not result from the use of EG embryo 
transfer medium. Miscarriage rate was also not significantly altered by the application of EG. 
The results of the present study may be due to the following limitations.  
 
The lack of randomization or pairing, although a logistical regression model with odds ratios 
was used to compensate for the observational nature of the study by trying to mimic the 
conditions and advantages associated with a randomized controlled trial. The small sample 
size limits the robustness of the study; the sample size was affected by the necessary 
exclusion criteria to limit confounding as well as the number of patients initiating cycles during 
the study period. There were also challenges in obtaining informed consent from all eligible 
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patients. Intern medical scientists are limited in their interaction with patients at the private 
practice and therefore had to rely on the help of their colleagues. A number of eligible patients 
also could not be included as their transfers took place before embryos had been in EG for the 
stipulated 10-minute minimum exposure. The success of a study such as this, in a private 
facility, not only depends on the commitment of the investigator but also on the participation of 
other members of the practice. Eligible patients in the treatment group who did not receive EG 
due to initial stocking difficulties and lack of availability also had to be excluded. 
 
Due to insufficient record keeping, the inability to identify patients for whom EG is indicated, 
such as those with recurrent implantation failure or repeated miscarriage, made it impossible to 
study this subgroup. The application of EG in all cycles, despite not being indicated for the 
general infertile population, was however done.  The system in place for data capturing and 
medical record keeping also makes the etiology of infertility difficult to determine. Patients of 
advanced age who make use of donor ova have their diagnosis recorded as “Donor Ova” rather 
than advanced maternal age for example. These inconsistencies meant that etiology of 
infertility, a potential confounder, could not always be adjusted for.  
 
Conclusion & Recommendations 
 
The results from the present study demonstrate that the routine application of EG as embryo 
transfer medium in all ART cycles does improve CPR and OPR but its significance disappears 
when known pregnancy confounding factors are adjusted for. However, literature suggests its 
usefulness in the treatment of couples presenting with specific indications of infertility such as 
those who have had recurrent implantation failure, repeated miscarriages and some studies 
also indicate its usefulness in patients with tubal factors (Valojerdi et al, 2006). Clinical 
significance and statistical significance may differ in a unique clinical setting.  A 37% greater 
likelihood for CP and and 41% greater likelihood for OP (although not statistically significant) for 
adjusted results may still be considered clinically significant if the use of a particular technique 
is also the safest and most cost effective option available. The hypothesis is one of superiority 
& difference.  One could also consider it from a perspective of equivalence. Given the 
confidence intervals and assuming equivalence limits of 10% the estimated confidence 
intervals between EG and the standard transfer medium show equivalence since the limits lie 
within -10 and +10%.  
 
The improvement in implantation rates observed in patients with previous failed cycles and 
recurrent implantation failure in literature, demands further investigation. The present study, as 
well as available literature, confirms a general increase in the likelihood of multiple pregnancy 
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resulting following EG [see Table 3.2 and 3.6] and it is therefore advisable to reduce the 
number of selected embryos for intrauterine transfer (or implement a policy of single embryo 
transfers) when using this transfer medium. A follow up study might include, (i) only patients 
with a specific diagnosis (advanced age, previously failed cycles, poor quality embryos as 
indicated by literature), (ii) randomization, (iii) analysis of implantation rates and live birth rates 
and (iv) a commitment to culturing embryos for transfer in EG for the prescribed 10 to 30 
minutes period prior to initiating transfer. A general awareness and commitment to ongoing 
research projects is necessary in order to effectively coordinate clinic staff and ensure the 
complete and accurate collection of data required for optimized study conditions.  
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Appendices 
 
APPENDIX I   Drs Aevitas Fertility Unit Standard Protocol: ICSI 
 
All forms and documents are prepared. 
The thorough check of the patient’s file and record is completed to eliminate all possible 
uncertainties/queries.    
 
Semen preparation 
 See section on semen preparation methods 
 
Aspiration 
Medium preparation – previous day 
 See section on medium preparation 
 
Ovum Pick up 
• Check suction pump (100-120 mmHg) 
• Prepare glass polished pipettes for pick up 
• Place pick-up tubes in heated block 
• Hand theatre medium tube to sister when needed 
• Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large Petri dish on a heated stage (37-40ºC) of a dissection 
microscope 
o Note obvious abnormal features and maturities 
• Put the complexes (with as little as possible blood and medium) in the pick-up tube 
• When done, rinse all complexes in small Petri dish with gassed fertilization medium – 
check number obtained 
• Leave in fertilization medium in CO2 incubator until time for denuding of oocytes 
o Try to do denuding ±38 hours post HCG injection 
Denuding of oocytes 
 
• Prepare pipettes for the process: fire polished glass Pasteur pipettes, hand drawn glass 
pipettes and the Cook stripper (Marcus Medical) pipette   
• Prepare a 4 well NUNC dish for denuding: (USE ONE DISH FOR EVERY 8 OOCYTES) 
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• In well 2, 3 and 4 place ± 0.8 – 0.9 ml warmed HEPES buffered flushing medium 
(Quinns, Cooper Surgical)  
 
• In well 1 place 0.6 ml HEPES buffered flushing medium and add 0.3 ml hyaluranidase 
[80 UI/ml] (Quinns, Cooper Surgical) 
 
• Place in the incubator [without CO2] at 37ºC for ± 10 minutes to reach 37ºC 
 
• Place a predetermined number of oocyte/cumulus complexes in well 1, wait for ± 30 
seconds 
 
• Gently flush the complexes with a standard fire polished pipette until all cumulus cells 
are digested (oocytes with corona cells and small number of cumulus cells form “fluffy 
balls”) 
 
o If complexes stay intact use two hypodermic needles to “tease” oocytes from the 
complexes 
 
• Use the same fire polished pipette and transfer the oocytes with as little as possible 
hyaluronidase solution to well 2  
 
• Now flush oocytes individually with a big [170-200um] pulled glass pipette to remove 
some of the loose cumulus cells and transfer to well 3 
 
• In well 3 start the stripping using the plastic Cook denuding pipette [130um] (Marcus 
Medical) – try to remove all corona cells to allow for evaluation of oocyte maturity 
o Make sure that the pipette works correctly before oocytes are aspirated 
o If oocytes seem stuck in pipette – blow out into one of the wells using a syringe 
and adapter  
 
 
 
       Hyaluronidase solution 
 
       HEPES buffered medium 
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• Place the denuded oocytes into a pre-prepared holding or “rugby ball” dish, into the 
elliptical fertilization wash medium drop. 
• [this dish is prepared the previous day and cultured at 6% CO2/37ºC – drops are 
covered with oil – Quinns- Cooper Surgical)  
 
   
      Cleavage medium 
 
      Fertilization medium 
 
• Now determine the maturity of the oocytes and transfer to the clean fertilization drops – 
all MII oocytes to the left drop and all MI and GV to the right drop  
• Culture until injection 
• Complete all forms  
• Set up the inverted microscope for ICSI [heated stage, holding and injection pipettes, 
manipulators] 
Injection 
 
• For ICSI with ejaculated semen, prepared the following injection dish: 
 
 
      Sperm preparation medium with sperm cells 
 
      PVP  
 
      HEPES buffered medium  
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• For ICSI with testicular biopsy sample or severe oligiozoospermia semen, prepare 
the following injection dish: 
 
 
       
 
 
 
 
 
• Incubate for ±30 minutes at 37ºC [no CO2] 
 
Sperm Immobilization 
• Add sperm cells to the sperm preparation medium 
• Select motile, morphological normal spermatozoa form the drop with the ICSI injection 
pipette and immobilize the sperm cell 
o Collect enough sperm cells for the injection procedure. 
 
[A detailed description of the immobilization process is given in Appendix II “ICSI handbook 
addendum”] 
 
Sperm injection 
• Place MII oocytes to be injected in the oocyte drops ( 2 per drop)  
• Select an immobilized sperm cell and carefully inject oocyte  
[for a detailed description of the injection process, see “ICSI handbook addendum”] 
• Continue until all oocytes are injected 
• Transfer back into the elliptical drop (fertilization) to wash and then to the cleavage 
drops for overnight culture (6% CO2/37ºC   
• Do injection ± 40 hours post HCG administration if at all possible 
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APPENDIX II    Drs Aevitas Fertility Unit: ICSI Handbook 
 
Intracytoplasmic sperm injection 
 
The microinjection procedure is performed on an inverted microscope equipped with: 
1.  A heated microscope stage (37oC). 
2. Two coarse and fine control manipulators. 
3. Two micro injectors, one for the holding pipette and the other for the injection 
pipette. 
 
The holding pipette is inserted into the pipette holder and manually positioned so that the 
angled section is perpendicular to the microscope stage. The pipette is positioned using the 
coarse manipulators. The microinjection pipette is inserted into the pipette holder and manually 
positioned so that the angled section is at angle of approximately 20o to the microscope stage. 
The angle is to ensure that the tip of the microinjection needle will touch the surface first. It 
must also be ensured that the two pipettes (holding and injection) move in line with each other. 
 
The microinjection dish is made according to the configuration of your microinjection system 
and the experience of the technician. The dish must, however, contain certain basic elements; 
an oocyte droplet, spermatozoa, PVP droplet. 
Selection and immoblization of sperm 
 
The microinjection pipette is first carefully lowered into the clean PVP droplet. Before the 
manipulation of sperm is attempted PVP medium is repeatedly aspirated and expelled to coat 
the inside of the microinjection pipette. A large enough volume (for optimum control) of PVP is 
aspirated and the pipette is lifted and moved to the sperm storage droplet. 
 
The motile spermatozoa pipetted into the storage droplet swim to the outer perimeter of the 
droplet. When selecting a sperm cell, preference is given to sperm cell which appear 
morphologically normal and which swim progressively forward. The motile sperm is aspirated 
into the injection pipette; the pipette is lifted and moved to the clean PVP droplet. The pipette is 
lowered to just above the surface (in the PVP) droplet), the sperm is slowly ejected moving the 
pipette up or down so that the sperm’s tail is transversally positioned to the pipette. The pipette 
point is lowered onto the section of the tail just below the midpiece. The pressure and the 
movement of the microinjection needle on and over the sperm tail, destabilizes the sperm 
membrane system and immobilizes the sperm. Destabilizing the sperm membrane before ICSI 
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appears to be of crucial importance for decondensation of the sperm head and pronuclei 
formation. It must be ensured that the sperm is immotile before injection, as a motile sperm 
may cause structural damage within the oocyte ooplasma. The sperm cell is aspirated and 
ejected repeatedly to ensure that the sperm cell does not stick to the injection pipette. The 
selected immobilized sperm is aspirated tail first into the microinjection pipette. The 
microinjection pipette containing the sperm is lifted and moved to the oocyte droplet. 
 
For testis biopsied sperm 
 
The number of sperm obtained after the separation process is extremely low. The resuspended 
pellet obtained from the gradient centrifugation must therefore be used to prepare a Petri dish 
as shown in the diagram above. Multiple sperm drops are placed directly into the injection dish 
as well as few very small sperm prep drops.  The configuration of the PVP and oocyte injection 
drops is the same as for ICSI with ejaculated sperm. After preparation the dish is placed into an 
incubator for a few minutes to allow all the cells to settle. The Petri dish is placed on the heated 
stage and the droplets searched for motile spermatozoa. Motile spermatozoa found in the 
droplets are aspirated with a special testis biopsy pipette and transferred to the small medium 
droplets, until a sufficient number has been obtained. The spermatozoa are then directly 
transferred to the PVP droplet of the microinjection Petri dish for immobilization and injection. 
Oocyte microinjection 
 
Using the microinjection pipette the oocyte is rotated to locate the polar body at the 12 o’clock 
or 6 o’clock position. The holding pipette is lowered and the oocyte held by gentle suction. The 
oocyte is lowered so that the oocyte touches the bottom, as this provides better control during 
injection. The microscope is focused on the oocyte’s equatorial plane and the internal lumen of 
the holding pipette. The microinjection pipette is lowered into the same focus plane at the 3 
o’clock position. The plane of the microinjection pipette can be corrected by gently pushing on 
the zona pellucida. The sperm cell is carefully brought forward to the point of the microinjection 
pipette and the pipette pushed carefully through the zona pellucida and through the oolemma 
into the ooplasma. The successful penetration of the oolemma is indicated by the ability to 
aspirate ooplasma into the pipette. The ooplasma and the sperm cell are then carefully ejected 
into the oocyte and the microinjection pipette withdrawn and the oocyte is released from the 
holding pipette. The process of penetrating the oolemma and the aspiration of a small volume 
of ooplasma also helps to activate the oocyte essential for the normal progress of fertilization. 
Care must be taken not to eject a large volume of PVP medium into the oocyte, because this 
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inevitably leads to oocyte degeneration. This whole procedure is repeated for all the oocytes in 
the microinjection dish. 
 
The oolemma of oocytes may have differing elasticity depending on the hyper stimulation 
regiment followed, the female patient’s age, the maturation of the oocyte and the in vitro age. A 
highly elastic oolemma makes penetration difficult (deeply invaginates when penetration is 
attempted). Repeat penetration may therefore be required to successfully penetrate the 
oolemma. These repeat penetrations must be performed without penetrating the opposite 
oolemma, as this may result in oocyte degeneration. 
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APPENDIX III   Drs Aevitas Fertility Unit: Embryo Culture & Evaluation 
 
Embryo evaluation 
 
Dish preparation for embryo culture 
• Prepare a culture dish with cleavage medium drops (Quinns – Cooper Surgical) for the 
next day 
• Make drops under oil (Quinns – Cooper Surgical)  
o Work as fast as possible to prevent evaporation 
o Work on a cold surface  
o Make drops equal to the number of oocytes (but add one extra for rinsing) 
o Maximum number of drops is 10 – make 2 dishes if more than 10  
 
 
 
                                                              For 6 embryos  
 
 
Fertilization check 
Day 1   (2 PN) 
 
• Check for pro nuclei (PN)  and polar body (PB) number on the inverted microscope with 
heated stage 
o Note any abnormal number of PN [ > or < than 2], or any other anomalies  
• Transfer to preincubated  cleavage medium drops covered with mineral oil in a small 
Petri dish 
• Incubate overnight at  37 ºC, 6% CO2 
 
Embryo quality/morphology check 
 
Day 2 (2- 4 cell) 
• Check for cell stage and embryo morphology on the inverted microscope with heated 
stage 
o See section on embryo morphology evaluation 
• Select embryos for transfer if a day 2 transfer 
o   See section on embryo transfer  
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Day 3 (6-8 cell) 
• Check for cell stage and embryo morphology on the inverted microscope with heated 
stage 
o See section on embryo morphology evaluation 
• Transfer embryos to preincubated  blastocyst medium drops covered with mineral oil  
• Select embryos for transfer if a day 3 transfer 
o   See section on embryo transfer  
 
Day 5/6 (Blastocyst transfer) 
• Check for cell stage/blastocyst morphology on the inverted microscope with heated 
stage 
o See section on blastocyst morphology evaluation 
• Transfer embryos/blastocysts  to preincubated  blastocyst medium drops covered with 
mineral oil  
• Select embryos/blastocysts for transfer if a day 5 transfer 
o   See section on embryo transfer  
 
Cryopreservation 
Select blastocysts for vitrification after transfers 
o See section on blastocyst vitrification 
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APPENDIX IV  Grading Criteria: Good Quality Embryos  
	
Embryo Grading (Good Quality Criteria) 
  Cell Grading 
Day 2 
2 
Cell 
4 
3 5 
4  
    
Day 3 
6 
Cell 
4 
7 5 
8  
 
Day 4 
10 Cell 4 
Early Compact (EC) 5 
Compact  
 
Day 5 
Blastocyst 1, 2, 3 B or A 
1 B or A  
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APPENDIX V  Modified Gardner & Schoolcraft Blastocyst Grading System 
 
Inner Cell Mass (ICM) Grading 
 
A Tightly packed, compacted cells 
B Larger, loose cells 
C No distinguishable ICM 
D Cells of the ICM appear degenerative 
 
Trophectoderm Grading 
 
 
A 
 
Many healthy cells forming a cohesive 
epithelium 
 
B 
 
Few, but healthy cells, large in size 
 
C 
 
Poor, very large, or unevenly distributed cells; 
may appear as few cells squeezed to the side 
 
D 
 
Cells of the trophectoderm appear 
degenerative 
Degree of Expansion & Hatching Status 
 
 
1 
Early blastocyst; the blastocoel filling more than half the volume of the conceptus, but 
no expansion in overall size as compared to earlier stages. 
 
 
2 
Blastocyst; the blastocoel filling more than half of the volume of the conceptus, with 
slight expansion in overall size and notable thinning of the zona pellucida. 
 
 
3 
Full blastocyst; a blastocoel more than 50% of the conceptus volume and overall size 
fully enlarged with a very thin zona pellucida. 
 
 
4 
Hatching blastocyst; non-preimplantation genetic diagnosis. The trophectoderm has 
started to herniate through the zona. 
 
 
5 
Fully hatched blastocyst; non-preimplantation genetic diagnosis. Free blastocyst fully 
removed from zona pellucida. 
 
 
6 
Hatching or hatched blastocyst; preimplantation genetic diagnosis. 
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APPENDIX VI   Sperm morphology (WHO) 
 
Spermatozoa consist of a head, middle piece (mid-piece), principal piece and end-piece. As the 
end-piece is difficult to see with a light microscope, the cell can be considered to comprise a 
head (and a neck) and tail (mid-piece and principal piece). Both the head and tail must be free 
from abnormalities for a spermatozoon to be considered normal.  All borderline forms should be 
considered abnormal. 
• The head should be smooth, regularly contoured and generally oval in shape. There 
should be a well-defined acrosomal region comprising 40 – 70% of the head area 
(Menkveld et al., 2001). The acrosomal region should contain no large vacuoles, and 
not occupy more than 20% of the sperm head. The post-acrosomal region should not 
contain any vacuoles. 
• The mid-piece should be slender, regular and about the same length as the sperm 
head. The major axis of the mid-piece should be aligned with the major axis of the 
sperm head. Residual cytoplasm is considered an anomaly only when in excess, i.e. 
when it exceeds one third of the sperm head size (Mortimer & Menkveld, 2001). 
• The principal piece should have a uniform calibre along its length, be thinner along the 
mid-piece, and be approximately 45µm long (about 10 times the head length). It may be 
looped back on itself, provided there is no sharp angle indicative of a flagellar break.   
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APPENDIX VII  Standard Protocol: PICSI® Procedure 
 
 
SOP 11: Physiological Intracytoplasmic sperm injection – PICSI® (Tygerberg Fertility 
Clinic) 
 
 
PICSI® procedure 
 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
Semen preparation, oocyte aspiration, denuding of oocytes, injection 
procedure/technique, embryo evaluation, embryo transfer and cryopreservation 
is exactly as for ICSI  [SOP 10] 
 
 
PICSI®® dish preparation for use 
• Hydrate the hyaluronan microdots by placing single 10-µL elliptical droplets of 
Sperm preparation medium [SAGE] at the end of each locating line covering the 
area where the microdot is situated 
 
• Also add a drop polyvinylpyrrolidone (PVP) and HEPES buffered drop and carefully 
flood the dish with tissue culture oil 
 
• Leave for ± 5minutes and add a small volume [10µL] of prepared sperm to the drop 
 
• Touch the tip of the micropipette containing the sperm to the edge of the 
hydrating drop at the bottom of the dish under the oil and expel the sperm 
• By delivering the sperm in a volume equal to the hydrating fluid, immediate 
mixing and delivery of sperm to the vicinity of the microdot is assured 
• If the sperm are delivered in a smaller volume at the edge of the drop, greater 
than 30 minutes may be required for them to swim through the hydrating fluid to 
the microdot 
 
• Alternatively, the sperm suspension can be added directly to the dry microdot.  
 
• Sperm binding begin normally in 5 minutes or less 
 
• Some microdots may require 30 minutes or more to reach full binding capability 
 
Therefore, whenever marginal sperm binding is observed, pre-hydrate for 30minutes or 
more, or allow sperm to incubate on the dot for 30 minutes or more before selecting 
sperm 
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      Sperm preparation medium with selected sperm 
       cells 
 
      PVP  
 
      HEPES buffered medium  
 
      Hyaluron drop with sperm  
 
 
 
Sperm Selection for injection 
• Once bound, hyaluronan bound sperm are easily identified: they exhibit no progressive 
migration despite vigorous tail beating 
• Factors governing sperm binding: To rapidly populate the microdot with bound sperm, 
place approximately 100,000 hyaluronan-binding sperm per mL (approximately 1,000-
2,000 total sperm in10-20 µL volume) over the microdot 
 
Sperm Location Selection 
• The wall of the hyaluronan microdot is a physical barrier to which many sperm will 
bind since this is usually the first point of contact 
• It is sometimes difficult to distinguish whether the sperm are bound or simply 
swimming against the edge of the microdot. You may be sure of selecting bound 
sperm by selecting them from the interior of the microdot 
• Obtaining a good density of bound sperm: If the density of bound sperm is too high 
or too low for good sperm selection, dilute or concentrate the prepared sperm 
sample and use the adjusted sperm sample to seed the next microdot 
• Three microdots are provided on each PICSI®® Sperm Selection Device to give a 
sufficient opportunity 
 
Sperm collection 
• To collect a bound sperm, position the tip of the ICSI micropipette next to the sperm 
and gently suck fluid into the pipette, drawing in the sperm 
• Place in the small reservoir drop of sperm prep  
• Continue collecting until 20-50 sperm are captured 
• Aspirate a single selected sperm cell and place in the PVP and immobilize 
• Proceed to do the standard ICSI injection [SOP 10] 
 
Temperature 
• Sperm bind best to hyaluronan hydrogel at temperatures below 30°C 
• At temperatures above 30°C, sperm swimming vigour increases and the swimming 
force may overcome the binding force 
• The result is that about one-third of sperm bound at room temperature will show 
some progressive migration at 37°C and may be deemed not bound and therefore  
immature 
• PICSI®® Sperm Selection Device dishes placed on a 37°C heated stage will come 
to about 33°C and then remain at that temperature 
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o Therefore select bound sperm at room temperature – store in Sperm prep 
drop and warm to 37ºC before final injection 
 
Technique considerations 
• Microdot shape: The PICSI®® Sperm Selection Device hyaluronan microdot is crater-
shaped. The edge of the microdot is a raised wall of hydrogel surrounding a low, flat 
interior layer. The wall is flexible and may be irregular in shape due to uneven hydration 
of the hydrogel. The hydrogel wall can be pierced and torn by an ICSI micropipette 
driven directly in to it. It is best to position the elevated micropipette tip over the 
microdot interior and lower it to the microdot surface for recovery of sperm.  
 
• Microdot caves: During manufacture, uneven hydration may cause segments of the 
microdot wall to create small “caves” that open toward the inside edge of the wall. 
Sperm that swim into a cave are trapped, not bound. Trapped sperm usually all face 
away from the centre of the microdot and show vigorously beating tails, often in 
clusters. The heads of trapped sperm can move laterally and sometimes back and forth 
within the walls of the cave. Trapped sperm should not be selected since their binding 
status is unclear. 
 
• Microdot stability: If a part of the wall separates from the polystyrene, the same forces 
that create caves can cause the microdot wall to progressively detach from the dish and 
coil up like a spring. When this occurs, some or all of the wall will separate from the 
microdot. However, the microdot interior hyaluronan layer will remain intact. The interior 
hyaluronan layer is stable for hours, it collects and houses bound sperm that may be 
used for ICSI. Sperm bound to the curled up wall remnant should not be used for sperm 
selection and isolation.  
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PICSI® Dish Package Insert 
 
 
Manufactured by Biocoat, Inc. • Distributed by ORIGIO a/s • Knardrupvej 2, 2760 Måløv, Denmark • Tel: +45 46 79 02 00 
E-mail: customer.service@origio.com •  www.origio.com • © Copyright ORIGIO a/s • Order No. 60010160 • version 3: June 18, 2013
Sperm selection for ICSI  
- based on Hyaluronic acid binding
PICSI® Dish
• Significantly reduces pregnancy loss rate 
• Binds only mature sperm with high DNA integrity 
• Correlates with maturity, strict morphology and reduced 
chromosomal aneuploidies 
• Clinically proven to benefit ICSI patients with low 
Hyaluronan Binding score (HBA® score)
0120
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Manufactured by Biocoat, Inc. • Distributed by ORIGIO a/s • Knardrupvej 2, 2760 Måløv, Denmark • Tel: +45 46 79 02 00 
E-mail: customer.service@origio.com •  www.origio.com • © Copyright ORIGIO a/s • Order No. 60010160 • version 3: June 18, 2013
Significantly reduces pregnancy Loss Rate
PICSI® Dish
PICSI® dish is indicated for the selection of mature sperm 
for ICSI. 
Early pregnancy loss can result from selecting a 
compromised spermatozoa during ICSI. This can be due 
to the fact that visual selection alone cannot identify 
mature spermatozoa with high DNA integrity and reduced 
chromosomal aneuploidies. Hyaluronic acid (HA)-sperm 
selection can.
Facts on Hyaluronan (Hyaluronic acid -HA):
• Hyaluronan is the major component of the Cumulus   
 Complex surrounding the human oocyte
• A sperm’s ability to bind to HA is a biochemical marker  
 of the sperm’s maturity and DNA integrity
• Only mature spermatozoa with developed receptors   
 for HA can bind
The PICSI® dish contains 3 microdots of Hyaluronic acid, 
where mature spermatozoa will bind for easy picking.
Clinical documentation
The ability to bind to HA correlates to:
• Maturity 
• Strict morphology
• High DNA integrity
• Reduced chromosomal aneuploidies
In an extensive study by Worrilow et al. (2012), it was 
found that the combination of the diagnostic abilities of 
the Hyaluronic Binding Assay (HBA®) and the HA-sperm 
selection in the PICSI® dish led to improved clinical 
Pregnancy Rate (CPL) and significantly reduced Pregnancy 
Loss Rate in ICSI patients diagnosed to have low HA-
binding ability (HBA® score ≤65% ).
This study further demonstrated that 15% of all ICSI patients 
express sperm samples with compromised developments 
(HBA® score≤ 65%) and would benefit from HA sperm 
selection. 
References
Worrilow et al. (2012) Use of hyaluronan in the selection of 
sperm for intracytoplasmic sperm injection (ICSI); significant 
improvement in clinical outcomes-multicenter, double 
blinded and randomized trial. Hum. Reprod., Nov 30.
Huszar et al. (2012) Sperm testing and ICSI selection by 
hyaluronic acid binding:  the hyaluronic acid coated glass 
slide and petri dish in the andrology and IVF laboratories. 
Practical Manual of in Vitro Fertilization: Advanced Methods 
and Novel Devices. New York: Springer. P.241-257
Yagci et al. (2010) Spermatozoa bound to solid state 
hyaluronic acid show chromatin structure with high DNA 
chain integrity: An acridine orange fluorescence study. J 
Androl; 31:566-572
Catalogue No. 
BCT-PICSI-20  20 PICSI® dishes,  
  individually packaged, sterile 
 
Find more information on www.origio.com 
A demonstration video as well as the instructions for use are 
availble on our website. You can also find out who your local 
ORIGIO distributor is.
Unbound, Motile Sperm Bound, Motile Sperm
0
5
10
15
4%
15%
>65% HBA score ≤65% HBA score 
HA bound
(PICSI)
Control 
(ICSI)
HA bound
(PICSI)
Control 
(ICSI)
5%
*
Pregnancy Loss Rate (%)
3%
n=114 n=133
• Multi-center trial  
(10 centers)
• Randomized, 
double blinded, 
controlled
• 804 patients
Statistical significance(*) is indicated at P<0.05
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APPENDIX VIII Standard Protocol: IMSI Procedure 
 
 
SOP 12: Intracytoplasmic Morphological Sperm Injection  - IMSI 
 
 
 
IMSI procedure 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
Semen preparation, oocyte aspiration, denuding of oocytes, injection 
procedure/technique, embryo evaluation, embryo transfer and cryopreservation 
is exactly as for ICSI  [SOP 10] 
 
IMSI Dish preparation for use 
• For IMSI with ejaculated semen, prepare the following injection dish 
(glass bottom dish): 
 
 
       spermatozoa 
       
       Sperm preparation medium   
        
       PVP 
         
       HEPES buffered medium 
 
 
● Incubate for ±30 minutes at 37ºC [no CO2] 
 
Sperm selection and immobilization 
● Add sperm cells to the sperm preparation medium 
● Select motile, morphological normal spermatozoa from the drop with the 
ICSI injection pipette using the 20x objective 
● Place the selected sperm into the left sperm preparation drop and focus on  
the edge of the drop 
● Change the heated stage  - metal one with a hole - the dish needs to come  
 in contact with the objective 
● Put the 100x objective in place and place a small drop of oil onto the  
 objective 
● Place the glass bottom dish containing the sperm onto the oil-covered  
objecti ve  
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● The left sperm preparation drop should be in the center of the objective.  
● Use the 100X magnification to focus on the sperm preparation drop edge 
● Bring the needle down and make an indentation in the drop edge 
o The sperm will swim into the indentation 
● Select morphologically normal sperm without any vacuoles and move them to 
the sperm preparation drop to the right 
● After selecting enough sperm, change the heated stage again and proceed 
   with  the normal ICSI protocol [SOP 10] 
 
Collect enough sperm cells for the injection procedure 
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APPENDIX IX   Patient Information Leaflet & Consent Forms 
 
PARTICIPANT INFORMATION LEAFLET AND CONSENT FORM 
 
TITLE OF THE RESEARCH PROJECT: 
 
“Examining The Effect of EmbryoGlue®®, Used as an Embryo Transfer Medium, on Assisted 
Reproductive Treatment Outcome and Success.” 
 
PRINCIPAL INVESTIGATOR: Lara Maree 
ADDRESS:  Drs Aevitas Fertility Clinic, Vincent Pallotti Hospital, Pinelands 
CONTACT NUMBER: 082 409 8227 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free 
to decline to participate.  If you say no, this will not affect you negatively in any way 
whatsoever.  You are also free to withdraw from the study at any point, even if you do agree to 
take part. 
 
This study has been approved by the Health Research Ethics Committee at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the 
international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and 
the Medical Research Council (MRC) Ethical Guidelines for Research. 
What is this research study all about? 
The study is to be conducted at Drs Aevitas Clinic at Vincent Pallotti Hospital. Approximately 
400 couples will be included in the study. The aim of the study is to improve successful 
implantation of the embryo after being transferred to the patient.  
 
EmbryoGlue®® is an embryo transfer specific medium containing a unique combination of 
hyaluronic acid and recombinant albumin. The hyaluron contained in EmbryoGlue®® is 
believed to act as a specialised adherence compound, supporting the implantation of a 
transferred embryo in the endometrium. A prospective randomized study in 2008 showed an 
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overall increase in implantation and clinical pregnancy rates where EmbryoGlue®® was 
favored above conventional transfer medium. 
The research is being conducted to determine whether the use of EmbryoGlue®® will improve 
implantation rates and ongoing pregnancy rates in Drs Aevitas Clinic. 
Why have you been invited to participate? 
You have been identified as a suitable candidate and invited to participate in the research 
based on your decision to undergo infertility treatment at Drs Aevitas Clinic. You qualify as a 
participant due to: 
 
• Female partner age ≤36 
• Normal BMI, unobstructed fallopian tubes,  
• Good response to ovarian stimulation (≥ 5 ova collected during aspiration)  
• ≥ 2 good embryos to transfer 
What will your responsibilities be? 
All we ask is that you read through the information and sign the form provided to give consent 
for the principle and co-investigators involved in this study to access to your personal 
information and for EmbryoGlue®® to be used for your embryo transfer. 
Will you benefit from taking part in this research? 
You will benefit from participating in this study in knowing that you are helping to make possible 
research that aims to improve the outcome of successful pregnancy of sub-fertile couples, 
including yourself, wishing to conceive through ART in fertility units.  
Are there in risks involved in your taking part in this research? 
There are no additional risks associated in taking part in this research.  
 
If you do not agree to take part, what alternatives do you have? 
If you choose not to take part in the research the standard protocol for embryo transfer will be 
used in your treatment. 
Who will have access to your medical records? 
Your identity and any additional information collected through your participation will be treated 
as confidential and protected.  If the research is used in a publication or thesis, the identity of 
Stellenbosch University  https://scholar.sun.ac.za
  118 
the participant will remain anonymous. This information will be available only to the principle 
and co-investigators involved in the research project described. 
What will happen in the unlikely event of some form injury occurring as a direct result of your 
taking part in this research study? 
The possibility of research related injury has been considered and it has been determined that 
it is highly unlikely that any form of injury may occur as a direct or indirect result of participation.  
 
Will you be paid to take part in this study and are there any costs involved? 
You will not be paid to take part in the study. Additional costs associated with the use of 
EmbryoGlue® will be covered by the research team.  
 
Is there anything else that you should know or do? 
• You can contact Dr. ML Windt de Beer at Tel: (021) 938 4851 if you have any further 
queries or encounter any problems. 
• You can contact the Health Research Ethics Committee at 021-938 9207 if you have 
any concerns or complaints that have not been adequately addressed by your study 
doctor. 
• You will receive a copy of this information and consent form for your own records. 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled (insert title of study). 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced 
in any way. 
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• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
.....................................................................   ................................................................... 
Signature of participant Signature of witness 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use a interpreter.  (If a interpreter is used then the interpreter must sign 
the declaration below. 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2015. 
 
.....................................................................   ................................................................... 
Signature of investigator Signature of witness
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 APPENDIX XI  Standard Operating Protocol: Semen Preparation 
 
 
SOP 5: Semen Preparation (Tygerberg Fertility Clinic) 
 
 
The sperm preparation method is determined by the quality of the sample produced, 
therefore the visual/microscopic analysis of the sample is extremely important. Factors 
that may influence the decision are; percentage motile sperm, rate of forward 
progression, concentration (total count) and the number of other cells in the semen 
sample. In addition, the assisted reproduction procedure being followed will also 
determine the procedure. Whereas with in vitro fertilization [IVF], gamete intrafallopian 
tube transfer [GIFT] and Intrauterine insemination [IUI] procedures you may need 100 
000 to 1x106 cells/oocyte, you only need 1 sperm/oocyte for an intracytoplasmic sperm 
injection [ICSI] procedure. 
 
Two basic procedures (wash and swim-up and continuous gradient centrifugation) and 
modifications of these, are used for the majority of sperm preparation procedures. The 
standard wash and swim-up procedure, however, remains the most commonly used 
procedure for sperm preparation, even for ICSI. The reasons; no foreign particles are 
introduced into the sample, the sample is free of other cells and the percentage of 
motile sperm is high. Gradient centrifugation have however been shown to yield sperm 
with less DNA damage due to eliminating reactive oxygen species [ROS] early on in the 
preparation method. 
 
The medium used for all the sperm preparation procedures is Quinn’s™ Sperm 
Washing Medium [SAGE]  
 
All tubes are labeled with the patient’s surname and all lids and tubes also with a 
colour sticker. 
 
The final tube should show both partners surnames and initials. 
 
Wash and swim-up [IUI and ICSI/PICSI®/IMSI] 
 
Three 15 mL round bottomed tubes are labelled correctly with the patent’s surname and 
initials. 5 mL sperm prep medium in one of the tubes is warmed to37ºC 
 
On the completion of liquefaction the semen sample - produced by masturbation in a 
accurately labelled semen container -  is diluted 1:2 (semen:medium) in a test tube and 
centrifuged at 350 to 400xg for 10 minutes 
 
The supernatant is aspirated after centrifugation and the pellet resuspended with 2mL of 
medium and re-centrifuged at 350 to 400xg for 10 minutes 
 
Stellenbosch University  https://scholar.sun.ac.za
  122 
After the 2nd centrifugation the supernatant is aspirated as close as possible to the 
pellet and the pellet then carefully overlayed with 0.5mL of medium taking care not to 
disturb the pellet  
 
The test tube is placed at an approximate 45o angle at 37ºC for 30 - 60 minutes 
 
After the swim-up period the top 2/3rds of the medium with motile sperm is carefully 
aspirated and placed in a clean correctly labeled test tube and stored at 37ºC until used 
 
Swim-up samples should be used within 1-hour, post preparation  
 
When faced with a problem sample the above procedure can be modified as follows; 
the number of test tubes the sample is divided into can be increased with a subsequent 
decrease in the volume of medium overlayed on each pellet. Different test tube shapes 
can also be employed. In cases of very low initial concentrations the standard flat-
bottomed tubes can be replaced with conical tubes 
 
Wash and swim-up [IVF] 
 
The procedure is exactly as for IUI/ICSI/PICSI®/IMISI, but the final 0.5mL medium for 
the swim-up step is replaced with equilibrated Quinn’s Advantage™ mLProtein Plus 
Fertilization(HTF) Medium  (equilibrated in a CO2 incubator to reach a pH of 7.2). The 
30-60 minute swim-up step is also done in a CO2 incubator 
 
Again, after the swim-up period the top 2/3rds of the medium with motile sperm is 
carefully aspirated and placed in a clean correctly labeled test tube and stored at 37ºC 
in the CO2 incubator until used. Swim-up samples should be used within 1-hour post 
preparation  
 
   
Swim-Up Method 
● Mix semen sample well (ensure sample has liquefied) 
● Dilute sample in a 1:2 ratio (semen: sperm washing medium [SAGE® test tube 
● Mix sample well, centrifuge at 450 x g for 10 minutes 
● Remove supernatant, leave pellet undisturbed 
● Resuspend pellet in 2 mL SpermPrep® 
● Centrifuge at 450 g for 10 minutes 
● Repeat once more 
● Remove supernatant and carefully overlay pellet with 0.5 mL SpermPrep® 
● Leave to stand at 45° angle in an 37°C incubator for 30 – 60 minutes 
● Aspirate the top layer of the sample, leaving pellet undisturbed 
● Estimate the concentration, motility and forward progression of the processed 
sample 
● Keep at 37°C for < 60 minutes until use 
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SilSelect (FertiPro) gradient centrifugation  
 
Masturbation samples 
 
This technique is mainly used for samples with low concentrations, poor motility, 
viscous samples, samples with high concentrations of other cells/debris and testis 
biopsy samples 
 
A Stock solution of SilSelect (100%) is used and different gradients created by adding 
Quinn’s™ Sperm Washing Medium [SWM]  
  
Gradients (in 15 mL round bottomed tubes) – prepared fresh weekly. 
 
90%: 9 mL of stock solution plus 1.0mL of SWM 
70%: 7 mL of stock solution plus 3 mL of SWM 
45%: 4.5 mL of stock solution plus5.5 mL of SWM 
 
For a 3-layer gradient, the 3  solutions are carefully layered on each other in a conical 
tube, starting with the 90% solution at the bottom and making sure they are not mixing  
 
The gradient is then allowed to equilibrate at 37oC for 15 minutes (Figure1) 
 
For a 2-layer gradient, the 905 and 45% is used 
 
The volumes of the solution for the gradient depends on the fertilization procedure and 
the semen sample  
In general I mL is used for IVF and IUI, 0.5 mL for ICSI/PICSI®/IMISI  and 0.3 mL for a 
testis biopsy sample 
 
The gradient should be used within 2 hours of preparation 
 
Two 15 mL round bottomed tubes and 2 conical tubes are labelled correctly with the 
patent’s surname and initials. 5 mL sperm prep medium in one of the round bottomed 
tubes is warmed to 37ºC and one of the conical tubes prepared with the gradient. 
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Figure 1: SilSelect gradient centrifugation 
 
 
   Mini gradient  Standard gradient Two-layer gradient 
   0.3-0.5mL  1.0mL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
   45% 
   
   70% 
 
   90% 
 
 
On the completion of liquefaction the semen sample - produced by masturbation in a 
accurately labelled semen container - is diluted 1:2 (semen:medium) in a test tube and 
centrifuged at 350 to 400xg for 10 minutes. Washing is performed to concentrate all 
possible sperm into a smaller volume t use in the gradient method. Ideally an unwashed 
sample should be overlaid on the gradient and can be done in samples with adequate 
concentration and motility. 
 
The pellet is re-suspended in 0.5mL of medium and carefully overlaid on the gradient 
 
The gradient is centrifuged for 15 minutes at 300xg 
 
After centrifugation the top layer/s are carefully aspirated and the pellet with ± 0.5 mL 
medium remaining, placed into a clean conical tube. The pellet is then washed twice 
with 2 mL medium by centrifugation 9400- 450xg) for 10 minutes each. 
 
The resulting pellet is resuspended in 0.5mL of sperm prep medium 
 
90% 90% 90% 
70% 
45% 70% 
45% 
45% 
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Frozen samples [I mL final volume – 2 straws] are overlayed directly onto the gradient 
 
When faced with a problem sample the volumes of the gradient can decreased (0.3mL; 
mini-gradient, Figure 1), the number of gradients can be increased and a two-step 
gradient can be used 
 
The concentrations for a two-step gradient are: 90% and 45% (Figure 1). The latter 
procedure results in a higher final sperm concentration, but a decreased percentage of 
motile sperm – often used for IUI 
 
Testis biopsy samples  
 
The method of preparation is similar to that of masturbated semen: 
 
An aliquot (± 0.3mL) of the fresh testis biopsy tissue/liquid containing the sperm is 
overlaid on the 3 layer “mini gradient”  The mini gradient is three 0.3mL layers [90%, 
70%, and 45% - Figure 1]. (the rest of the sample is frozen) 
 
The gradient is then centrifuged for 20 minutes at 400g 
 
After centrifugation the top layer/s are carefully aspirated and the pellet with ± 0.3 mL 
medium remaining, placed into a clean conical tube. The pellet is then washed twice 
with 2 mL medium by centrifugation (450xg) for 10 minutes each. 
 
The resulting pellet is resuspended in 0.2-0.3 mL of sperm prep medium and kept at 
ROOM TEMPERATURE until use  
 
It is preferable to use a thin glass pipette for aspirations to facilitate very fine and 
accurate removal of the supernatants 
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Density Gradient Centrifugation 
 
● This technique makes use of 3 different density gradient solutions (stock solution 
used is SilSelect® FertiPro); 
o 90% : 9mL of stock solution plus 1.0mL SpermPrep® 
o 70% :7mL of stock solution plus 3mL SpermPrep® 
o 45% : 4.5mL of stock solution plus 5.5mL SpermPrep® 
● The solutions are carefully layered on top of each other, starting with the 90% 
solution at the bottom of a conical tube and allowed to equilibrate at 37°C 
● Mix semen sample well (ensure sample has liquefied) 
● Dilute sample in a 1:2 ratio (semen: sperm washing medium [SAGE® Advantage 
HEPES buffered sperm preparation medium - SpermPrep®]) in a test tube or use 
unwashed 
● Centrifuge at 350 - 400g for 10 minutes 
● Resuspend pellet in 0.5 mL SpermPrep® and carefully overlay on gradient 
● Centrifuge sample at 400g between 15 – 20 minutes 
● Remove top gradient layers, leaving only the pellet and some medium 
● Place pellet  (0.3 – 0.5 mL) into a clean conical tube 
● Wash twice with 2mL medium at 450 g for 10 minutes 
● Resuspend in 0.3 – 0.5mL SpermPrep® 
 
Normal sample: 1mL or 0.5 mL gradients – 2 layer or 3 layer 
Testis biopsy sample: 0.3 mL gradient – 3 layer 
Centrifuge for 20 minutes at  400g  
 
Stellenbosch University  https://scholar.sun.ac.za
  127 
HIV positive and hepatitis positive samples  
 
On the completion of liquefaction the semen sample - produced by masturbation in a 
accurately labelled semen container - is diluted 1:2 (semen:medium) in a test tube and 
centrifuged at 350 to 400xg for 10 minutes  
 
The pellet isresuspended in 0.5 mL sperm prep medium  and overlaid on a three layer 
SilSelect gradient [45%, 70%, and 90%) with 90% at the bottom 
 
The tube is centrifuged at 350-400g for 15 minutes 
 
The 45% and 70%  layer are  were aspirated and the resultant pellet placed in a clean 
conical, test tube 
 
The pellet is then washed twice with 2mL sperm prep medium at 400g for 10 minutes 
 
After the second wash the resultant pellet is overlaid with 0.6-5mL sperm prep and 
allowed to swim up for 60 minutes at 37°C 
 
After the swim-up period the top 2/3rds of the medium with motile sperm is carefully 
aspirated and placed in a clean correctly labeled test tube and stored at 37ºC in the CO2 
incubator until used 
 
Samples should be used within 1 hour post preparation  
 
following hour, it was not necessary to freeze the supernatant at 70°C (13, 14)  
 
The remaining 0.7 mL was used for IUI if the results of the PCR test for HIV-1 were 
negative 
 
Sep-D preparation 
 
On the completion of liquefaction the semen sample  - produced by masturbation in a 
accurately labelled semen container -  is placed in a small petri dish 
 
The device (Surelife SEP-D kit) contains 1mL of pre-filled semen processing medium 
and is `placed at 37ºC for 15 minutes to equilibrate  
 
The cap from the tip of the device is removed and any air bubbles removed 
 
 1-1.5 mL of liquefied semen is slowly aspirated into the syringe (from a small petri dish) 
ensuring that no mixing of semen and mediums occurs. Keeping the device vertical is 
recommended 
 
The cap is replaced and the device kept vertical without shaking and incubated at 37oC 
for one hour 
 
After 1 hour, the cap is removed and the semen layer gently expelled followed by 
culture medium retaining only 0.5mL of culture medium containing the motile sperm in 
the device 
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The last 0.5 mL is then place in a round bottomed tube and concentration, motility and 
forward progression estimated 
 
The sample is kept at 37ºC until use 
 
Very viscous samples 
 
Viscous samples can be treated in the same way as poorly liquefied samples 
 
Bromolaine (proteolytic enzyme)Box 2.2 Preparation of bromelain) 
Prepare 10 IU/mL bromelain in Dulbecco’s phosphate-buffered saline 
Dilute semen 1+1 (1:2) with the 10 IU/mL bromelain 
Stir with a pipette tip, and incubate at 37 °C for 10 minutes 
Mix the sample well before further analysis 
 
Washing 
Add an equal volume of physiological medium (e.g. Dulbecco’s phosphate-
buffered saline, followed by repeated pipetting 
 
Needle 
Pass the sample gently (6–10 times) through blunt gauge 18 (internal diameter 
0.84 mm) or gauge 19 (internal diameter 0.69 mm) needle attached to a syringe 
 
 
These treatments may affect seminal plasma biochemistry, sperm motility and sperm 
morphology, and their use must be recorded 
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 APPENDIX XII Standard Operating Protocol: In Vitro Fertilization 
 
 
SOP 9: In Vitro Fertilization –IVF 
 
 
Make sure that all forms and documents are prepared 
Check patient’s file and record to eliminate all possible uncertainties/queries    
 
 
Semen preparation 
 See section on semen preparation methods [SOP 5]  
 
Aspiration 
Medium preparation – previous day 
See section on medium preparation [SOP 4] 
 
Ovum Pick up 
• Check suction pump (100-120 mmHg) 
• Prepare glass polished pipettes for pick up 
• Place pick-up tubes in heated block 
• Place aspirated follicular fluids in heated block and examine for oocyte-cumulus 
complexes using a large Petri dish on a heated stage (37-40ºC) of a dissection 
microscope 
• Determine maturity [see appendix at end of section] 
o GV, MI, MII   
o Spread complexes to visualize the first polar body (if possible)  
o Note maturity and all other features on the ova form 
• Put the complexes (with as little as possible blood and medium) in the pick-up 
tubes (MI and MII separate) 
• When done, rinse all complexes in small Petri dish with gassed fertilization 
medium – check number obtained 
• Now transfer to 4 well NUNC dish – maturities separate and not more than 5 
complexes per well 
• Incubate in the CO2 incubator until insemination 
• Complete all forms  
 
Insemination 
• Inseminate complexes with the correct number/volume of prepared sperm 
o Morphology  ≤ 4 % - up to 2 x 106 sperm/ovum            
o Morphology > 4, ≤ 14 % – 500 000 sperm/ovum                       
o Morphology  > 14 %  – 100 000 sperm/ovum                
§ (work out the correct volume) 
• Do insemination ± 40 hours post HCG administration if at all possible 
• Incubate overnight at  37 ºC, 6% CO2 
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Embryo evaluation 
 
Dish preparation for embryo culture 
• Prepare a culture dish with cleavage medium drops (Quinns – Cooper Surgical) for 
the next day 
• Make drops under oil (Quinns – Cooper Surgical)  
o Work as fast as possible to prevent evaporation 
o Work on a cold surface  
o Make drops equal to the number of oocytes (but add one extra for rinsing) 
o Maximum number of drops is 10 – make 2 dishes if more than 10  
 
 
 
                                                             For 6 embryos  
 
 
 
 
 
Fertilization check 
 
Day 1  (2 PN) 
 
• Clean oocytes with denuding pipettes ( Cook Australia)  
o If oocytes are not clearly visible – dislodge first with two sterile, hypodermic 
needles   
• Rinse well in clean 4 well NUNC dish  
• Check for pro nuclei (PN)  and polar body (PB) number on the inverted microscope 
with heated stage 
o Note any abnormal number of PN [ > or < than 2], or any other anomalies
  
• Transfer to preincubated  cleavage medium drops covered with mineral oil in a small 
Petri dish 
• Incubate overnight at  37 ºC, 6% CO2 
 
 
Embryo quality/morphology check 
 
Day 2 (2- 4 cell) 
• Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation [SOP 17] 
• Select embryos for transfer if a day 2 transfer 
o   See section on embryo transfer [SOP 18]  
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Day 3 (6-8 cell) 
• Check for cell stage and embryo morphology on the inverted microscope with 
heated stage 
o See section on embryo morphology evaluation [SOP 17]   
• Transfer embryos to preincubated  blastocyst medium drops covered with mineral oil  
• Select embryos for transfer if a day 3 transfer 
o   See section on embryo transfer [SOP 18]  
 
Day 5/6 (Blastocyst) 
• Check for cell stage/blastocyst morphology on the inverted microscope with heated 
stage 
o See section on blastocyst morphology evaluation [SOP 17] 
• Transfer embryos/blastocysts  to preincubated  blastocyst medium drops covered 
with mineral oil  
• Select embryos/blastocysts for transfer if a day 5 transfer 
o   See section on embryo transfer [SOP 18]  
 
Cryopreservation 
 
Select blastocysts for vitrification after transfers 
o See section on blastocyst vitrification  [SOP13] 
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• Immature COC displays an unexpanded cumulus and a dense corona forming a 
compact layer of cells adhering to the zona pellucida of a prophase I (germinal vesicle-
bearing) oocyte. The ooplasm cannot be seen through the cumulus mass associated 
with small parietal granulosa cells which appear in compact clumps 
  ê 
 
 
 
• In stimulated cycles it is common to recover COC that display some degree of cumulus 
expansion but a compact corona layer or even an expanded cumulus-corona complex 
and nevertheless contain immature prophase I oocytes. If they are not recognized at 
harvest, and are inseminated immediately, they will result in an absent or delayed 
fertilization 
 
• A typical mature preovulatory COC displays an expanded radiating corona surrounded 
by the loose mass of cumulus cells, macroscopically visible. The sparse structure of 
these cells allows identification of the oocyte with a spherical, homogeneous ooplasm 
and sometimes the first polar body extruded in the perivitelline space (PVS). Usually, 
however, cumulus and or corona layers are dense in appearance and at times darkened 
and the polar body cannot be observed 
 ê 
 
 
 
• Post-mature COC has also been described. They are thought to arise from cycles where 
there has been a premature attenuated LH surge or a delayed HCG administration. The 
cumulus displays clusters of darkened cells while the corona is usually dark and tight   
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  ê 
 
 
 
 
• Degenerative or atretic COC: At recovery, -3% of COC exhibit clear signs of 
anomalies, e.g. oocytes with a dark and/ or contracted irregular ooplasm, disrupted 
zonae pellucidae, empty zonae surrounded by a retracted cumulus mass. These COC 
are discarded from further culture and insemination 
   
 
 
 
 
 
Jacqueline Mandelbaum.  Oocytes. Human Reproduction, Vol. 15, (Suppl. 4), pp. 11-
18, 2000 
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APPENDIX XIII Standard Operating Protocol: Vitrification & Warming-Blastocysts  
 
 
SOP 13: Vitrification and Warming – Blastocysts 
 
 
 
Blastocyst Vitrification procedure 
 
Make sure that all forms and documents are prepared 
Make sure the patients are aware of extra cost and have signed the consent form  
Check patient’s file and record to eliminate all possible uncertainties/queries 
 
Modified from the FertiproTM Vitrifreeze kit method and using the CryotopTM from 
Kitazato® as carrier/storage device  
 
Medium Preparation and labeling  
• Remove an aliquot of the vitrification mediums [FertiproTM]and place into eppendorf 
tubes and label  
§ Pre-incubation medium [P] or 1 
§ Vitrification medium 1 [E] or 2 
§ Vitrification medium 2 [V] or 3 
  
• Allow to  reach room temperature   
• Use finely drawn glass pipettes  
o Use whatever pipette and suction device you find you have the best control 
with 
• Label cryotops in the correct manner with a non-toxic permanent marker pen  
o Female partner surname and initials 
o DOB or Id number 
o Date of vitrification 
• Complete and duplicate all applicable vitrification forms  
• Find a suitable LN2 storage place 
• Check the availability of LN2 
• Get LN2 vitri container ready  
• Place 300µL of P medium in a well of a 4 well dish 
• Use a big petri dish for 100 µL the medium drops of  E and V respectively – make 
these drops just before use 
• Get the LN2 ready and put the cryotop cover straws in the LN2     
 
Artificial collapsing of blastocoel cavity  
§ Do artificial collapsing of expanded blastocysts – all 2 and 3 gradings of expansion 
§ Use a drop of flushing medium covered with oil (37ºC) 
§ Hold blastocyst with holding pipette at ICM side 
§ Push collapsing pipette through trophectoderm 
§ If blast does not collapse by itself, perform gentle suction to collapse 
blast 
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Method 
• Place blastocysts (maximum 3) in the P medium in the w 4 well dish well. 
• Leave for 5-7 minutes 
o During this time make two 50µL drops of E medium in a petri dish lid   
• Set a timer for 2 minutes 
• Place the blastocysts in the E medium – using as little as possible of the P medium 
• Empty the pipette of all excess medium  
• Move blastocysts gently around the drop to different areas 
• Set a timer for 30 seconds  
• After 1 minute transfer to second E drop 
o During this time make two 50µL drops of V medium in the petri dish lid   
• After another 1 minute [total time in E  - 2 minutes] move to the V medium drop- using 
as little as possible of the E medium 
• Blastocysts will float – so make sure to find them and place them at the bottom of the 
drops  
• Empty the pipette of all excess medium  
• Within 30 seconds move from 1st to second V medium drop and place on CryotopTM  tip 
in the correct manner 
 
ALWAYS EMPTY THE PIPETTE BETWEEN TRANSFERS TO MINIMIZE DILUTION OF 
DROPS  
 
• Aspirate blastocysts in a VERY small amount of V medium and place on tip of cryotop – 
remove most of the V medium while ensuring to keep the blastocysts on the cryotop 
o Insert the cryotop tip into the LN2 and swirl around for a few seconds 
o Using a metal clamp to hold the cover straw, and place the tip into the cover 
straw – NEVER TAKE THE TIP/DEVICE OUT OF THE LN2 
• Immerge the whole device into the LN2  
• While keeping the cryotop unit under LN2 at all times, place into a goblet and place in 
storage tank in the correct place 
 
Finalize all the forms and carefully note the storage identification 
Write all the details about the cryopreservation into the patient file 
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Vitrified blastocyst warming procedure for embyo transfer 
 
Make sure that all forms and documents are prepared 
Make sure the patients are aware of extra cost  
Make sure the correct blastocysts are warmed  
Make sure how many blastocysts should be warmed Check patient’s file and record to 
eliminate all possible uncertainties/queries 
 
Modified from the FertiproTM Vitrithaw kit method and using the CryotopTM from 
Kitazato® as carrier/storage device  
 
Medium preparation 
• Prepare a transfer dish one day before the transfer  
o 4 well dish with blastocyst medium in well 1 and 3 and blastocyst transfer 
medium in well 2 and 4 (37ºC, 6% CO2) 
 
• Remove an aliquot of the warming mediums [FertiproTM] and place into an 
eppendorf tube and label  (to reach  37ºC)  
§ Thaw medium 1  ( ± 1 ml in centre well dish) [1] 
§ Thaw medium 2     [2] 
§ Thaw medium 3     [3]  
§ Thaw medium 4     [4] 
• ALL MEDIUMS MUST BE AT 37ºC 
• Use finely drawn glass pipettes  
o Use whatever pipette and suction device you find you have the best control with 
• Check names, initials and storage place 
• Use a big petri dish for the 100 µLmedium drops (Thaw 2-4) 
• Get all paperwork in place 
 
Method 
• Remove CryoTopTM from the LN2 storage tank and place into the LN2 in container without 
exposing CryoTopTM to the air and take to lab 
• Remove cover straw very carefully 
• Insert CryoTopTM tip with embryos directly into the 1ml thaw medium 1 at 37ºC  
• Stir for a few seconds and dislodge embryos with a pipette if necessary – keep this part 
of the step as short as possible 
• Incubate the embryos 3 minutes in thaw medium 1 (37ºC) 
o During this time make 100µL drops each of thaw solution 2,3 and 4 in a  big 
petri dish 
• Transfer the embryos to the thaw solution 2 drop and incubate for 2 minutes (37ºC) 
• Transfer the embryos to the thaw solution 3 drop and incubate for 2 minutes (37ºC) 
• Transfer the embryos to the thaw solution 4 drop and incubate for at least 1 minute 
(37ºC) 
 
• Transfer now to ± 0.7 ml equilibrated blastocyst medium in a 4 well dish ( well 1), and 
wash once more in the second well of the 4 well dish at 37ºC, 6% CO2  
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• Note survival, expansion and blastocyst grading/quality after 2 hours 
• Confirm number to be transferred 
• Transfer to ET well [usually 4] just before ET 
 
• Fill in all applicable forms correctly 
 
Embryo transfer is done according to SOP 20 
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APPENDIX XIV Standard Operating Protocol: Embryo Transfer Technique 
 
 
SOP 18: Embryo Transfer Technique 
 
 
Embryo Transfer Method 
 
Preparation 
• Decide which and how many embryos will be transferred after consultation with the 
patients and the clinician 
• Transfer to the  transfer dish [4 well NUNC]- prepared the previous day or 6 hours 
pre ET 
o 0.8 mL cleavage/blastocyst in well 2 and 3 and 2 ml medium in the middle 
 
• Place sterile instruments [forceps, speculum, valsellum], sterile gauze, and the 
transfer catheter and stylet on a sterile green cloth  
• A stylet is placed into the cannula of the soft catheter, ready for the clinician to use 
• Keep 5 mL warm sterile rinsing medium ready 
• The procedure and what to expect is discussed with couple and pictures of similar 
types of embryos also shown to them 
• The patient is positioned on the bed so that she is comfortable and the clinician has 
good access and vision to the vagina and cervix   
• The procedure starts by placing a speculum in the vagina to visualize the cervix, 
which is rinsed with sterile medium. The cervix is the cleaned to remove al old blood 
and also mucus 
• It is important that the patient’s bladder is full before the transfer occurs as this 
ensures that the endometrial cavity can be accessed easily and atraumatically and 
embryos transferred easily and exactly at the right place 
• The procedure starts by placing a speculum in the vagina to visualize the cervix, 
which is rinsed with sterile medium. The cervix is the cleaned to renmoev al old blod 
and also mucus 
 
Embryo Catheter loading 
 
Once the clinician is ready for the transfer – with good sonar vision of the uterus cavity 
and confirmation that the cannula can be visualized in the correct place, the embryo/s 
are loaded into the catheter: 
 
Method: 
• Aspirate medium [blast or cleavage] from well 2 into a nontoxic 1 ml syringe 
• Connect the soft catheter and expel the whole volume back inti well 2 
• Make an air space of about 1 cm at the tip of the catheter 
o Visualize the embryos 
o Aspirate ± 10 µL of medium [± 4 cm] into the catheter and then the embryos until a 
total of ± 20µL in total has been aspirated  
o Take to the clinician 
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        
    air 20µL medium with embryos  
 
Catheter tip 
     
 
Transfer Procedure 
A soft transfer catheter, which contains the embryos to be transferred, is inserted 
through the cannula into uterine cavity.  
 
After insertion of the catheter, the media containing the embryos are deposited into the 
uterine cavity. It is important that the embryos be placed in the correct position andthat 
care is taken NOT to touch the fundus 
 
After the deposit of the embryos, the embryologist checks the catheter immediately to 
ensure that the embryos did not remain inside the catheter – if they did they can just be 
transferred againt.  
 
The transfer is guided with an ultrasound (abdominal ultrasound) to ensure correct 
placement in the uterine cavity.  
 
Anesthesia is not required when performing an embryo transfer. 
 
It is recommended that the patient remains lying down for 15 minutes befire she gets up 
to empty her bladder 
 
It is also recommended that the couple abstain from sex until the pregnancy test, the 
female partner avoid strenuous exercise, alcohol, caffeine, medication and cigarette 
smoke 
 
Progesterone support is given until the pregnancy test – a blood 10 days after the 
transfer   
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APPENDIX XV Statistical Analysis Results (Retrospective)  
	
Procedure Frequencies 
 
           |              proc3 
      Proc |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         1 |        41          0          0 |        41  
         2 |         0          0        129 |       129  
         3 |         0         29          0 |        29  
         4 |         0          0         52 |        52  
         5 |         0         14          0 |        14  
         6 |         0        120          0 |       120  
         8 |         0          0          2 |         2  
        12 |         0          0          1 |         1  
-----------+---------------------------------+---------- 
     Total |        41        163        184 |       388  
 
 
Age of Ova 
 
a) Mean age of ova 
 
proc3        variable |      mean         N        sd 
----------------------+------------------------------ 
IVF            ageova |  30.73171        41  4.636941 
PICSI®          ageova |  30.76687       163  4.619565 
ICSI           ageova |  29.91304       184  5.074639 
----------------------+------------------------------ 
Total          ageova |  30.35825       388  4.848933 
----------------------------------------------------- 
 
 
b) Mean Age of Ova Compared Between Methods 
 
Analysis of variance (anova) used to compare the means 
 
                         Number of obs =        388    R-squared     =  0.0076 
                         Root MSE      =    4.84294    Adj R-squared =  0.0025 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  69.405028          2   34.702514      1.48  0.2290 
                         | 
                   proc3 |  69.405028          2   34.702514      1.48  0.2290 
                         | 
                Residual |  9029.7986        385   23.454022   
              -----------+---------------------------------------------------- 
                   Total |  9099.2036        387   23.512154   
 
No difference in mean age of ova between methods p=.2290 
 
 
c) PICSI®: Male Diagnosis Frequencies 
 
           |              proc3 
     Mdiag |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         1 |        17         36         93 |       146  
           |     42.50      25.53      54.07 |     41.36  
-----------+---------------------------------+---------- 
         2 |         0         10         10 |        20  
           |      0.00       7.09       5.81 |      5.67  
-----------+---------------------------------+---------- 
         3 |         0          8          1 |         9  
           |      0.00       5.67       0.58 |      2.55  
-----------+---------------------------------+---------- 
         4 |         0          1          3 |         4  
           |      0.00       0.71       1.74 |      1.13  
-----------+---------------------------------+---------- 
         5 |         0          3         14 |        17  
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           |      0.00       2.13       8.14 |      4.82  
-----------+---------------------------------+---------- 
         6 |         0          3          1 |         4  
           |      0.00       2.13       0.58 |      1.13  
-----------+---------------------------------+---------- 
         8 |         0         11         19 |        30  
           |      0.00       7.80      11.05 |      8.50  
-----------+---------------------------------+---------- 
         9 |        21         34          5 |        60  
           |     52.50      24.11       2.91 |     17.00  
-----------+---------------------------------+---------- 
        10 |         1          1          1 |         3  
           |      2.50       0.71       0.58 |      0.85  
-----------+---------------------------------+---------- 
        11 |         1          6          2 |         9  
           |      2.50       4.26       1.16 |      2.55  
-----------+---------------------------------+---------- 
        12 |         0          2         21 |        23  
           |      0.00       1.42      12.21 |      6.52  
-----------+---------------------------------+---------- 
        13 |         0          0          1 |         1  
           |      0.00       0.00       0.58 |      0.28  
-----------+---------------------------------+---------- 
        15 |         0         24          1 |        25  
           |      0.00      17.02       0.58 |      7.08  
-----------+---------------------------------+---------- 
        16 |         0          1          0 |         1  
           |      0.00       0.71       0.00 |      0.28  
-----------+---------------------------------+---------- 
        20 |         0          1          0 |         1  
           |      0.00       0.71       0.00 |      0.28  
-----------+---------------------------------+---------- 
     Total |        40        141        172 |       353  
           |    100.00     100.00     100.00 |    100.00  
 
Pearson chi2(14) = 103.2437   Pr = 0.000 for comparison of PISCI versus ICSI profile.  
 
(descriptive statistics) 
 
 
d) PICSI®: Female Diagnosis Frequencies 
 
           |              proc3 
     Fdiag |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         1 |        17         65        137 |       219  
           |     42.50      46.43      74.86 |     60.33  
-----------+---------------------------------+---------- 
         2 |         6          5          9 |        20  
           |     15.00       3.57       4.92 |      5.51  
-----------+---------------------------------+---------- 
        13 |         0          3          1 |         4  
           |      0.00       2.14       0.55 |      1.10  
-----------+---------------------------------+---------- 
        14 |         4         12          6 |        22  
           |     10.00       8.57       3.28 |      6.06  
-----------+---------------------------------+---------- 
        15 |         5         12         14 |        31  
           |     12.50       8.57       7.65 |      8.54  
-----------+---------------------------------+---------- 
        16 |         6         36         13 |        55  
           |     15.00      25.71       7.10 |     15.15  
-----------+---------------------------------+---------- 
        17 |         2          5          1 |         8  
           |      5.00       3.57       0.55 |      2.20  
-----------+---------------------------------+---------- 
        18 |         0          1          0 |         1  
           |      0.00       0.71       0.00 |      0.28  
-----------+---------------------------------+---------- 
        19 |         0          1          1 |         2  
           |      0.00       0.71       0.55 |      0.55  
-----------+---------------------------------+---------- 
        28 |         0          0          1 |         1  
           |      0.00       0.00       0.55 |      0.28  
-----------+---------------------------------+---------- 
     Total |        40        140        183 |       363  
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e) Number of Ova 
 
  
. ANOVA NrOva 
 
                         Number of obs =        387    R-squared     =  0.0055 
                         Root MSE      =    7.59128    Adj R-squared =  0.0004 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  123.29723          2   61.648613      1.07  0.3441 
                         | 
                   proc3 |  123.29723          2   61.648613      1.07  0.3441 
                         | 
                Residual |  22128.982        384   57.627557   
              -----------+---------------------------------------------------- 
                   Total |  22252.279        386   57.648391   
 
 
 
. tabstat NrOva , statistics( mean sd count median ) by(proc3) varwidth(14) columns(stati 
> stics) 
 
proc3        variable |      mean        sd         N       p50 
----------------------+---------------------------------------- 
IVF             NrOva |  11.90244  7.265689        41        11 
PICSI®           NrOva |  12.8589   7.649641       163        11 
ICSI            NrOva |  13.65027  7.609139       183        12 
----------------------+---------------------------------------- 
Total           NrOva |  13.13178  7.592654       387        11 
--------------------------------------------------------------- 
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f) Number of MII Ova 
 
  
. ANOVA mii 
 
                         Number of obs =        388    R-squared     =  0.0003 
                         Root MSE      =    6.38634    Adj R-squared = -0.0048 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  5.4036589          2   2.7018295      0.07  0.9359 
                         | 
                   proc3 |  5.4036589          2   2.7018295      0.07  0.9359 
                         | 
                Residual |  15702.377        385   40.785396   
              -----------+---------------------------------------------------- 
                   Total |  15707.781        387   40.588581   
 
 
. tabstat mii , statistics( mean sd count median ) by(proc3) varwidth(14) columns(statist 
> ics) 
 
proc3        variable |      mean        sd         N       p50 
----------------------+---------------------------------------- 
IVF               mii |  10.56098  6.241189        41        10 
PICSI®             mii |   10.8773  6.599451       163         9 
ICSI              mii |  10.96196  6.223845       184        10 
----------------------+---------------------------------------- 
Total             mii |  10.88402  6.370917       388        10 
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g) Number of MII Ova Fertilized 
 
  
. ANOVA fertmii  
 
                         Number of obs =        388    R-squared     =  0.0020 
                         Root MSE      =    5.07117    Adj R-squared = -0.0032 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  19.455913          2   9.7279567      0.38  0.6853 
                         | 
                   proc3 |  19.455913          2   9.7279567      0.38  0.6853 
                         | 
                Residual |  9900.9642        385    25.71679   
              -----------+---------------------------------------------------- 
                   Total |  9920.4201        387    25.63416   
 
 
. tabstat fertmii , statistics( mean sd count median ) by(proc3) varwidth(14) columns(sta 
> tistics) 
 
proc3        variable |      mean        sd         N       p50 
----------------------+---------------------------------------- 
IVF           fertmii |  8.585366  5.049632        41         8 
PICSI®         fertmii |  8.282209  5.030167       163         7 
ICSI          fertmii |  8.755435  5.111861       184         7 
----------------------+---------------------------------------- 
Total         fertmii |   8.53866  5.063019       388         7 
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h) Fertilization Rate of MII Ova 
 
  
. ANOVA p_fertmii  
 
                         Number of obs =        388    R-squared     =  0.0130 
                         Root MSE      =    .176816    Adj R-squared =  0.0079 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  .15902647          2   .07951324      2.54  0.0799 
                         | 
                   proc3 |  .15902647          2   .07951324      2.54  0.0799 
                         | 
                Residual |  12.036554        385   .03126378   
              -----------+---------------------------------------------------- 
                   Total |  12.195581        387   .03151313   
 
Some indication 
. tabstat p_fertmii , statistics( mean sd count median ) by(proc3) varwidth(14) columns(s 
> tatistics) 
 
proc3        variable |      mean        sd         N       p50(median) 
----------------------+---------------------------------------- 
IVF         p_fertmii |  .8372943  .1753909        41        .9 
PICSI®       p_fertmii |  .7741294   .180331       163        .8 
ICSI        p_fertmii |  .8039342  .1739599       184  .8333333 
----------------------+---------------------------------------- 
Total       p_fertmii |  .7949383  .1775194       388  .8181818 
 
Non-parametric regression model to compare the procedure. Quantile regression model used which 
models the medians. Adjusted for covariate; age of ova, donor ova and surrogate status 
 
 
. xi: qreg p_fertmii i.proc3 ageova i.donova i.surr, quantile(50) 
i.proc3           _Iproc3_0-2  (naturally coded; _Iproc3_0 omitted) (IVF the reference) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
i.surr            _Isurr_0-1          (naturally coded; _Isurr_0 omitted) 
Iteration  1:  WLS sum of weighted deviations =  26.838704 
 
Median regression                                   Number of obs =        387 
  Raw sum of deviations 26.97327 (about .81818181) 
  Min sum of deviations 26.68316                    Pseudo R2     =     0.0108 
 
------------------------------------------------------------------------------ 
   p_fertmii |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   _Iproc3_1 |  -.0923273   .0422314    -2.19   0.029    -.1753632   -.0092915 PICSI® vs IVF 
   _Iproc3_2 |  -.0605286   .0417895    -1.45   0.148    -.1426955    .0216384 ICSI vs IVF 
      ageova |  -.0015345   .0036046    -0.43   0.671     -.008622     .005553 
  _Idonova_2 |  -.0271952   .0389234    -0.70   0.485    -.1037267    .0493363 
    _Isurr_1 |    .047144   .0791453     0.60   0.552    -.1084722    .2027602 
       _cons |   .9352941   .1226313     7.63   0.000     .6941752    1.176413 
------------------------------------------------------------------------------ 
The estimated median difference in fertilisation between PICSI® and IVF is 9.2% (95%CI: .9% to 
17.5%) with PICSI® lower then IVF.  p=.029 
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The estimated median difference in fertilisation between ICSI and IVF is 6.1% (95%CI: -2.2% to 
14.3%) with ICSI lower then IVF , p=.148 
These contrast interesting but not the main focus of your study  
 
Testing whether median PICSI®= median of icsi 
 
. test _Iproc3_1= _Iproc3_2 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
       F(  1,   381) =    1.47 
            Prob > F =    0.2258 
 
Estimated difference in median fertilisation from the model between PCSI and ICSI 
. lincom _Iproc3_1- _Iproc3_2 (PICSI®-ICSI) 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
------------------------------------------------------------------------------ 
   p_fertmii |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         (1) |  -.0317988   .0262103    -1.21   0.226    -.0833337    .0197361 
------------------------------------------------------------------------------ 
Medians are not different p=.226 
 
 
 
 
Testing for overall procedure effect: 
 
. test _Iproc3_1 _Iproc3_2 
 
 ( 1)  _Iproc3_1 = 0 
 ( 2)  _Iproc3_2 = 0 
 
       F(  2,   381) =    2.53 
            Prob > F =    0.0811 
Overall there is no procedure effect. p-value similar tp that of anova above which is also an 
overall tests  (.0811 vs .0799) 
 
Thus no real difference between PICSI® and ICSI with respect to fertilisation of mii 
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i) Embryo Quality 
 
Day2 to Day 5: Absolute number of good embryos 
 
  
 
Good Fertilisation rate of number of ova over the days 
. generate pergd2= GQDAY2/ NrOva 
(10 missing values generated) 
 
. generate pergd3= GQDAY3/ NrOva 
(12 missing values generated) 
 
. generate pergd5= GQDAY5/ NrOva 
(104 missing values generated) 
 
. tabstat pergd2 pergd3 pergd5 , statistics( mean sd count median ) by(proc3) varwidth(14 
> ) columns(statistics) 
 
proc3        variable |      mean        sd         N       p50 
----------------------+---------------------------------------- 
IVF            pergd2 |  .6544362  .2257433        41      .625 
               pergd3 |  .4649209  .2460165        40        .4 
               pergd5 |  .2396426  .1777277        29  .2222222 
----------------------+---------------------------------------- 
PICSI®          pergd2 |  .5403402   .171408       160   .532563 
               pergd3 |  .3881474   .207578       160  .3603896 
               pergd5 |  .2148705  .1670671       120  .1961538 
----------------------+---------------------------------------- 
ICSI           pergd2 |  .5600827  .1893657       177  .5555556 
               pergd3 |  .3998904  .1987751       176        .4 
               pergd5 |   .248487  .1760843       135  .2222222 
----------------------+---------------------------------------- 
Total          pergd2 |  .5619602  .1888624       378  .5454546 
               pergd3 |  .4018115  .2085882       376  .3846154 
               pergd5 |  .2333797    .17263       284  .2163743 
--------------------------------------------------------------- 
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Profile of PICSI® and ICSI nearly identical 
 
j) Comparison over each date between PICSI® and ICSI: Day2 
 
. ttest pergd2 if proc3>0, by(proc3) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   PICSI® |     160    .5403402     .013551     .171408     .513577    .5671033 
    ICSI |     177    .5600827    .0142336    .1893657    .5319922    .5881732 
---------+-------------------------------------------------------------------- 
combined |     337    .5507094    .0098632    .1810645     .531308    .5701108 
---------+-------------------------------------------------------------------- 
    diff |           -.0197425    .0197516               -.0585953    .0191103 
------------------------------------------------------------------------------ 
    diff = mean(PICSI®) - mean(ICSI)                               t =  -0.9995 
Ho: diff = 0                                     degrees of freedom =      335 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.1591         Pr(|T| > |t|) = 0.3183          Pr(T > t) = 0.8409 
 
 
k) Comparison over each date between PICSI® and ICSI: Day3 
 
. ttest pergd3 if proc3>0, by(proc3) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   PICSI® |     160    .3881474    .0164105     .207578    .3557367     .420558 
    ICSI |     176    .3998904    .0149832    .1987751    .3703193    .4294615 
---------+-------------------------------------------------------------------- 
combined |     336    .3942985    .0110634    .2027952     .372536    .4160609 
---------+-------------------------------------------------------------------- 
    diff |           -.0117431    .0221757               -.0553648    .0318786 
------------------------------------------------------------------------------ 
    diff = mean(PICSI®) - mean(ICSI)                               t =  -0.5295 
Ho: diff = 0                                     degrees of freedom =      334 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.2984         Pr(|T| > |t|) = 0.5968          Pr(T > t) = 0.7016 
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l) Comparison over each date between PICSI® and ICSI: Day5 
 
. ttest pergd5 if proc3>0, by(proc3) 
 
Two-sample t test with equal variances 
------------------------------------------------------------------------------ 
   Group |     Obs        Mean    Std. Err.   Std. Dev.   [95% Conf. Interval] 
---------+-------------------------------------------------------------------- 
   PICSI® |     120    .2148705    .0152511    .1670671    .1846719    .2450692 
    ICSI |     135     .248487    .0151549    .1760843    .2185133    .2784608 
---------+-------------------------------------------------------------------- 
combined |     255    .2326675    .0107952     .172385    .2114081    .2539269 
---------+-------------------------------------------------------------------- 
    diff |           -.0336165    .0215672               -.0760906    .0088575 
------------------------------------------------------------------------------ 
    diff = mean(PICSI®) - mean(ICSI)                               t =  -1.5587 
Ho: diff = 0                                     degrees of freedom =      253 
 
    Ha: diff < 0                 Ha: diff != 0                 Ha: diff > 0 
 Pr(T < t) = 0.0602         Pr(|T| > |t|) = 0.1203          Pr(T > t) = 0.9398 
 
No significant difference at all days 
 
 
m) Pregnancy 
 
 
           |              proc3 
        PR |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         0 |        18         66         66 |       150  
           |     43.90      43.71      36.67 |     40.32  
-----------+---------------------------------+---------- 
         1 |         0         12         17 |        29  
           |      0.00       7.95       9.44 |      7.80  
-----------+---------------------------------+---------- 
         2 |         0          0          1 |         1  
           |      0.00       0.00       0.56 |      0.27  
-----------+---------------------------------+---------- 
         3 |         0          0          1 |         1  
           |      0.00       0.00       0.56 |      0.27  
-----------+---------------------------------+---------- 
         4 |         0          0          3 |         3  
           |      0.00       0.00       1.67 |      0.81  
-----------+---------------------------------+---------- 
         5 |         4         13          3 |        20  
           |      9.76       8.61       1.67 |      5.38  
-----------+---------------------------------+---------- 
         6 |        17         37         73 |       127  
           |     41.46      24.50      40.56 |     34.14  
-----------+---------------------------------+---------- 
         7 |         0          6          2 |         8  
           |      0.00       3.97       1.11 |      2.15  
-----------+---------------------------------+---------- 
         8 |         1          6          6 |        13  
           |      2.44       3.97       3.33 |      3.49  
-----------+---------------------------------+---------- 
         9 |         0          2          1 |         3  
           |      0.00       1.32       0.56 |      0.81  
-----------+---------------------------------+---------- 
        31 |         0          4          2 |         6  
           |      0.00       2.65       1.11 |      1.61  
-----------+---------------------------------+---------- 
        32 |         0          4          4 |         8  
           |      0.00       2.65       2.22 |      2.15  
-----------+---------------------------------+---------- 
        33 |         1          1          1 |         3  
           |      2.44       0.66       0.56 |      0.81  
-----------+---------------------------------+---------- 
     Total |        41        151        180 |       372  
           |    100.00     100.00     100.00 |    100.00  
 
 
 
. tabulate proc3 pr56, chi2 exact row 
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           |         pr56 
     proc3 |         0          1 |     Total 
-----------+----------------------+---------- 
      IVF  |        20         21 |        41  
           |     48.78      51.22 |    100.00  
-----------+----------------------+---------- 
     PICSI® |       101         50 |       151  
           |     66.89      33.11 |    100.00  
-----------+----------------------+---------- 
      ICSI |       104         76 |       180  
           |     57.78      42.22 |    100.00  
-----------+----------------------+---------- 
     Total |       225        147 |       372  
           |     60.48      39.52 |    100.00  
 
          Pearson chi2(2) =   5.4917   Pr = 0.064 
           Fisher's exact =                 0.064 
 
 
  
 
Binomial model of pregnancy outcome on procedure adjusted for; age of ova, donor status, number 
of mii  and surrogate status. Risk ratios estimated. IVF is the reference category in the model. 
 
. xi: binreg pr56 i.proc3 ageova i.donova mii i.surr, rr 
i.proc3           _Iproc3_0-2         (naturally coded; _Iproc3_0 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
i.surr            _Isurr_0-1          (naturally coded; _Isurr_0 omitted) 
 
Generalized linear models                         No. of obs      =        371 
Optimization     : MQL Fisher scoring             Residual df     =        364 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  483.2354669                   (1/df) Deviance =    1.32757 
Pearson          =  371.0150968                   (1/df) Pearson  =   1.019272 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u)                   [Log] 
 
                                                  BIC             =  -1670.262 
 
------------------------------------------------------------------------------ 
             |                 EIM 
        pr56 | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   _Iproc3_1 |   .6634862   .1242177    -2.19   0.028     .4596954    .9576209 PICSI® vs IVF 
   _Iproc3_2 |   .8094789   .1391561    -1.23   0.219     .5779324    1.133794 ICSI vs IVF 
      ageova |   1.007773   .0191153     0.41   0.683     .9709953    1.045943 
  _Idonova_2 |   1.429199   .2691808     1.90   0.058     .9880391    2.067337 
         mii |   1.018637   .0088676     2.12   0.034     1.001404    1.036166 
    _Isurr_1 |   .9181965   .3506057    -0.22   0.823     .4344216    1.940706 
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       _cons |   .2945997   .1949929    -1.85   0.065     .0805062    1.078041 
------------------------------------------------------------------------------ 
 
Test for overall effect of method: 
 
. test _Iproc3_1 _Iproc3_2 
 
 ( 1)  _Iproc3_1 = 0 
 ( 2)  _Iproc3_2 = 0 
 
           chi2(  2) =    4.96 
         Prob > chi2 =    0.0838  no difference 
 
Testign whether PICSI® is different from ICSI: 
 
. test _Iproc3_1= _Iproc3_2 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
           chi2(  1) =    1.97 
         Prob > chi2 =    0.1605    no difference 
 
Estimating the risk ratio beween PICSI® and ICSI: 
 
 
. lincom _Iproc3_1- _Iproc3_2, rr 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
------------------------------------------------------------------------------ 
        pr56 |        RRR   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         (1) |    .819646   .1161671    -1.40   0.161     .6208503    1.082096 
------------------------------------------------------------------------------ 
Risk ratio of PICSI® relative to ICSI for ongoing/full pregnancy outcome is .82 (95%CI .62 to 
1.08), p=.161 
 
PICSI® has lower pregnancy outcome rate but from this data we cannot say that it is different 
from ICSI.  Sample size of the study is probably too small. 
 
The crude unadjusted risk ratio from the table above is rr(crude)=.33/.42=.78. Thus the 
adjustment for covariates  ‘reduces’ the rr to become closer to 1 the value for the risk ratio 
where pregnancy rate are the same. 
 
n) Miscarriage 
 
Defining indicator 
 
generate pr_mis=0 
replace pr_mis=1 if PR==3 | PR==31 | PR==32 | PR==33 
 
. tabulate proc3 pr_mis, chi2 exact row 
 
 
 
           |        pr_mis 
     proc3 |         0          1 |     Total 
-----------+----------------------+---------- 
      IVF  |        40          1 |        41  
           |     97.56       2.44 |    100.00  
-----------+----------------------+---------- 
     PICSI® |       154          9 |       163  
           |     94.48       5.52 |    100.00  
-----------+----------------------+---------- 
      ICSI |       176          8 |       184  
           |     95.65       4.35 |    100.00  
-----------+----------------------+---------- 
     Total |       370         18 |       388  
           |     95.36       4.64 |    100.00  
 
          Pearson chi2(2) =   0.7707   Pr = 0.680 
           Fisher's exact =                 0.779     
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o) Embryo Transfers 
 
 
. tabstat NRET NRGQRT , statistics( mean sd count p25 median p75  ) by(proc3) varw 
> idth(14) columns(statistics) 
 
proc3        variable |      mean        sd         N       p25       p50 
----------------------+-------------------------------------------------- 
IVF              NRET |  2.073171  .5652541        41         2         2 
               NRGQRT |      1.65  .6998168        40         1         2 
----------------------+-------------------------------------------------- 
PICSI®            NRET |  1.969325  .5602393       163         2         2 
               NRGQRT |   1.56051  .7623982       157         1         2 
----------------------+-------------------------------------------------- 
ICSI             NRET |   2.13587  .7377534       184         2         2 
               NRGQRT |  1.662921   .801747       178         1         2 
----------------------+-------------------------------------------------- 
Total            NRET |  2.059278  .6542183       388         2         2 
               NRGQRT |  1.618667  .7747163       375         1         2 
------------------------------------------------------------------------- 
 
proc3        variable |       p75 
----------------------+---------- 
IVF              NRET |         2 
               NRGQRT |         2 
----------------------+---------- 
PICSI®            NRET |         2 
               NRGQRT |         2 
----------------------+---------- 
ICSI             NRET |         2 
               NRGQRT |         2 
----------------------+---------- 
Total            NRET |         2 
               NRGQRT |         2 
--------------------------------- 
 
 
• Boxplot: double embryo return is the standard practice in all procedure groups 
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• Identical embryo transfer profiles 
 
          |              proc3 
      NRET |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         0 |         1          6          6 |        13  
           |      2.44       3.68       3.26 |      3.35  
-----------+---------------------------------+---------- 
         1 |         2         10          6 |        18  
           |      4.88       6.13       3.26 |      4.64  
-----------+---------------------------------+---------- 
         2 |        31        130        137 |       298  
           |     75.61      79.75      74.46 |     76.80  
-----------+---------------------------------+---------- 
         3 |         7         17         32 |        56  
           |     17.07      10.43      17.39 |     14.43  
-----------+---------------------------------+---------- 
         5 |         0          0          1 |         1  
           |      0.00       0.00       0.54 |      0.26  
-----------+---------------------------------+---------- 
         6 |         0          0          2 |         2  
           |      0.00       0.00       1.09 |      0.52  
-----------+---------------------------------+---------- 
     Total |        41        163        184 |       388  
           |    100.00     100.00     100.00 |    100.00  
 
           Fisher's exact =                 0.536 
• Overall no difference in profiles p=.536 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
2
3
4
N
R
G
Q
R
T
IVF PICSI ICSI
Stellenbosch University  https://scholar.sun.ac.za
  154 
           |              proc3 
    NRPQET |      IVF       PICSI®       ICSI |     Total 
-----------+---------------------------------+---------- 
         0 |        26        103        114 |       243  
           |     65.00      65.61      64.04 |     64.80  
-----------+---------------------------------+---------- 
         1 |        10         34         37 |        81  
           |     25.00      21.66      20.79 |     21.60  
-----------+---------------------------------+---------- 
         2 |         3         17         20 |        40  
           |      7.50      10.83      11.24 |     10.67  
-----------+---------------------------------+---------- 
         3 |         1          3          6 |        10  
           |      2.50       1.91       3.37 |      2.67  
-----------+---------------------------------+---------- 
         4 |         0          0          1 |         1  
           |      0.00       0.00       0.56 |      0.27  
-----------+---------------------------------+---------- 
     Total |        40        157        178 |       375  
           |    100.00     100.00     100.00 |    100.00  
 
           Fisher's exact =                 0.981 
• profiles are very similar  
 
ANOVA NRET  
 
                         Number of obs =        388    R-squared     =  0.0145 
                         Root MSE      =    .651134    Adj R-squared =  0.0094 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  2.4062235          2   1.2031117      2.84  0.0598 
                         | 
                   proc3 |  2.4062235          2   1.2031117      2.84  0.0598 
                         | 
                Residual |  163.23037        385     .423975   
              -----------+---------------------------------------------------- 
                   Total |   165.6366        387   .42800155   
 
ANOVA NRPQET  
 
                         Number of obs =        375    R-squared     =  0.0018 
                         Root MSE      =     .81179    Adj R-squared = -0.0035 
 
                  Source | Partial SS         df         MS        F    Prob>F 
              -----------+---------------------------------------------------- 
                   Model |  .45112896          2   .22556448      0.34  0.7104 
                         | 
                   proc3 |  .45112896          2   .22556448      0.34  0.7104 
                         | 
                Residual |  245.14887        372   .65900234   
              -----------+---------------------------------------------------- 
                   Total |      245.6        374   .65668449   
 
 
Quantile regression model:  
 
 
. xi: qreg NRET i.proc3  , quantile(50) 
i.proc3           _Iproc3_0-2         (naturally coded; _Iproc3_0 omitted) 
Iteration  1:  WLS sum of weighted deviations =  57.229663 
 
 
Median regression                                   Number of obs =        388 
  Raw sum of deviations     55.5 (about 2) 
  Min sum of deviations     55.5                    Pseudo R2     =     0.0000 
 
------------------------------------------------------------------------------ 
        NRET |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   _Iproc3_1 |          0  (omitted) 
   _Iproc3_2 |          0  (omitted) 
       _cons |          2          .        .       .            .           . 
------------------------------------------------------------------------------ 
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. xi: qreg NRGQRT i.proc3  , quantile(50) 
i.proc3           _Iproc3_0-2         (naturally coded; _Iproc3_0 omitted) 
 
Median regression                                   Number of obs =        375 
  Raw sum of deviations     95.5 (about 2) 
  Min sum of deviations     95.5                    Pseudo R2     =     0.0000 
 
------------------------------------------------------------------------------ 
      NRGQRT |      Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
   _Iproc3_1 |          0  (omitted) 
   _Iproc3_2 |          0  (omitted) 
       _cons |          2          .        .       .            .           . 
------------------------------------------------------------------------------ 
 
• no variability of any kind thus no significance tests for differences between the medians 
 
  
 
p) Clinical Pregnancy 
 
Nicole code the clinical pregnancy and I ran an analysis on that 
 
 
. tabulate proc3 clin_pr, chi2 row 
 
           |        clin_pr 
     proc3 |         0          1 |     Total 
-----------+----------------------+---------- 
      IVF  |        19         22 |        41  
           |     46.34      53.66 |    100.00  
-----------+----------------------+---------- 
     PICSI® |        90         61 |       151  
           |     59.60      40.40 |    100.00  
-----------+----------------------+---------- 
      ICSI |        93         87 |       180  
           |     51.67      48.33 |    100.00  
-----------+----------------------+---------- 
     Total |       202        170 |       372  
           |     54.30      45.70 |    100.00  
 
          Pearson chi2(2) =   3.2605   Pr = 0.196 
 
 
Overall no difference = 0.20 
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 barchart looks similar to my own pr indicator 
 
 
Some more modelling of risk difference (rd). Adjusted for incubator used, age of ova, procedure 
used (IVF,PICSI® ,ICSI),donor ova used, surrogate used and number of mii. 
 
 
. xi: binreg clin_pr i.inc2 ageova i.proc3 i.donova i.surr mii, rd 
i.inc2            _Iinc2_1-2          (naturally coded; _Iinc2_1 omitted) 
i.proc3           _Iproc3_0-2         (naturally coded; _Iproc3_0 omitted) 
i.donova          _Idonova_1-2        (_Idonova_1 for donova==0 omitted) 
i.surr            _Isurr_0-1          (naturally coded; _Isurr_0 omitted) 
 
Iteration 1:   deviance =  494.2373 
Iteration 2:   deviance =  494.2327 
Iteration 3:   deviance =  494.2327 
Iteration 4:   deviance =  494.2327 
 
Generalized linear models                         No. of obs      =        369 
Optimization     : MQL Fisher scoring             Residual df     =        361 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  494.2326504                   (1/df) Deviance =   1.369066 
Pearson          =  369.0002449                   (1/df) Pearson  =   1.022161 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = u                       [Identity] 
 
                                                  BIC             =  -1639.565 
 
------------------------------------------------------------------------------ 
             |                 EIM 
     clin_pr | Risk Diff.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
    _Iinc2_2 |   .0482779   .0733129     0.66   0.510    -.0954128    .1919686 
      ageova |   .0085928   .0077341     1.11   0.267    -.0065657    .0237514 
   _Iproc3_1 |   -.152674   .0871449    -1.75   0.080    -.3234748    .0181268 
   _Iproc3_2 |  -.0766151   .0860183    -0.89   0.373    -.2452078    .0919777 
  _Idonova_2 |   .1953642   .0808181     2.42   0.016     .0369636    .3537648 
    _Isurr_1 |  -.0306542   .1606965    -0.19   0.849    -.3456136    .2843051 
         mii |   .0077962   .0042126     1.85   0.064    -.0004604    .0160528 
       _cons |   .1486018   .2748562     0.54   0.589    -.3901065    .6873101 
------------------------------------------------------------------------------ 
 
Testing for overall procedure effect 
. test _Iproc3_1 _Iproc3_2 
 
 ( 1)  _Iproc3_1 = 0 
 ( 2)  _Iproc3_2 = 0 
 
           chi2(  2) =    3.80 
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         Prob > chi2 =    0.1497    no effect 
 
 
q) Testing for overall procedure effect  
 
. test _Iproc3_1= _Iproc3_2 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
           chi2(  1) =    1.93 
         Prob > chi2 =    0.1644   no significant difference 
 
Estimated difference in adjusted clinical pregnancy rate 
. lincom _Iproc3_1- _Iproc3_2 
 
 ( 1)  _Iproc3_1 - _Iproc3_2 = 0 
 
------------------------------------------------------------------------------ 
     clin_pr |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
         (1) |  -.0760589   .0546974    -1.39   0.164    -.1832638     .031146 
 
PICSI® has 7.6% lower clinical pregnancy rate. 
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APPENDIX XVI  Statistical Analysis Results (Prospective) 
 
 
Clinical Pregnancy (Fetal Sac) 
 
Unadjusted: Crude Analysis 
 
           |         group 
      FSAC |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       455        116 |       571  
           |     67.61      58.88 |     65.63  
-----------+----------------------+---------- 
         1 |       172         52 |       224  
           |     25.56      26.40 |     25.75  
-----------+----------------------+---------- 
         2 |        43         26 |        69  
           |      6.39      13.20 |      7.93  
-----------+----------------------+---------- 
         3 |         3          3 |         6  
           |      0.45       1.52 |      0.69  
-----------+----------------------+---------- 
     Total |       673        197 |       870  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(3) =  13.2800   Pr = 0.004 
 
• Crude unadjusted comparison shows a significant difference in FSAC profile between 
groups, p=.004  
 
. generate FSAC2=FSAC 
(1 missing value generated) 
 
. recode FSAC2 (1/max=1) 
(FSAC2: 75 changes made) 
 
Binary tabulation for FSAC 
. tabulate FSAC2 group, chi2 column 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
 
           |         group 
     FSAC2 |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       455        116 |       571  
           |     67.61      58.88 |     65.63  
-----------+----------------------+---------- 
         1 |       218         81 |       299  
           |     32.39      41.12 |     34.37  
-----------+----------------------+---------- 
     Total |       673        197 |       870  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   5.1425   Pr = 0.023 
 
• unadjusted comparison shows a significant difference in FSAC2 profile between groups, 
p=.004 (  41% for glue versus 32% for control) 
 
. xi:binreg FSAC2  group   , or 
 
Generalized linear models                         No. of obs      =        870 
Optimization     : MQL Fisher scoring             Residual df     =        868 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  1114.547297                   (1/df) Deviance =   1.284041 
Pearson          =  869.9996593                   (1/df) Pearson  =   1.002304 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -4760.505 
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------------------------------------------------------------------------------ 
             |                 EIM 
       FSAC2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.457411   .2427861     2.26   0.024     1.051435    2.020139 
       _cons |   .4791209   .0394656    -8.93   0.000     .4076908     .563066 
------------------------------------------------------------------------------ 
• crude odds ratio = 1.46 (95% CI: 1.05 to 2.02) , p=.024 
. 
 
Number of Ova Per Patient 
 
. tab NUMOVA , missing 
 
     NUMOVA |      Freq.     Percent        Cum. 
------------+----------------------------------- 
          1 |         10        1.15        1.15 
          2 |         36        4.13        5.28 
          3 |         64        7.35       12.63 
          4 |         53        6.08       18.71 
          5 |         60        6.89       25.60 
          6 |         57        6.54       32.15 
          7 |         55        6.31       38.46 
          8 |         41        4.71       43.17 
          9 |         34        3.90       47.07 
         10 |         38        4.36       51.44 
         11 |         23        2.64       54.08 
         12 |         31        3.56       57.63 
         13 |         46        5.28       62.92 
         14 |         32        3.67       66.59 
         15 |         20        2.30       68.89 
         16 |         21        2.41       71.30 
         17 |         17        1.95       73.25 
         18 |         16        1.84       75.09 
         19 |         12        1.38       76.46 
         20 |         10        1.15       77.61 
         21 |         10        1.15       78.76 
         22 |          3        0.34       79.10 
         23 |          4        0.46       79.56 
         24 |          3        0.34       79.91 
         25 |          7        0.80       80.71 
         26 |          4        0.46       81.17 
         27 |          2        0.23       81.40 
         28 |          1        0.11       81.52 
         29 |          3        0.34       81.86 
         31 |          3        0.34       82.20 
         32 |          2        0.23       82.43 
         33 |          1        0.11       82.55 
         34 |          2        0.23       82.78 
         35 |          1        0.11       82.89 
         40 |          2        0.23       83.12 
         48 |          1        0.11       83.24 
         50 |          1        0.11       83.35 
          . |        145       16.65      100.00 
------------+----------------------------------- 
      Total |        871      100.00 
 
 
• 17% of records had missing ova data which is similar to the first analysis 
• will do a model with and without this covariate 
 
 
 
 
• logistic regression model- estimating odds ratios. 
• number good quality embryos returned used as categorical outcome. 
 
 
. xi:binreg FSAC2  group  DAYET i.DONOVA AGEOVA  i.NRGQRT NRET , or 
i.DONOVA          _IDONOVA_0-1        (naturally coded; _IDONOVA_0 omitted) 
i.NRGQRT          _INRGQRT_0-4        (naturally coded; _INRGQRT_0 omitted) 
 
 
Generalized linear models                         No. of obs      =        868 
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Optimization     : MQL Fisher scoring             Residual df     =        858 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  1009.657967                   (1/df) Deviance =   1.176758 
Pearson          =  886.1456204                   (1/df) Pearson  =   1.032804 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -4795.735 
 
------------------------------------------------------------------------------ 
             |                 EIM 
       FSAC2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.340349   .2430039     1.62   0.106     .9394983    1.912229 
       DAYET |   1.172206   .0785816     2.37   0.018     1.027878    1.336799 
  _IDONOVA_1 |   1.626416   .4046024     1.96   0.051      .998801    2.648406 
      AGEOVA |    .991486   .0187284    -0.45   0.651     .9554503    1.028881 
  _INRGQRT_1 |    2.63016   .8231654     3.09   0.002     1.424231    4.857179 
  _INRGQRT_2 |   6.869349   2.033207     6.51   0.000     3.845695    12.27033 
  _INRGQRT_3 |   10.07205   4.340887     5.36   0.000     4.327767    23.44076 
  _INRGQRT_4 |   16.44466   12.32993     3.73   0.000     3.782758    71.48936 
        NRET |   .7846531   .1121211    -1.70   0.090     .5929898    1.038265 
       _cons |   .1161102   .0986886    -2.53   0.011     .0219476    .6142628 
------------------------------------------------------------------------------ 
 
  
 
 
-> group = control 
           |         FSAC2 
      gnrt |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |        94         12 |       106  
           |     88.68      11.32 |    100.00  
-----------+----------------------+---------- 
         1 |       163         57 |       220  
           |     74.09      25.91 |    100.00  
-----------+----------------------+---------- 
         2 |       197        149 |       346   ( 2 or more) 
           |     56.94      43.06 |    100.00  
-----------+----------------------+---------- 
     Total |       454        218 |       672  
           |     67.56      32.44 |    100.00  
0
.5
1
0 1 2 3 4 0 1 2 3 4
control glue
FS
AC
2
NRGQRT
bandwidth = .8
Lowess smoother
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---------------------------------------------------------------------------------- 
-> group = glue 
           |         FSAC2 
      gnrt |         0          1 |     Total 
-----------+----------------------+---------- 
         0 |        29          3 |        32  
           |     90.63       9.38 |    100.00  
-----------+----------------------+---------- 
         1 |        40         18 |        58  
           |     68.97      31.03 |    100.00  
-----------+----------------------+---------- 
         2 |        47         60 |       107  ( 2 or more) 
           |     43.93      56.07 |    100.00  
-----------+----------------------+---------- 
     Total |       116         81 |       197  
           |     58.88      41.12 |    100.00  
 
 
Same model as before but with grouped good number of embryos returned (gnrt) 
The pooled variables provide stable estimates for this covariate 
 
Model to report 
 
. xi:binreg FSAC2  group  DAYET i.DONOVA AGEOVA  i.gnrt NRET , or 
i.DONOVA          _IDONOVA_0-1        (naturally coded; _IDONOVA_0 omitted) 
i.gnrt            _Ignrt_0-2          (naturally coded; _Ignrt_0 omitted) 
 
 
Generalized linear models                         No. of obs      =        868 
Optimization     : MQL Fisher scoring             Residual df     =        860 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  1011.974076                   (1/df) Deviance =   1.176714 
Pearson          =  881.1282539                   (1/df) Pearson  =   1.024568 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -4806.951 
 
------------------------------------------------------------------------------ 
             |                 EIM 
       FSAC2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.373411   .2472335     1.76   0.078     .9650996    1.954469 
       DAYET |   1.165432   .0778451     2.29   0.022     1.022424    1.328444 
  _IDONOVA_1 |   1.661143   .4114165     2.05   0.040     1.022326    2.699136 
      AGEOVA |   .9949428    .018509    -0.27   0.785     .9593191    1.031889 
    _Ignrt_1 |   2.725016   .8497077     3.21   0.001     1.478936    5.020981 
    _Ignrt_2 |   7.142529   2.096908     6.70   0.000     4.017499    12.69838 
        NRET |   .8622799   .1083063    -1.18   0.238     .6741142    1.102969 
       _cons |    .086797    .071505    -2.97   0.003     .0172691     .436255 
------------------------------------------------------------------------------ 
• adjusted  odds  ratio for glue is 1.37 ( 95%CI: .97 to 1.96) , p=.078. Thus the adjusted 
effect is not significant 
• DAYET significant  
• AGEOVA not significant 
• Donor ova a significant factor 
• NRQRT is strongly associated with FSAC2 with much higher odds for a positive outcome with 
2 or more embryos returned (ngrt) 
• NRET not significant 
• interaction between group and good number returned is not significant,  0.4946 from 
results not shown. 
 
 
With number of ova and more missing data 
 
. xi:binreg FSAC2  group  DAYET i.DONOVA AGEOVA  i.gnrt NRET NUMOVA , or 
i.DONOVA          _IDONOVA_0-1        (naturally coded; _IDONOVA_0 omitted) 
i.gnrt            _Ignrt_0-2          (naturally coded; _Ignrt_0 omitted) 
Generalized linear models                         No. of obs      =        726 (vs 868) 
Optimization     : MQL Fisher scoring             Residual df     =        717 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  825.4726572                   (1/df) Deviance =   1.151287 
Pearson          =  740.9955876                   (1/df) Pearson  =   1.033467 
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Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -3897.801 
------------------------------------------------------------------------------ 
             |                 EIM 
       FSAC2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.408185   .2839809     1.70   0.090      .948424    2.090821 
       DAYET |   1.193995   .1050304     2.02   0.044     1.004908    1.418662 
  _IDONOVA_1 |   1.913229   .5675678     2.19   0.029     1.069681    3.421997 
      AGEOVA |    .994941   .0217762    -0.23   0.817      .953163     1.03855 
    _Ignrt_1 |   2.454154    .802143     2.75   0.006     1.293259    4.657126 
    _Ignrt_2 |   6.844299   2.060154     6.39   0.000     3.794153    12.34648 
        NRET |    .830324    .114445    -1.35   0.177     .6337602    1.087853 
      NUMOVA |   1.017089   .0153375     1.12   0.261     .9874674    1.047598 
       _cons |   .0798519   .0750233    -2.69   0.007     .0126635    .5035177 
• Thus model without adjustment for number of ova not that different from a model without 
it but minimal missing data 
 
 
Ongoing Clinical Pregnancy (Fetal Heart) 
 
Unadjusted: Crude Analysis  
 
 
           |         group 
        FH |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       463        120 |       583  
           |     68.80      60.91 |     67.01  
-----------+----------------------+---------- 
         1 |       155         49 |       204  
           |     23.03      24.87 |     23.45  
-----------+----------------------+---------- 
         2 |        53         27 |        80  
           |      7.88      13.71 |      9.20  
-----------+----------------------+---------- 
         3 |         2          1 |         3  
           |      0.30       0.51 |      0.34  
-----------+----------------------+---------- 
     Total |       673        197 |       870  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(3) =   7.4629   Pr = 0.059 
 
 
 
 
           |         group 
       FH2 |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       463        120 |       583  
           |     68.80      60.91 |     67.01  
-----------+----------------------+---------- 
         1 |       210         77 |       287  
           |     31.20      39.09 |     32.99  
-----------+----------------------+---------- 
     Total |       673        197 |       870  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   4.2835   Pr = 0.038 
 
. xi:binreg FH2  group , or 
 
Generalized linear models                         No. of obs      =        870 
Optimization     : MQL Fisher scoring             Residual df     =        868 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  1099.127015                   (1/df) Deviance =   1.266275 
Pearson          =   869.999513                   (1/df) Pearson  =   1.002304 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -4775.925 
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------------------------------------------------------------------------------ 
             |                 EIM 
         FH2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.414722   .2377494     2.06   0.039     1.017709    1.966613 
       _cons |   .4535637   .0377351    -9.50   0.000     .3853195    .5338947 
------------------------------------------------------------------------------ 
• crude odds ratio 1.41 (95% CI: 1.02 to 1.97) , p=.039 glue relative control 
 
 
Adjusted model ( without number of ova) – model to report 
 
xi:binreg FH2  group  DAYET i.DONOVA AGEOVA  i.gnrt NRET  , or 
i.DONOVA          _IDONOVA_0-1        (naturally coded; _IDONOVA_0 omitted) 
i.gnrt            _Ignrt_0-2          (naturally coded; _Ignrt_0 omitted) 
 
Generalized linear models                         No. of obs      =        868 
Optimization     : MQL Fisher scoring             Residual df     =        860 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  1000.726327                   (1/df) Deviance =   1.163635 
Pearson          =  882.3516975                   (1/df) Pearson  =    1.02599 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -4818.199 
 
------------------------------------------------------------------------------ 
             |                 EIM 
         FH2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.338471   .2424758     1.61   0.108     .9384392    1.909025 
       DAYET |   1.160714   .0781347     2.21   0.027     1.017246    1.324418 
  _IDONOVA_1 |   1.528168   .3791739     1.71   0.087     .9396543    2.485272 
      AGEOVA |   .9878271   .0184733    -0.65   0.513     .9522756    1.024706 
    _Ignrt_1 |   2.524728   .7896279     2.96   0.003     1.367713     4.66052 
    _Ignrt_2 |   6.643011   1.953776     6.44   0.000     3.732657    11.82257 
        NRET |   .8157298   .1050124    -1.58   0.114     .6338222    1.049845 
       _cons |   .1281487   .1058551    -2.49   0.013     .0253859    .6468974 
------------------------------------------------------------------------------ 
 
 
 
With NUMBER OF OVA  
 
xi:binreg FH2  group  DAYET i.DONOVA AGEOVA  i.gnrt NRET  NUMOVA , or 
i.DONOVA          _IDONOVA_0-1        (naturally coded; _IDONOVA_0 omitted) 
i.gnrt            _Ignrt_0-2          (naturally coded; _Ignrt_0 omitted) 
 
Generalized linear models                         No. of obs      =        726 
Optimization     : MQL Fisher scoring             Residual df     =        717 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  817.2487832                   (1/df) Deviance =   1.139817 
Pearson          =  740.1390779                   (1/df) Pearson  =   1.032272 
 
Variance function: V(u) = u*(1-u/1)               [Binomial] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =  -3906.025 
 
------------------------------------------------------------------------------ 
             |                 EIM 
         FH2 | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.315619   .2672194     1.35   0.177     .8835683    1.958936 
       DAYET |   1.225927   .1085062     2.30   0.021     1.030683    1.458156 
  _IDONOVA_1 |   1.820598   .5391887     2.02   0.043     1.018877    3.253165 
      AGEOVA |   .9860384   .0216619    -0.64   0.522     .9444829    1.029422 
    _Ignrt_1 |   2.360404   .7731689     2.62   0.009     1.242135     4.48543 
    _Ignrt_2 |   6.377573   1.922783     6.15   0.000      3.53204    11.51557 
        NRET |   .7949667   .1122711    -1.62   0.104     .6027483    1.048484 
      NUMOVA |   1.011153   .0152045     0.74   0.461      .981788    1.041397 
       _cons |   .1147275   .1079861    -2.30   0.021     .0181336    .7258588 
------------------------------------------------------------------------------ 
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• estimates show some small changes, glue odds smaller, 1.32 compared to 1.34. Thus missing 
data is has no serious  bias or effect. 
 
 
Miscarriage Rates 
 
Unadjusted: Crude Analysis 
 
           |         group 
      abrt |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       637        184 |       821  
           |     94.51      93.40 |     94.26  
-----------+----------------------+---------- 
         1 |        37         13 |        50  
           |      5.49       6.60 |      5.74  
-----------+----------------------+---------- 
     Total |       674        197 |       871  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   0.3467   Pr = 0.556 
 
. xi:binreg abrt  group   , or 
 
 
Generalized linear models                         No. of obs      =        871 
Optimization     : MQL Fisher scoring             Residual df     =        869 
                   (IRLS EIM)                     Scale parameter =          1 
Deviance         =  382.4989498                   (1/df) Deviance =   .4401599 
Pearson          =  870.9674498                   (1/df) Pearson  =   1.002264 
 
Variance function: V(u) = u*(1-u)                 [Bernoulli] 
Link function    : g(u) = ln(u/(1-u))             [Logit] 
 
                                                  BIC             =   -5500.32 
 
------------------------------------------------------------------------------ 
             |                 EIM 
        abrt | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
       group |   1.216363   .4051655     0.59   0.557     .6331864    2.336657 
       _cons |   .0580848   .0098223   -16.83   0.000     .0416987      .08091 
------------------------------------------------------------------------------ 
• odds for miscarriage not different between the glue and non-glue cycles , or=1.22 ( 
95%CI: .63 to 2.34) , p=.557 
• Thus no further adjustment  was made 
 
 
Subgroup Analysis for Descriptive Purposes 
 
Age of Ova 
 
 
           |         group 
     ovage |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       416        115 |       531  
           |     61.72      58.38 |     60.96  
-----------+----------------------+---------- 
         1 |       258         82 |       340  (36+) 
           |     38.28      41.62 |     39.04  
-----------+----------------------+---------- 
     Total |       674        197 |       871  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   0.7169   Pr = 0.397 
 
• age distribution the same between the groups, p=.397 
 
Embryos Transferred 
 
 
           |         group 
      NRET |   control       glue |     Total 
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-----------+----------------------+---------- 
         1 |       108         45 |       153  
           |     16.02      22.84 |     17.57  
-----------+----------------------+---------- 
         2 |       421        107 |       528  
           |     62.46      54.31 |     60.62  
-----------+----------------------+---------- 
         3 |       123         31 |       154  
           |     18.25      15.74 |     17.68  
-----------+----------------------+---------- 
         4 |        19         13 |        32  
           |      2.82       6.60 |      3.67  
-----------+----------------------+---------- 
         5 |         3          0 |         3  
           |      0.45       0.00 |      0.34  
-----------+----------------------+---------- 
         6 |         0          1 |         1  
           |      0.00       0.51 |      0.11  
-----------+----------------------+---------- 
     Total |       674        197 |       871  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(5) =  16.4762   Pr = 0.006 
 
 
 
           |         group 
     nebet |   control       glue |     Total 
-----------+----------------------+---------- 
         1 |       108         45 |       153  
           |     16.02      22.84 |     17.57  
-----------+----------------------+---------- 
         2 |       566        152 |       718  (2 or more embryos returned) 
           |     83.98      77.16 |     82.43  
-----------+----------------------+---------- 
     Total |       674        197 |       871  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   4.8951   Pr = 0.027 
 
 
• number of embryos returned is significantly different between the groups  
 
 
Donor Ova 
 
           |         group 
   DON OVA |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |       554        144 |       698  
           |     82.20      73.10 |     80.14  
-----------+----------------------+---------- 
         1 |       120         53 |       173  
           |     17.80      26.90 |     19.86  
-----------+----------------------+---------- 
     Total |       674        197 |       871  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   7.9299   Pr = 0.005 
 
• number of donor ova used is more in the glue group 27% versus 674 
 
 
 
Cycle Number 
 
.  tabulate CYCLE group, chi2 col 
 
+-------------------+ 
| Key               | 
|-------------------| 
|     frequency     | 
| column percentage | 
+-------------------+ 
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           |         group 
     CYCLE |   control       glue |     Total 
-----------+----------------------+---------- 
         0 |         1          0 |         1  
           |      0.19       0.00 |      0.15  
-----------+----------------------+---------- 
         1 |       308         80 |       388  
           |     57.46      53.33 |     56.56  
-----------+----------------------+---------- 
         2 |       126         33 |       159  
           |     23.51      22.00 |     23.18  
-----------+----------------------+---------- 
         3 |        50         19 |        69  
           |      9.33      12.67 |     10.06  
-----------+----------------------+---------- 
         4 |        23          8 |        31  
           |      4.29       5.33 |      4.52  
-----------+----------------------+---------- 
         5 |        11          6 |        17  
           |      2.05       4.00 |      2.48  
-----------+----------------------+---------- 
         6 |        11          3 |        14  
           |      2.05       2.00 |      2.04  
-----------+----------------------+---------- 
         7 |         1          0 |         1  
           |      0.19       0.00 |      0.15  
-----------+----------------------+---------- 
         9 |         2          0 |         2  
           |      0.37       0.00 |      0.29  
-----------+----------------------+---------- 
        10 |         2          0 |         2  
           |      0.37       0.00 |      0.29  
-----------+----------------------+---------- 
        11 |         0          1 |         1  
           |      0.00       0.67 |      0.15  
-----------+----------------------+---------- 
        15 |         1          0 |         1  
           |      0.19       0.00 |      0.15  
-----------+----------------------+---------- 
     Total |       536        150 |       686  
           |    100.00     100.00 |    100.00  
 
         Pearson chi2(11) =   9.3766   Pr = 0.587 
 
 
           |         group 
    cycle2 |   control       glue |     Total 
-----------+----------------------+---------- 
         1 |       309         80 |       389  
           |     57.65      53.33 |     56.71  
-----------+----------------------+---------- 
         2 |       227         70 |       297 (2nd or later cycle) 
           |     42.35      46.67 |     43.29  
-----------+----------------------+---------- 
     Total |       536        150 |       686  
           |    100.00     100.00 |    100.00  
 
          Pearson chi2(1) =   0.8892   Pr = 0.346 
• no difference in number of cycles between the groups 
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